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ABSTRACT 
 
SHIH-YIN CHEN: Second-generation Antidepressant Use in Treatment for Major 
Depressive Disorder - An Examination of Guideline Components and Healthcare Utilization 
(Under the direction of Dr. Matthew Maciejewski) 
 
Major depressive disorder (MDD) is a prevalent mental health illness and 
antidepressant therapy is the most frequently provided treatment option. Clinical guidelines 
have been developed for depression management. Guidelines recommend that depressed 
patients receive frequent follow-up visits and complete an acute phase regimen lasting a 
minimum of 6-8 weeks to remove symptoms, followed by a continuation phase for 4-9 
months to prevent relapse. The objectives of this dissertation are to examine whether there 
are differences between patients initially prescribed an antidepressant by providers with 
different specialties, to understand what factors are associated with receipt of guideline-
concordant care, and investigate how subsequent healthcare utilization varies by provider 
specialty and guideline concordance.  
 Claims data from a large national plan in 2000-2004 were used to identify individuals 
who initiated antidepressant treatment for MDD. Guideline-concordant follow-up visits were 
identified based on service claims, and completion of acute phase and continuation phase 
antidepressant regimens was evaluated based on prescription refill records. All-cause and 
mental health-related hospitalizations and emergency room visits were examined during a 
 iv 
one-ear period after treatment completion. Logistic regressions were conducted to assess the 
association of the outcomes with initial prescriber specialty and other factors. 
  We found that several pre-disposing, enabling and need variables differ among 
patients with different types of providers. After adjustment, patients initially prescribed an 
antidepressant by psychiatrists were more likely to receive guideline-concordant follow-up 
visits, and no provider differences were found for antidepressant treatment completion. 
Patients who received guideline-concordant follow-up visits were more likely to complete 
antidepressant treatment. Completion of acute phase treatment was negatively associated 
with all-cause hospitalization during the one-year period afterwards. 
These results showed that routine care for antidepressant management falls short of 
guideline recommendations. These findings underscore the need for quality improvement 
particular in primary care. Strategies to promote frequent follow-up should be encouraged 
given the positive association with antidepressant adherence. This study also helps identify 
the modifiable factors to target for intervention and provides evidence to justify resource 
allocation to promote quality of care among patients with MDD.  
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CHAPTER I 
INTRODUCTION 
1.1 Specific Aims 
Major depressive disorder (MDD) is a prevalent mental health illness that impacts 32.6 
to 35.1 million Americans.1 Among the available treatment options for MDD, antidepressant 
therapy is most frequently used because of its easy administration and high effectiveness. 
The effectiveness of antidepressant therapy relies heavily on patient adherence, which has 
been estimated to range from 11% to 65%. 2-7 
Clinical practice guidelines, such as the Agency for Health Care Policy and Research 
(AHCPR) Depression Guideline Panel Report and the practice guideline for treatment of 
patients with major depression by the American Psychiatric Association (APA), have been 
developed to assist patients and providers in the treatment of MDD. If pharmacotherapy is 
chosen, it is recommended that an acute phase regimen lasting a minimum of 6-8 weeks 
should be completed in order to remove symptoms, followed by a continuation phase for 4-9 
months to prevent relapse.8, 9  
Guidelines also suggest frequent outpatient follow-up visits during the acute phase. 
Although guidelines have been developed for over a decade, routine primary care 
management for depression still falls short of guideline recommendations. Only half to two 
thirds of patients receive care for MDD.1, 10 Among those seeking healthcare, only one forth 
received appropriate treatment.1, 11
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 This dissertation seeks to understand the care patients with MDD receive, and the 
association between initial prescriber specialty, receipt of guideline-concordant outpatient 
follow-up visits, completion of antidepressant treatment phases and subsequent healthcare 
utilization. The dissertation used a retrospective cohort of patients with MDD between 2000 
and 2004. Medical and pharmacy claims data from a large national healthcare plan affiliated 
with i3 Innovus were analyzed to address the following aims: 
Aim 1: To examine characteristics among patients initially prescribed an 
antidepressant by providers with different specialties to treat major depressive disorder 
(MDD) 
This aim examines characteristics among patients initially prescribed an 
antidepressant by providers with different specialties. Information on prescribing provider 
specialty was obtained from the index antidepressant prescription claim. Patient cohorts were 
identified based on the specialty of the provider who prescribed the index antidepressant 
from: 1) a primary care provider; 2) a psychiatrist; or 3) a non-psychiatric specialist. Patient 
difference by the initial prescriber specialty may indicate potential confounders of the 
provider effect related to outpatient follow-up, antidepressant treatment completion, and 
subsequent healthcare utilization. There might be substantial differences in patient 
characteristics as well as depression outcomes for patients seen by different types of 
providers, and failure to acknowledge this might mask important differences.  
Aim 2: To examine the association of antidepressant treatment with initial prescriber 
specialty and receipt of guideline-concordant outpatient follow-up visits among patients 
with MDD 
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H2.1: Receipt of guideline-concordant outpatient follow-up visits varies by initial prescriber 
specialty 
This aim examines the association between initial prescriber specialty and receipt of 
guideline-concordant outpatient follow-up visits during acute phase. Receipt of guideline-
concordant follow-up visits is defined as having at least three visits during the first 90 days 
since treatment initiation using the National Committee for Quality Assurance (NCQA) 
Health Effectiveness Data and Information Set (HEDIS) measure.12 Prior studies found 
mental health specialty care were associated with increased likelihood of receipt of guideline-
concordant follow-up visits.4, 6 This dissertation extended prior work by incorporating risk 
adjustment in the analytical models and propensity score matching to account for imbalance 
of patient characteristics among provider specialties. Furthermore, we conducted additional 
sensitivity analyses by varying the approach to identify follow-up visits to evaluate how our 
results may change based on how we define follow-up visits. The findings from this aim 
could inform quality improvement by identifying the population at risk of less frequent 
follow-up and targeting modifiable components for intervention. 
H2.2: Completion of antidepressant acute and continuation phase varies by initial prescriber 
specialty 
This aim investigates the association between initial prescriber specialty and 
antidepressant treatment. Clinical guidelines suggest that a patient should complete an acute 
phase regimen (6-8 weeks) and a continuation phase treatment (4-9 months).8, 9 Previous 
findings about the association between provider specialty and antidepressant treatment were 
inconsistent. 2-4, 6, 7, 13-17 Further, empirical evidence of the association between receipt of 
guideline-concordant follow-up visits and antidepressant treatment is needed to demonstrate 
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whether follow-up visits reinforce patient’s completion of antidepressant treatment, but only 
one study based on a military veterans sample has controlled for provider specialty and 
follow-up visits simultaneously.4 This dissertation extends earlier work by incorporating both 
provider specialty and guideline-concordant follow-up visits in the analytical model, 
measuring antidepressant use aligned with guideline recommendations, and utilizing 
propensity score matching to control for confounders. Since suboptimal antidepressant 
treatment is widespread in real-world practice, it is critical to understand factors associated 
with patient’s antidepressant treatment completion. The knowledge gained from this aim can 
provide a basis for developing interventions to improve the quality of antidepressant 
treatment that patients with MDD receive. 
Aim 3: To examine the association of subsequent healthcare utilization with initial 
prescriber specialty and antidepressant treatment among patients with MDD 
This aim examines subsequent all-cause and mental health-related emergency room 
visits and hospitalization during one-year period after acute phase and continuation phase to 
understand the relationship with initial prescriber specialty and antidepressant treatment. 
Even though emergency room visits or hospitalization are rare events, they account for a 
large portion of healthcare costs and might indicate a clinical exacerbation of the condition. 
As the majority of depression patients are treated in primary care settings11, it is important to 
examine the influence of provider specialty on subsequent emergency room visits and 
inpatient admissions to understand what the downstream economic implications of treatment 
by providers with different specialties are. Empirical evidence linking antidepressant 
treatment duration to economic outcomes is more limited, particularly for hospitalization.18-20 
With increasing prescription drug expenditures, it is important to link antidepressant 
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treatment duration to subsequent utilization of healthcare to understand potential cost offset 
effects. If reduction in these costly healthcare events can be attributed to adequate use of 
medication, costs associated with medication use can be justified both by its cost offset 
effects as well as the expected improvement in health outcomes. Findings from this analysis 
can provide empirical evidence to assess the importance of antidepressant treatment with 
guideline-recommended duration from both clinical and economic perspectives.  
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1.2 Background of Major Depressive Disorder 
1.2.1 Diagnosis 
Major depressive disorder (MDD) is a psychiatric mood disturbance characterized by 
one or more major depressive episodes without a history of manic, mixed, or hypomanic 
episodes.21 A major depressive episode is a period of at least two weeks during which there is 
depressed mood or loss of interest or pleasure in nearly all activities. The criteria for major 
depressive episode in the Diagnostic and Statistical Manual of Mental Disorders Forth 
Edition (DSM-IV)21 are listed in Appendix 1. 
The cause of MDD can be idiopathic or related to a wide range of systemic or 
neurological medical illnesses, substance intoxication or withdrawal. Clinical history and 
mental status examination are the most important components of the diagnostic evaluation 
because depressive disorders are defined by syndrome criteria. Although MDD is a common 
and treatable mood disorder, it is still under-diagnosed. The reasons for under-diagnosis 
range from lack of screening to denial by patients due to stigma.22 Depression is also often 
under-treated. Only half to two thirds of patients with defined MDD receive treatment.1, 10 
Among those who seek care, the majority of MDD patients see primary care providers (78%), 
while only 18% visited mental health specialists.11 Only one fourth of those seeking health 
care receive appropriate treatment.1, 11 
1.2.2. Epidemiology and Burden of Illness 
MDD affects 32.6 to 35.1 million adults in the United States, with higher rates among 
women1 (Table 1.1). Mean age at onset of MDD is 30.4 years.10 There is a 40% rate of 
recurrence over a two-year period after the first episode.23 Among those with lifetime MDD, 
the mean number of episodes was 4.7, and the median duration was 24.3 weeks for the 
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longest episode.10 MDD is also commonly comorbid with anxiety and substance disorders.1, 
10
  
Table 1.1 Prevalence of Major Depressive Disorder in the United States 
Study Year Diagnostic Criteria 1-year prevalence Lifetime prevalence 
Robins et al. 24 1980s DSM-III 3.0% 5.2% 
Kessler et al. 25 1990-1992 DSM-III-R 8.6% 14.9% 
Kessler et al. 1 2001-2002 DSM-IV 6.6% 16.2% 
Hasin et al. 10 2001-2002 DSM-IV 5.3% 13.2% 
 
The World Health Organization ranked MDD as the most burdensome disease in the 
world,26 and projected that depression will be the second leading cause of disability in the 
developed world by 2020.27  MDD interferes with functioning in work, household, 
relationship and social roles, and individuals with 12-month MDD reported a mean of 35.2 
days of role impairment.1  In addition, the economic burden of depression is high. The 
average annual costs per case ranged from $1,000 to $2,500 in direct healthcare costs, from 
$2,000 to $3,700 for morbidity costs and from $200 to $400 mortality costs.28 In the United 
States, the annual burden of depression was estimated to be $81.5 billion in 2000.29  
1.2.3 Treatment Options 
After a confirmed diagnosis, treatment should be initiated according to clinical need 
(e.g. severity of symptoms) and patient preferences. Treatment options for MDD include 
pharmacotherapy, psychotherapy, combination of pharmacotherapy and psychotherapy, and 
electroconvulsive therapy. 
Pharmacotherapy is the most frequently used treatment for MDD, particularly for 
patients with mild to moderate MDD.30 It is estimated that 62% of depressed patients are 
initiated with pharmacotherapy.31 The major classes of drugs are the selective serotonin 
reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic 
antidepressants, heterocyclics, monoamine oxidase inhibitors, and a few other compounds. 
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Antidepressants are efficacious and associated with a 50-60% response rate among patients 
in primary care settings.32 Second-generation antidepressants, including SSRIs and SNRIs, 
are usually used as the first-line choice in primary care because of their lower side effect 
profiles and markedly lower risk of overdose.33 The advantages of pharmacotherapy are easy 
administration, high effectiveness and low patient time requirement compared with 
psychotherapy. Some of the disadvantages of pharmacotherapy include need for repeated 
medical visits to monitor response and adjust dosage, unwanted side effects, and most 
importantly, failure to complete treatment (e.g. non-adherence).8  
Psychotherapy, such as cognitive therapy, behavioral therapy, and interpersonal 
therapy, is also effective in treating depression.34 Cognitive therapies aim at symptom 
removal by identification and correction of the patient's distorted, negatively biased, 
moment-to-moment thinking.35 Behavioral therapies usually involve a functional analysis of 
behavior and/or social learning. Interpersonal therapies aim at the clarification and resolution 
of the interpersonal difficulties. Psychotherapy is more time-consuming and expensive than 
pharmacotherapy, and the treatment effects appear much later.8 A combination of 
pharmacotherapy and psychotherapy can be given if either treatment alone is only partially 
effective, or the clinical circumstances suggest both aspects to be targeted at the same time. 8 
Finally, electroconvulsive therapy is only appropriate for patients with severe and/or 
psychotic depressions who have not responded to other treatment. 8 
1.2.4 Clinical Practice Guidelines for Antidepressant Therapy in Treating Major 
Depressive Disorder 
Clinical practice guidelines such as the Agency for Health Care Policy and Research 
(AHCPR) Depression Guideline Panel Report8 and American Psychiatric Association (APA) 
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Practice Guideline for the Treatment of Patients with Major Depressive Disorder9 have been 
developed to assist  patients and providers in the treatment of MDD. According to these 
guidelines, the overall aim of the treatment is the attainment of a stable, fully asymptomatic 
state and full restoration of psychosocial function (a remission). The treatment phases of 
MDD are outlined in Figure 1.1 and Table 1.2. 
Figure 1.1 Treatment Phases of Major Depressive Disorder 
  
 
Source: Kupfer DJ. Long-term treatment of depression. J Clin Psychiatrty 1991;52(Suppl 5):28-34. 
Once treatment is initiated, the severity of symptoms should decrease if patients 
respond to the treatment. It is recommended that an acute phase medication regimen lasting a 
minimum of 6-8 weeks should be completed in order to remove symptoms. The acute phase 
ends when patients achieve remission. If patients respond to medication during the acute 
phase, a continuation regimen for another 4 to 9 months with the same medication at the 
same dosage should be followed to prevent relapse. Patients who have had three or more 
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episodes of major depression are potential candidates for long-term maintenance 
antidepressant treatment.  
Table 1.2 Treatment Phases of Major Depressive Disorder 
 Acute Phase Continuation Phase Maintenance Phase 
Duration 6-12 weeks 4-9 months ≥ 1 year 
Aim removing all depressive 
symptoms 
preventing relapse1 preventing recurrence2 
1. Relapse: the symptoms return and are severe enough to meet the criteria for MDD within 6 months following remission. 
2. Recurrence: a new episode of MDD 
 
 Guidelines also suggest frequent outpatient follow-up visits in the acute phase in 
order to provide patient support, adjust dosage, and monitor side effects and clinical response. 
The AHCPR panel recommends that patients be seen every 10 to 14 days for the first 6 to 8 
weeks or more frequently with more severe depression.8 The APA also recommends that 
patients be seen on a weekly basis during the acute phase.9 There is no current 
recommendations on appropriate interval of visits specifically for continuation phase, but 
AHCPR panel suggests that visits every 4 to 12 weeks are reasonable once the depression has 
resolved. 
1.2.5 Quality of Antidepressant Treatment in Practice 
Routine management for depression still falls short of guideline recommendations. 
Only half to two thirds of patients with confirmed MDD receive any health care.1, 10 Among 
those seeking healthcare, only one fourth received appropriate treatment.1, 11 The National 
Committee on Quality Assurance (NCQA) assesses quality of care of healthcare 
organizations every year based on the Healthcare Effectiveness Data and Information Set 
(HEDIS) antidepressant medication management measures.36 According to NCQA’s 2004 
annual report, 11-20% of MDD patients receiving antidepressant treatment had optimal 
follow-up visits, 46-61% completed acute phase treatment, and 29-44% completed 
continuation phase treatment.37 Past empirical studies using similar HEDIS measures found 
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that 27%-62% of depression patients receiving treatment had optimal follow-up visits4, 6, 18, 
11%-65% completed acute phase treatment2-7, and 42%-44% completed continuation phase 
treatment.2, 6 In general, patients with MDD obtained suboptimal pharmacotherapy 
management and inconsistent follow-up visits.38 
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1.3 Previous Research 
Prior research in this area is reviewed below in two major sections. The first section 
describes the differences in care patterns between generalists and specialists. The second 
section summarizes: 1) studies examining the types of providers seen by patients with MDD; 
2) studies examining outpatient follow-up visits; 3) studies examining the factors associated 
with antidepressant treatment patterns; 4) studies investigating the association between 
provider specialty, antidepressant treatment patterns and healthcare utilization. 
1.3.1 Differences between Generalists and Specialists 
A body of literature comparing care patterns between generalists and specialists is 
accumulating. Despite the variety of specialty areas, the findings generally suggest that 
specialists are more knowledgeable about their area of expertise;39-41 they are more likely to 
use novel medications and technology;39, 41 they are more likely to comply with guidelines;41 
and they are more likely to use more resources.40, 41 Specialists, with advanced education and 
training, typically have a superior knowledge about specific clinical conditions than 
generalists. Specialists treat a narrower range of clinical problems, so they can focus on 
updating the technology and continuing education related to their therapeutic area. With 
greater exposure to the latest medical information in a particular therapeutic area, specialists 
adopt emerging technologies more aggressively than generalists. Specialists may have 
greater exposure of the guidelines via specialty training or professional activities, and the 
number of guidelines is typically smaller than general medicine. Specialists are qualified to 
perform many diagnostic and therapeutic procedures which may increase costs of care.  
The majority of studies comparing generalists to specialists have typically been based 
on observational study designs, which are subject to selection and patient case-mix 
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differences.39, 42 Studies favoring specialists were less likely to adequately address case-mix 
adjustment.42 In addition, many studies failed to address the characteristics of the physicians 
such as physician gender, years of practice, and patient volume.42 In this dissertation, we 
attempt to improve upon prior studies comparing depression care between primary care 
providers and psychiatrists by utilizing multivariable analyses with adjustment of 
comorbidities with application of propensity score matching. 
1.3.2 Literature Relevant to Specific Aims 
1.3.2.1 Aim 1: Types of Providers Seen by Patients with MDD 
 Research Aim 1 examines the patient characteristics in the choice of provider 
specialty to initiate antidepressant therapy for treatment of MDD. Three major sources have 
been used to identify provider specialty type in prior studies that examined depression care 
by provider specialty: 1) type of clinic or location of the initial visits, 2) type of provider seen 
during a visit, and 3) type of provider who wrote a prescription for an antidepressant. The 
following section describes each source in detail and reports their findings (Table 1.3). 
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Table 1.3 Summary of Studies Examining Provider Specialty 
Study Study 
population 
Sample 
size 
Data used to define 
provider specialty 
Care categories Significant differences in 
patient characteristics 
Akincigil, 
20072 
Commercially 
insured 2003-
2005 
4,312 Type of provider on initial 
visit 
Mental health professional; general medical care None examined 
Bambauer, 
200713 
Commercially 
insured 2002-
2004 
11,878 Initial prescribing 
provider from prescription 
drug claims 
Primary care physician (PCP), psychiatrist, physician 
with other specialty 
Age, gender, comorbidities, 
multiple prescribing provider, 
use of multiple antidepressant, 
antidepressant type 
Busch, 200443 VA 2000-2001 27,713 Type of clinic of initial 
visit 
MD in mental health clinic, MD in non-mental health 
clinic, non-MD in mental health clinic, non-MD in 
non-mental health clinic, missing 
None examined 
Charbonneau, 
20033 
VA 1999 12,678 Type of clinic of initial 
visit 
Primary care clinic only, primary care clinic and 
psychiatry clinic, psychiatry clinic only, and other 
clinical settings only. 
None examined 
Fairman, 
199815 
Commercially 
insured 1994-
1995 
3,101 Initial prescribing 
provider from prescription 
drug claims 
Non-specialist, psychiatrist, non-psychiatric 
specialist 
Age, gender, insurance type, 
previous totally monthly drug 
cost, chronic disease score 
Hylan, 199916 Commercially 
insured 1993-
1994 
1,034 Provider specialty of 
initial outpatient visit 
Family practitioner, other non-specialist health care 
clinicians, acute care clinic or other primary care 
setting, and psychiatrist 
None examined 
Jones, 20064 VA 1997-2005 2,178 Type of clinic of initial 
visit 
Inpatient, primary care, mental health and other 
outpatient 
None examined 
Robinson, 
20066 
Commercially 
insured 2001-
2004 
60,386 Billed contact coded with 
a psychiatrist, mental 
health and chemical 
dependency treatment 
facility, psychologist, or 
psychiatric nurse 
Received any mental health specialty care or not None examined 
Simon, 20017 Commercially 
insured 1994-
1996 
369 Prescribing provider from 
prescription drug claims 
PCP and psychiatrists Age, gender, emotional role, 
social function, physical 
function, physical role, prior 
specialty care 
Weilburg, 
200317 
Commercially 
insured 1996-
1999 
1,550 Prescribing provider from 
prescription drug claims 
PCP only , psychiatrists only, and other provider 
type only, PCP and psychiatrist, PCP and other, 
psychiatrist and other, PCP and psychiatrist and 
other 
None examined 
  15 
Type of clinic or location of the initial visit 
Three Veterans Administration (VA) studies used type of clinic or location code from 
service claims of the outpatient visits to identify provider type because specific provider 
codes were unavailable. Jones et al. used location of initial depression diagnosis (inpatient, 
primary care, mental health and other outpatient) as the definition of provider specialty.4  
They found that majority of their study population received care in a primary care outpatient 
clinic (65%), while 21.4% of patients were diagnosed in a mental health outpatient clinic. 
Busch et al. also used initial clinic type but with a more detailed categorization.43 They found 
49% of subjects were diagnosed by a medical doctor (MD) in a mental health clinic, 12% by 
a MD in a non-mental health clinic, 3% by a non-MD in a mental health clinic, and 6% by a 
non-MD in a non-mental health clinic. The provider variable was missing in 31% of subjects. 
Charbonneau and colleagues3 classified the type of clinic where care was provided during a 
three month profiling period into 4 categories: primary care clinic only, primary care clinic 
and psychiatry clinic, psychiatry clinic only, and other clinical settings only. They found 26% 
of patients went to a primary care clinic, 21% of patients went to a psychiatry clinic, and 
40% of patients went to both. None of these studies examined patient differences by provider 
specialty 
Location of diagnosis visit does not necessarily identify the type of provider a patient 
has seen because primary care clinics might receive collaborative support from psychiatrists 
during the visits. Therefore, this source might not truly identify the type of provider that truly 
managed patients’ antidepressant treatment. 
Type of provider seen during a visit 
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Three studies utilized provider specialty codes from service claims of outpatient visits 
to identify provider specialty. Robinson and colleagues used a dichotomous variable to 
indicate whether the patient received any mental health specialty care. 6 If patients had any 
billed contact coded with a psychiatrist, mental health and chemical dependency treatment 
facility, psychologist, or psychiatric nurse during the study period, they were characterized as 
receiving mental health specialty care which accounted for 13.8% of their study population. 
Hylan and colleagues16 categorized initial provider into family practitioner, other non-
specialist health care clinicians, acute care clinic or other primary care setting, and 
psychiatrist. They found 32% of patients had seen family practitioner as their initial provider, 
8% had seen a non-specialist health care clinician as their initial provider, 27% had been 
treated in other acute care clinic or other primary care setting, and 33% had seen a 
psychiatrist as their initial provider. Akincigail and colleagues went a step further to examine 
types of provider on initial visit and follow-up separately.2 Among the study population, 
50.5% of patients saw a general medical provider in an initial visit and 49.5% saw a mental 
health professional. They did find that 27.7% of patients had follow-up with a psychiatrist 
and 23.7% of patients with other mental health providers. None of these studies compared 
patient characteristics by provider specialty. The provider identified from outpatient visits 
may not accurately reflect the provider that managed antidepressant treatment if patients see 
different providers to obtain antidepressant prescriptions. 
Type of provider who wrote a prescription for an antidepressant  
Four studies identified provider based on provider specialty identified from 
prescription claims. Simon et al. dichotomized their patients as treated by primary care 
providers and psychiatrists.7 In their study, 55% of patients were initially treated by a 
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primary care provider, and 45% by a psychiatrist. They found that patients treated by 
psychiatrists were younger, more likely to be male, and more impaired in emotional role and 
social function. Fairman and colleagues categorized initial prescriber into non-specialist, 
psychiatrist, and non-psychiatric specialist.15 They found 41% of initial antidepressant 
prescriptions were written by non-specialists, 32% by non-psychiatrist specialists, and 13% 
by psychiatrists. They found patients initially prescribed an antidepressant by a psychiatrist 
were more likely to be younger, male, in an indemnity plan, have lower chronic disease score, 
and have lower previous monthly drug costs.15  
Bambauer and colleague defined initial prescriber into three categories: primary care 
physician, psychiatrist, and physician with other specialty.13 In their study population, 67% 
of patient’s antidepressant was initially prescribed by a primary care physician, 20% by a 
psychiatrist, and 13% by a non-psychiatric specialist. They found that patients treated by 
psychiatrists were more likely to be younger and male than patients treated by other 
physicians. Patients whose treatment was initiated by a non-psychiatric specialist were more 
likely to see more than one type of provider during the treatment episode, while patients 
treated by psychiatrists were more likely than other patients to use more than one type of 
antidepressant during the treatment episode.  
Weilburg and colleagues17 looked at more detailed provider combinations beyond the 
initial prescriber. Prescribing providers were assigned into three categories: primary care 
physicians, psychiatric specialists, and non-psychiatric specialists, resulting in seven different 
combinations of providers (Table 1.3). They found more patients with prescriptions written 
solely by psychiatric specialists (28%) than solely by primary care physicians (26%) or 
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solely from other provider types (18%). 28% of patients had prescriptions written by multiple 
types of providers. They did not examine patient differences by provider specialty. 
Several sources have been utilized to identify provider type. Only three studies 
examined the baseline characteristics between patients receiving care from different provider 
specialties.7, 13, 15 To isolate the provider effect, one must consider patient case-mix between 
generalists and specialists. The Medical Outcome Study (MOS) is an observational study of 
the differences in process and outcomes of care of patients from a wide range of plans.44 
Particularly, patients were screened with a depression case finding procedure which allows 
further analysis for differences of depressed patients receiving care from various payment 
settings and provider specialties.45 Among characteristics of depressed patients, sickness has 
the strongest effect on the probability of specialty care.46 Mental health specialists, especially 
psychiatrists, encountered more severely depressed patients.47 Patients of mental health 
specialists tend to have worse mental health and more limitations in social activities 
compared with patients of medical clinicians. On the other hand, patients of medical 
clinicians had worse physical functioning and worse health perceptions.48  
Most of the studies listed in Table 1.3 failed to examine patient differences among 
provider specialties. This dissertation extends the earlier work by identifying the provider 
specialty based on index antidepressant which we considered as a more reliable source of 
provider specialty because specialty information based on clinic or visit may not correctly 
identify the types of providers who managed antidepressant treatment if the visits provider 
did not prescribe an antidepressant or the clinic received collaborative support from different 
types of providers. In the present study, patient characteristics were examined by the 
following three distinct groups who received index antidepressant from: 1) a primary care 
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provider; 2) a psychiatrist; 3) a non-psychiatric specialist, which is comparable to the 
definitions used by Bambauer et al.13  
1.3.2.2 Aim 2: Outpatient Follow-up Visits 
This aim seeks to understand whether receipt of guideline-concordant outpatient 
follow-up visits during acute phase varies by initial prescriber specialty among patients with 
MDD treated with antidepressant. Five studies have examined the frequency of outpatient 
follow-up visits, and three included provider specialty as a predictor in their analysis (Table 
1.4). 4, 6, 7 
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Table 1.4 Summary of Studies for Completion of Outpatient Follow-up visits 
Study Study 
population 
Sample 
size 
Definition of adequate 
follow-up care 
Percentage 
population 
achieving 
adequate 
follow-up care 
Significant 
predictors of 
adequate follow-
up visits 
Charbonneau, 
20033 
VA 1999 12,678 at least 3 visits with a CPT 
code for 
psychotherapy/medication 
management, ICD-9 code 
for depression, or visits 
made to primary care or 
psychiatry clinics within 3 
months of the initial 
depression encounter 
62% Not measured 
Jones, 20064 VA 1997-
2005 
2,178 at least 3 visits to primary 
care or psychiatry clinics 
within 3 months of the 
initial depression encounter 
27% Increased 
medical and 
psychiatric 
comorbidity, and 
diagnosis in a 
non-primary care 
clinic 
Morrato, 
200849 
Commercially 
insured 1998-
2005 
193,151 At least 3 billable claims for 
contacts with a primary care 
or mental health practitioner 
coded with a mental health 
diagnosis during the 84 days 
following the new diagnosis 
and at least one of the three 
follow-up contacts must be 
with a prescribing 
practitioner (HEDIS) 
40% Not measured 
Robinson, 
20066 
Commercially 
insured 2001-
2004 
60,386 HEDIS 44% Comorbid 
anxiety, 
comorbid 
bipolar, non-
capitated 
insurance, any 
mental health 
specialty care, 
age 
Simon, 20017 Commercially 
insured 1994-
1996 
369 HEDIS 57% for 
patient treated 
by 
psychiatrists 
and 26% by 
PCP 
Initially treated 
by psychiatrists 
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Jones et al. and Charbonneau et al. investigated follow-up care for depression in a VA 
population based on the VA depression guidelines that define adequate follow-up care as at 
least 3 visits to primary care or psychiatry clinics within 3 months of the initial depression 
encounter.3, 4  Charbonneau and colleagues found that 62% of veterans received guideline-
concordant follow-up visits, but they did not assess whether receipt of guideline-concordant 
follow-up visits differ between patients initially treated in primary care and in mental health 
clinics. Jones and colleagues found that 27% of subjects received three or more visits within 
12 weeks and initial diagnosis in a mental health clinic was the most significant predictor of 
adequate follow-up care (OR=4.15, 95% CI: 2.86-6.01).4 
Robinson et al. used a definition of optimal practitioner contacts from the NCQA 
HEDIS measures6 which define optimal follow-up as at least 3 billable claims for contacts 
with a primary care or mental health practitioner coded with a mental health diagnosis during 
the 84 days following the new diagnosis and at least one of the three follow-up contacts must 
be with a prescribing practitioner, the same definition used in this dissertation. They found 
that 44.3% of depressed patients in commercially insured population had adequate follow-up 
care. Receipt of mental health specialty care was the most significant predictor of adequate 
follow-up care (OR=5.83, 95% CI: 5.62-6.06). Using the same HEDIS measure, Morrato et 
al. found that 40% of patient had adequate follow-up care.49 Simon et al. found that a 
significantly higher proportion of patients treated initially by psychiatrists had adequate 
follow-up care than patients treated initially by primary care (57% vs. 26%, p<0.01). 7  
Despite the difference in definitions, these five studies showed that the follow-up care 
for antidepressant users is suboptimal, but initial treatment by a mental health provider or in a 
mental health clinic was the most important factor associated with adequate follow-up care.  
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1.3.2.3 Aim 2: Antidepressant Treatment Patterns 
In recent years, ten studies have examined refill adherence patterns among 
antidepressant users. The following section describes the studies that include either mental 
health specialty care or follow-up visits as covariates in predicting antidepressant adherence 
(Table 1.5).  
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Table 1.5 Summary of Studies Examining Predictors of Antidepressant Adherence 
Study Study population Sample 
size 
Antidepressant use measure Identification 
of mental 
health 
specialty care 
Identification 
of optimal 
follow-up 
visits 
Other significant predictors of 
antidepressant adherence 
Akincigil, 
20072 
Commercially 
insured 2003-2005 
4,312 Acute phase adherent: MPR>=75% during first 16 
weeks after treatment initiation. Continuation phase 
adherent: MPR>=75% during week 17-33 
Y 
(significant) 
N  Older age, higher income, no 
headache or migraine, no 
CVD/diabetes, more number of 
medications excluding 
psychotropics, newer-generation 
antidepressant, no other substance 
abuse 
Whether patients filled their index antidepressant 
prescription (immediate non-adherence) 
Y 
(significant) 
N Initial antidepressant type Bambauer, 
200713 
Commercially 
insured 2002-2004 
11,878 
Less than 52 days without antidepressant treatment 
during the 180-day episode of treatment was considered 
adherence 
Y (not 
significant) 
N Older age, no prior use of pain 
medication, treatment by multiple 
providers, antidepressant type. 
Busch, 
200443 
VA 2000-2001 27,713 At least 84 days (acute treatment phase), and 180 days 
(continuation phase) during a 180 days follow up period 
Y (not 
significant) 
N Older age, women, married 
patients, higher income, comorbid 
mental health diagnosis 
Charbonneau
, 20033 
VA 1999 12,678 Refill adherence with MPR >79% during a fixed 3-
month calendar profiling period (June 1, 1999 to August 
31, 1999) was deemed adequate. The patient could be in 
acute, continuation, or maintenance phases. 
Y 
(significant) 
N White race, married 
Fairman, 
199815 
Commercially 
insured 1994-1995 
3,101 Termination of antidepressant treatment before or on 
first month 
Y (not 
significant) 
N Older age, female, newer-
generation antidepressant 
Hylan, 
199916 
Commercially 
insured 1993-1994 
1,034 Dichotomous. 1=had four or more prescriptions without 
switching or augmentation 
Y 
(significant) 
N Female, present of other mental 
diseases 
Jones, 20064 VA1997-2005 2,178 Refill adherence with MPR>=80% in 12 weeks was 
deemed adequate 
Y (not 
significant) 
Y  
(significant) 
Female, not married, higher 
number of medical or psychiatric 
comorbidities 
Robinson, 
20066 
Commercially 
insured 2001-2004 
60,386 Effective acute-phase treatment: at least 84 days of 
supply of antidepressant during the first 114 days. 
Effective continuation-phase treatment: at least 180 days 
of supply of antidepressant during the first 214 days. 
Y 
(significant) 
N Newer-generation antidepressant, 
older age, female, higher wage, 
less medical comorbidity, 
capitated insurance 
Simon, 
20017 
Commercially 
insured 1994-1996 
369 Received at least 90 days of continuous antidepressant 
treatment at a minimally  adequate dose  
Y (not 
significant) 
N - 
Weilburg, 
200317 
Commercially 
insured 1996-1999 
1,550 Treatment adequacy was defined with at least one trial 
of an average daily dosage of 20mg fluoxetine 
equivalents of a period of 90 days 
Y 
(significant) 
N Newer-generation antidepressant 
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Ten studies examined adherence patterns in four ways: 1) early termination, 2) 
prescription refill count during follow-up period, 3) adherence during a fixed calendar 
profiling period, and 4) adherence during guideline-concordant acute and continuation phases. 
Early termination 
 In a commercially insured population, Fairman et al.15 defined early termination of 
antidepressant if the length of therapy was less than 30 days. Receipt of an initial 
antidepressant prescription from a non-psychiatrist was associated with a 28% increase in the 
odds of one-month termination compared to receipt from a psychiatrist, even though it was 
marginally statistically significant (p=0.052).15 Bambauer and colleagues examined factors 
predicting whether patients ever filled their index antidepressant prescription (immediate 
non-adherence).13 They found that being treated by a psychiatrist was associated with 
significantly lower odds of immediate non-adherence (OR=0.7, 95%CI: 0.61-0.8), while 
being treated by physician with other specialty was associated with significantly higher odds 
(OR=1.39, 95%CI: 1.22-1.6) compared with patients treated by primary care physicians. 
Prescription refill count during follow-up period 
 Hylan et al. found that the odds of receiving four or more antidepressant prescription 
refills in six months after initial diagnosis were significantly lower for patient initially seen 
during an office visit by a family practitioner, in other non-specialist healthcare clinic, and 
other acute care clinic compared with patient initially seen by a psychiatrist.16 Their measure 
did not consider the actual days-of-supply with each refill record, and count of number of 
refills might not be able to precisely capture the actual consumption of antidepressant. A 
more stringent measure with consideration of days-of-supply and intervals between refills is 
necessary to more correctly measure the antidepressant adherence. 
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Adherence during a fixed calendar profiling period 
In a VA sample, Charbonneau et al. defined duration adequacy as antidepressant refill 
adherence with medication possession ratio (MPR) >75% during a fixed 3-month calendar 
profiling period (June 1, 1999 to August 31, 1999). Because the antidepressant treatment 
period was cross-sectional, the profiling period could have been in acute, continuation, or 
maintenance phases of the treatment depending on a patient’s index diagnosis date. They 
found that receipt of care exclusively from a primary care clinic significantly reduced the 
probability of adequate antidepressant duration (OR=0.84, 95% CI: 0.72-0.94).3  
Adherence during guideline-concordant acute/continuation phases 
Three studies investigated adherence with a guideline-concordant acute phase4, 7, 17, 
and four studies examined both acute and continuation phases.2, 6, 13, 43 In a VA sample, Jones 
et al. defined antidepressant duration adequacy in acute phase if refill adherence had an MPR 
greater or equal to 80% in the first 12 weeks.4 They found that adequate outpatient follow-up 
(three or more during acute phase) was associated with increased odds for duration adequacy 
of acute phase antidepressant therapy (OR=2.1, 95% CI: 1.54-2.88), but initial diagnosis 
from mental health clinic was non-significant. This study included both optimal follow-up 
and location of initial diagnosis as covariates in the model predicting duration adequacy in 
acute phase. Simon and colleagues found that the proportion of patients receiving 90 days of 
continuous antidepressant therapy at minimally adequate dose was similar between primary 
care patients and patients initially treated by psychiatrists and patients initially treated by 
primary care providers.7 Weilburg et al. defined treatment adequacy as at least one trial of an 
average daily dosage of 20mg fluoxetine equivalents of a period of 90 days.17 Compared with 
patients receiving antidepressant prescriptions from primary care providers exclusively, they 
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found that the patients being cared by the following combination of providers were more 
likely to have adequate antidepressant treatment: primary care and other types of providers 
(OR=2.33, 95% CI: 1.56-3.48), psychiatrist exclusively (OR=2.64, 95% CI: 1.97-3.55), 
primary care and psychiatrist (OR=3.29, 95% CI: 1.99-5.51), psychiatrist and other type of 
providers (OR=5.04, 95% CI: 3.29-7.81), and primary care, psychiatrist, and other type of 
providers (OR=5.13, 95% CI: 2.86-9.61).  
Busch et al., Bambauer et al., Akincigil et al, and. Robinson et al. conducted 
retrospective studies using HEDIS measures to define adherence in acute and continuation 
phases, which are most closely concordant with guideline recommendations.2, 6, 13, 43 Busch et 
al. examined whether veterans remained on antidepressant treatment for at least 84 days 
(acute treatment phase) and 180 days (continuation phase).43 They found that antidepressant 
adherence did not differ between patients treated in a mental health clinic and patients treated 
in a non-mental health clinic. Bambauer et al defined adherence as having less than 52 days 
without antidepressant treatment during the 180-day episode of treatment.13 They found that 
being initially prescribed by physicians with other specialty was associated with an increased 
risk of non-adherence (OR=1.4, 95% CI: 1.24-1.59) compared with patients treated by 
primary care physicians, but no differences were found between primary care physicians and 
psychiatrists. In addition, treatment by multiple providers was associated with lower odds of 
non-adherence (OR=0.83, 95% CI: 0.75-0.92). Akincigil et al. defined acute phase adherence 
as refill adherence with an MPR ≥ 75% during first 16 weeks after treatment initiation.2 
Among patients who were adherent in acute phase, continuation phase adherence was 
defined as refill adherence with an MPR ≥ 75% from 17th to 33rd week. They found that 
initial provider type was not significant in predicting adherence, but follow-up with a 
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psychiatrist was associated with higher odds of adherence in both the acute (OR=1.19, 95% 
CI: 1.03-1.38) and continuation phases (OR= 1.25, 95% CI: 1.02-1.53). Robinson et al. 
defined effective acute phase treatment as at least 84 days-of-supply of antidepressant during 
the first 114 days following initiation of the index antidepressant, and effective continuation 
phase treatment as at least 180 days-of-supply of antidepressant during the first 214 days 
following initiation of the index medication.6 They found that receipt of any mental health 
specialty care by a psychiatrist, mental health and chemical dependency treatment facility, 
psychologist, or psychiatric nurse significantly increased the odds of adherence in both the 
acute (OR=1.38, 95% CI: 1.33-1.43) and continuation phases (OR=1.46, 95% CI: 1.41-1.51). 
In summary, five out of ten studies showed that patients with some form of contact 
with mental health specialists had better antidepressant adherence (Table 1.5). Several 
approaches have been used to evaluate antidepressant adherence. Studies using early 
termination might preclude inference beyond treatment initiation and measure based on 
prescription count is less precise without considering the days-of supply of each refill as well 
as the intervals between refills. Use of antidepressants can be more precisely estimated if the 
patients are followed when they initiate antidepressant treatment. The definition of provider 
specialty varied widely across prior studies. As discussed in 1.3.2.1, this dissertation used 
provider specialty based on index antidepressant as the source of information which gives a 
closer link to the actual provider who prescribed, and most likely, managed a patient’s 
antidepressant therapy. In addition, only one study included both mental health specialty care 
and follow-up visits as covariates in the regression model predicting antidepressant 
adherence in a VA sample.4 This dissertation contributes to the literature by measuring 
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provider effect with control over receipt of guideline-concordant outpatient follow-up visits 
during acute phase in a non-VA sample. 
1.3.2.4 Aim 3: Provider Specialty, Antidepressant Treatment and Healthcare Utilization 
Aim 3 of this dissertation examined whether provider specialty and completion of 
antidepressant treatment are associated with differences in subsequent healthcare utilization. 
The next section describes the prior research in this area.  
Prior literature suggests that specialists tend to use more resources than generalists.40, 
41
 Literature specifically examining differences for provider specialty in utilization for mental 
health illness is scarce. It was found that patients treated in the mental health specialty sector 
had higher expenditures and hypothesized that it was due to a combination of longer episodes 
and more intensive treatment. 6, 50, 51 Only one study conducted by Sewitch et al. based on a 
Canadian population used all-cause hospitalization as an outcome and they found that being 
diagnosed by a psychiatrist significantly increased the odds of hospitalization (OR=2.76, 
95% CI=1.62-4.68)19 (Table 1.6). This dissertation adds to the literature by examining this 
association in the U.S. population. 
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Table 1.6 Summary of Studies Examining Provider Specialty, Antidepressant Treatment Patterns and Future Healthcare Utilization 
Study Study 
population 
Sample 
size 
Main healthcare 
utilization 
outcome 
Provider 
Specialty 
Antidepressant use 
measure 
Major findings Other predictors of  
healthcare utilization 
All-cause hospitalization: 
older age, black race, prior 
hospitalization, higher 
comorbidity index, 
alcoholism 
Charbonneau, 
200418 
VA 1999 12,678 All-cause and 
psychiatric 
hospitalization 
None Refill adherence with 
MPR >79% during a 
fixed 3-month calendar 
profiling period (June 
1, 1999 to August 31, 
1999) was deemed 
adequate 
Adequate duration of 
antidepressant therapy 
significantly reduced the 
risk of psychiatric 
hospitalization, but it was 
marginally significant in 
risk of all-cause 
hospitalization (p=0.05) 
Psychiatric hospitalization: 
younger age, male, black 
race, not married, prior 
hospitalization, lower 
comorbidity index, 
alcoholism, PTSD 
Sheffield, 
200320 
Commerci
ally 
insured 
1996-
1997 
566 Depression-
related 
hospitalization 
None 1) switching and 
augmentation if 
received another 
antidepressant in place 
of or in addition to the 
index drug during 12-
month period, 2) 
discontinuation if 
patients had less than 
120 days of continuous 
index therapy, 3) stable 
if had at least 120 days 
of continuous index 
therapy 
Switching/augmentation 
was associated with 
increased risk of 
depression-related 
hospitalization compare to 
stable group. No 
difference was found 
between discontinuation 
and stable group. 
prior outpatient visits 
ER: male, personality 
disorder, substance 
dependence, insurance 
type 
Sewitch, 
200719 
Canadian 
public 
insured 
2000-
2001 
2,047 All-cause 
emergency room 
visits and all-
cause 
hospitalization 
Initial 
diagnosis by 
primary care 
provider or 
psychiatrists 
Minimum supply of 
150 days’ worth 
medication in a 180 
days period 
Adequate duration of 
antidepressant treatment 
was not associated with 
risk of emergency room 
visits or hospitalization. 
Initial diagnosis by 
psychiatrists increased the 
likelihood of all-cause 
hospitalization 
hospitalization: age, 
comorbidity, personality 
disorder, substance 
dependence 
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There are three studies identified that examined the association between 
antidepressant treatment and subsequent hospitalization and/or emergency room visits (Table 
1.6). Sheffield and colleagues examined how differences in antidepressant usage patterns 
affect the risk of depression-related hospitalization among persons taking three selective 
serotonin reuptake inhibitors (SSRI) for their depression.20 They categorized the usage 
patterns into three groups: switch/augmentation, discontinuation, and stable. They found that 
patients whose therapy was switched or augmented were 3.17 (95% CI: 1.26-7.99) times 
more likely to require hospitalization related to their depression than those patients whose 
therapy was stable. Their study was limited to three SSRI agents, which reduced the 
generalizability of the results. In a VA sample, Charbonneau and colleagues found that 
adequate antidepressant duration was associated with lower risk of psychiatric hospitalization 
(OR=0.82, 95% CI: 0.69-0.96), and the change in risk of all-cause hospitalization was 
marginally significant (OR=0.9, 95% CI=0.81-1.0).18 Sewitch et al. found that duration 
adequacy (150 days-of-supply antidepressants during a 180-days period) was not associated 
with risk of emergency room visit or hospitalization during 1-year follow up period in a 
Canadian public insured population.19  
Charbonneau et al has found a protective effect of adequate use of antidepressant over 
risk of psychiatric hospitalization among veterans18, and it is necessary to generalize the 
results to other population. The dissertation achieves this goal by incorporating guideline-
concordant antidepressant treatment patterns measurement with inclusion of wide selection 
of antidepressant agents in a more generalized population.  
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1.4 Significance 
Untreated or under-treated MDD may lead to a substantial burden to patients, 
healthcare systems, and society. This dissertation seeks to provide a comprehensive picture 
of the care that MDD patients received in a managed care setting.  
Aim 1 describes the differences among patient initially prescribed an antidepressant 
by different types of providers. Before examination of how patients taking antidepressants to 
treat MDD are managed differently between primary care setting and mental health specialty 
care setting, it is an important first step to understand whether patients are systematically 
different between these two settings. This knowledge leads us to correctly measure the 
provider effect related to outcomes in Aim 2 and Aim 3.  
Aim 2 investigates whether receipt of guideline-concordant outpatient follow-up 
visits during acute phase varies by provider specialty. Empirical studies showed that the 
follow-up care for antidepressant users is still suboptimal in real-world settings, and it is 
important to understand what factors are associated with receipt of guideline-concordant 
follow-up visits. Investigation over patient characteristics may help identify the population 
who may under the risk of less frequent follow-up. This knowledge can aid clinicians to pay 
more attention when they encounter these vulnerable patients in their practice, and assist 
policymakers to develop organizational strategies to target the population who might 
experience poor follow-up. It is also important to identify modifiable factors, such as access 
to care and burden of out-of-pocket copayment, where the intervention is plausible. In 
particular, we examined provider differences in this dissertation. Several studies has shown 
mental health specialty contact increased the likelihood of more frequent follow-up.4, 6 This 
dissertation improves upon by identifying provider specialty based on prescription claims. 
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We consider this source more accurately represent the actual provider specialty since it is the 
provider who wrote the prescription and is likely to educate and continue to monitor patient’s 
antidepressant treatment. By examination of level of guideline-concordance for managing 
antidepressant treatment by provider specialty, the findings can support and justify where the 
quality improvement for depression care is needed.  
Aim 2 also examines whether provider specialty and other factors are associated with 
antidepressant completion. In addition to the aforementioned significance for follow-up visits 
model which is applicable to antidepressant completion model, this dissertation also attempt 
to link the association between guideline-concordant follow-up visits and completion of 
antidepressant treatment phases. Only one study has examined the association between 
completion of follow-up visits and antidepressant acute phase completion4, and this 
relationship has not been examined in a general population. Findings from this aim will 
provide empirical evidence of the significance of follow-up care by investigating how it 
quantitatively reinforce patient’s adherence to antidepressant treatment. The promotion of 
follow-up care for depressed patients could have a more solid ground if positive outcome in 
treatment adherence can be expected. This dissertation improves upon prior studies by 
controlling for provider specialty and guideline-concordant follow-up visits simultaneously 
in a general population of commercially insured patients because leaving out one of the 
variables may result in bias if their effects on antidepressant treatment completion are not 
independent.  
Linking provider specialty, antidepressant treatment patterns to economic outcomes 
in Aim 3 is critical. Economic outcomes, such as emergency room visits and hospitalization, 
have not been widely examined for patients with MDD receiving antidepressant treatment. 
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These events, although rare, takes up large healthcare costs and also implies worse health of 
the patients. While resources are limited for quality improvement, it is crucial to understand 
where the cost saving might be in order to allocate the resources efficiently. In particular, if 
the cost offset effects of antidepressant therapy in concordant to guideline-recommended 
duration can be found, we will be able to justify the increase in expenditures associated with 
prolong antidepressant treatment.  
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1.5 Summary 
This dissertation adds to the literature by carefully examining the relationship 
between provider specialty, guideline-concordant elements of antidepressant treatment 
(completion of follow-up visits, acute phase, and continuation phase), and subsequent 
healthcare utilization. The large sample size of privately insured subjects from a large 
national plan across the United States increases the generalizability of the results to a 
privately insured population. While antidepressant treatment remains suboptimal in the real 
world, the findings from this dissertation will provide valuable information by identifying the 
types of provider whose practice fell short of guideline recommendations. With further 
understanding of factors associated with guideline-concordant treatment completion and 
subsequent healthcare utilization, the knowledge gained from this dissertation will provide 
empirical evidence to support quality improvement and justify resource allocation to improve 
quality of care for depression. 
CHAPTER II 
CONCEPTUAL FRAMEWORK 
A conceptual framework is needed to provide context for the specific aims. The 
conceptual framework of the dissertation is based on Andersen’s Behavioral Model and the 
Chronic Care Model (CCM). Andersen’s Behavioral Model and the CCM each contain parts 
of the relationships that this dissertation intends to examine. Therefore, a new conceptual 
framework is necessary to bring every aspect of the dissertation into a whole picture. Both 
models contribute to the framework in identifying the relationships among patient, provider, 
and health system variables.
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2.1 Theoretical Models 
This section describes original theoretical models that were adapted in my conceptual 
framework. 
2.1.1 Andersen’s Behavioral Model 
Andersen’s Behavioral Model (Figure 2.1) was developed in the 1960s to understand 
why families use health services, and to define, measure, and promote equitable access to 
healthcare.52 It was revised in 1995 to incorporate the external environment as an important 
input for health services and added health outcomes into the model.53 Patient characteristics 
include predisposing, enabling, and need factors. Predisposing factors include demographic 
variables (age, gender, and race), socioeconomic variables (education, occupation, and 
ethnicity), and health beliefs (attitudes, values and knowledge toward health). These 
variables exist regardless of whether or not a person uses health services. Enabling factor 
are community resources (health personnel and facilities) and personal resources (income, 
health insurance) for the use of health services. Enabling factors are considered the most 
mutable among the three components, and mutability is an important concept in the model 
because it suggests an opportunity for behavioral change through policies. Need variables 
include self-perceived needs due to health beliefs, and evaluated needs made by healthcare 
professionals. They are often the most immediate causes of health service use according to 
Andersen’s Behavioral Model.53  
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Figure 2.1 Andersen’s Behavioral Model 
 
Source: Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc 
Behav 1995;36:1-10 
 
2.1.2 Chronic Care Model 
The Chronic Care Model (CCM), developed by Wagner and colleagues during the 
1990s, is a model for quality improvement and service redesign.54 The model emphasizes 
important interlinked areas of organization to improve care of patients with long term and 
chronic conditions (Figure 2.2). The elements that involve the community and health system 
are: self management support, delivery system design, decision support, and clinical 
information systems. The model highlights the importance of evidenced-based guidelines to 
inform planned care.55 The model emphasizes productive interactions between informed 
patients and prepared providers resulting in improved outcomes.  
Medical practices have long been designed to respond to the acute and urgent needs 
of the patients, particularly in primary care. In the United States, chronic illnesses account for 
a large portion of healthcare expenditures,56 but the traditional systems of care do not serve 
the needs of patients with chronic illness well.57 The management of healthcare delivery has 
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undergone substantial reform in recent decades, and systematic reviews have demonstrated 
that implementing components of the model is associated with significant improved 
outcomes in patients with chronic diseases such as diabetes mellitus, asthma, depression, and 
congestive heart failure.58, 59 In particular, many studies have identified this model as a guide 
to improve quality of care for treatment of depression.60, 61 
Figure 2.2 Chronic Care Model 
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2.2 Conceptual Framework 
The conceptual framework for the dissertation, which integrates Andersen’s 
Behavioral Model and the CCM, is presented in Figure 2.3. Andersen’s Model provides a 
framework to link patient characteristics and outcomes of interest, which informs patient 
demand for depression care. In addition, it is crucial to control for patient case-mix and other 
patient factors to isolate the impact of provider specialty on patient outcomes. The inclusion 
of patient characteristics can also help identify the population that is vulnerable to poor 
outcomes.  
Even though the purpose of the CCM is to guide practice re-design to improve 
outcomes among chronically ill patients and this dissertation did not evaluate any 
intervention for the study population, this model still provides a context for the specific aims 
examined. The CCM contributes to the conceptual framework by acknowledging the 
importance of the healthcare system in influencing provider behavior, which informs supply 
differences in provider of depression care. Healthcare systems are the context where the care 
is provided, and healthcare providers are direct personnel to deliver the care to patients.  
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Figure 2.3 Conceptual Framework for the Dissertation 
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2.2.1 Synthesis of the Conceptual Framework 
This section describes the synthesis of the conceptual framework of this dissertation 
based on the Andersen’s Behavioral Model and the CCM in detail (Figure 2.3). The 
management of depression for these patients occurred under the context of the healthcare 
system with consideration of characteristics of supply side (provider) and demand side 
(patient). Once a diagnosis of MDD is made, the decision to initiate antidepressant therapy is 
determined by patients and providers. This dissertation focuses on the cohort of MDD 
patients who initiated antidepressant treatment. Patient characteristics were examined among 
initial prescriber specialties to evaluate confounders for provider effect (Aim 1). It was 
hypothesized that patients initially prescribed an antidepressant by psychiatrists have greater 
mental health morbidity, and patients initially prescribed an antidepressant by non-
psychiatric specialists have greater physical sickness than patients initially prescribed an 
antidepressant by primary care providers (PCPs), based on the Andersen’s Behavioral Model 
which suggests need factors are the immediate causes for healthcare utilization. 
Patient characteristics are hypothesized to predict follow-up visits, completion of 
acute and continuation antidepressant phases which are types of health behaviors according 
to Andersen’s Behavioral Model. The CCM suggests that productive interactions could be 
simulated via community or health system changes derived by evidence-based guidelines, 
and this concept is relevant to this dissertation that intends to examine guideline components 
of antidepressant treatment for depression.55 In this dissertation, it is hypothesized that 
patients initially prescribed an antidepressant by psychiatrists are more likely to complete 
follow-up visits, complete acute phase treatment, and complete continuation phase treatment  
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because psychiatrists are more knowledgeable and to have greater exposure of depression 
guidelines because of training and practicing environment (Aim 2). 
The importance of follow-up has been acknowledged in clinical guidelines by a panel 
of experts because patients should be carefully monitored in follow-up visits to assess the 
response of the treatment and the emergence of side effects.8, 9 Visits should be frequent 
enough to promote treatment adherence, and to reduce communication gaps between patients 
and treating physicians about the expected antidepressant therapy duration.62 Hence, frequent 
follow-up visits may provide opportunities for patient-provider interactions to reinforce 
expected duration of antidepressant treatment, aligned to the concepts in CCM. If the 
communication gap was partially due to patients’ failure to remember specific information 
communicated to them, frequent follow-up could subsequently influence antidepressant 
adherence. It is hypothesized that patients who received guideline-concordant follow-up 
visits are more likely to complete antidepressant acute and continuation phase than patients 
who did not receive guideline-concordant follow-up visits (Aim 2). 
Although unobservable, it is assumed that guideline-concordant care will result in 
better mental health status of the study population and less health care use. According to 
Andersen’s Behavioral Model, patient outcomes can subsequently affect healthcare 
utilization (Figure 2.1). Patients who complete antidepressant phases are expected to achieve 
remission or have their depression symptoms under control, which results in better mental 
health status. This might directly influence the possibility for future health utilization such as 
mental health-related hospitalization. Uncontrolled depression might also indirectly influence 
the risk for hospitalization for other medical conditions. Therefore, it is hypothesized that 
patients with desired antidepressant treatment (defined by completion of phases) as suggested 
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by guidelines will be less likely to have all-cause hospitalization/emergency room visits and 
mental health-related hospitalization/emergency room visits compared to those who do not 
complete (Aim 3).  
The direction of provider effect on hospitalization and emergency room is less 
obvious. Patients treated by psychiatrists might be less likely to suffer from those events due 
to more guideline-concordant treatment based on the CCM model. If patient characteristics 
are not perfectly adjusted for in the model, higher risk of those events among patients treated 
by psychiatrists may partially represent patient effects according to the Andersen’s 
Behavioral Model (Aim 3).   
2.2.2 Analytical Model Formulation and Competing Hypothesis  
The conceptual framework also guides the dissertation in building the analytical 
models. It is also important to formulate the possible mechanisms that could explain the 
variations in outcomes related to provider specialty and identify potential confounding 
effects.  
2.2.2.1 Provider Specialty  
This dissertation seeks to understand how provider specialty influences receipt of 
guideline-concordant follow-up visits, antidepressant treatment phase completion, and 
subsequent healthcare utilization. The analytical models might only be able to present 
whether there is any association, but not why such difference occurs. It is important to lay out 
and conceptualize the potential competing hypotheses explaining why provider specialty may 
impact these outcomes. Several differences between primary care providers and psychiatrists 
observed in prior literature are attitudes toward depression, knowledge about treatment and 
guidelines, and competing demand. 
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Attitudes toward depression. Previous studies have shown that psychiatrists tend to 
have more favorable attitudes to acknowledge that depression is treatable than PCPs.63 In 
addition, it was found that PCPs are less comfortable in dealing with patients with depression 
and found the work harder and less rewarding than psychiatrists.64 Such difference in 
attitudes might influence providers’ willingness to continuously treat depression. If attitudes 
toward depression differ between psychiatrists and PCPs as suggested from the literature, we 
may expect to see that patients seen by psychiatrists are more likely to receive guideline-
concordant follow-up visits and to complete antidepressant treatment compared to those seen 
by PCPs.  
Knowledge about treatment and guidelines. Previous studies have shown that providers 
with formal qualifications for mental health training were less likely to identify incomplete 
knowledge about assessment and treatment of depression as a barrier.65 Being more 
knowledgeable about efficacy and side effects of antidepressants and more adaptive toward 
newer agents or approaches may lead to better follow-up care and antidepressant adherence 
of patients treated by mental health specialists. The CCM also suggests practice based on 
evidence-based guidelines could simulate productive interactions between patients and 
providers. Certain barriers for primary care providers to adhere to the treatment guideline are 
lack of awareness and familiarity.66 A study showed that only 33.6% of family physicians 
were aware of the existence of the AHCPR depression guideline one year after its release, 
and those who were aware were more likely to treat depression and believed they had more 
knowledge about the treatment.67 Although we were not able to directly measure the 
awareness of the guidelines or knowledge toward treatment, we were able to know how 
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different types of providers perform differently in treating depression by including a 
guideline-concordant measure of treatment. 
Competing demands For most patients, generalists are the first point of contact with the 
health care system as primary care providers. The Institute of Medicine designates primary 
care by four major attributes including accessibility, communication, coordination, and 
comprehensiveness.68 Hence, generalists usually see more patients and confront a greater 
variety of illnesses,69, 70 and face more competing demands for other medical conditions that 
need to be managed during their visit with patients compared with mental health specialists.71  
This might reduce the time available to educate or communicate with patients about their 
antidepressant treatment, which may result in poor adherence and reduce the chance for 
follow-up visits. 
 In summary, while the higher competing demands that PCPs face is mostly due to the 
fundamental role as first-line care providers, attitudes toward depression and knowledge 
about treatment and guidelines are factors more related to difference in training between 
PCPs and psychiatrists. All the hypotheses listed above lean toward a positive association 
between psychiatrists and receipt of guideline-concordant follow-up visits and antidepressant 
treatment completion. 
2.2.2.2 Patient Characteristics 
 In order to correctly model the association of provider specialty, patient 
characteristics based upon Andersen’s Behavioral Model need to be included. Predisposing 
variables available in the data include age, gender, and region of residence. Some studies 
found age and gender of patients varied by provider specialties,13, 15 and several studies found 
that female gender, and older age of patients were associated with better antidepressant 
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adherence.2, 4, 6, 13, 15, 16, 43 However, other predisposing factors which might be predictors in 
the conceptual framework including race3, attitudes72, and stigma73 are not available.  
Examples of need factors observed in the data include comorbidities and other mental 
health conditions. Evidence from the literature showed that patients seen by psychiatrists had 
more mental health comorbidities, while patients seen by primary care providers had more of 
other chronic comorbidities.13, 15 Poor psychological health increases the probability of 
obtaining care from a mental-health specialist and poor physical health increases the 
probability of obtaining care from a general medical provider.46 Comorbidities may be a 
burden on adherence because of polypharmacy or stress related to other disease. In addition, 
comorbidities may compete for the limited healthcare resources that patients have and reduce 
the possibility to have follow-up visits for depression. Previous studies found that other 
mental health conditions were associated with antidepressant adherence.2, 16, 43, 74 In order to 
accurately estimate the provider effect, case-mix adjustment is crucial. However, depression 
severity which is the major need factor for our study population is unobservable. 
Enabling factors play an important role in determining whether a patient has access to 
care or medications. The population this dissertation examined is commercially insured, and 
is homogenous in terms of having health insurance. Unfortunately, there is no information on 
individual’s income or education. Proxies of income and education were created based on 
individual’s state of residence. 
Examination of differences in patient characteristics between those who seek care from 
PCPs and psychiatrists is an important first step in determining how unobservable patient 
characteristics might confound provider effects. There are several competing hypotheses at 
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the patient level that arise from Andersen’s Behavioral Model. These possible patient factors 
are: perceived stigma, attitudes toward treatment for depression, and depression severity.  
 Perceived stigma toward depression. Perceived social barriers may be important 
obstacles for adherence to pharmacologic treatment, particularly for mental health diseases.  
In Andersen’s Behavioral Model, perceived stigma is a predisposing health belief variable. 
Lower perceived stigma has been found to be associated with better antidepressant 
adherence.73 If patients seek different providers based on their perceived stigma, it is likely 
that PCPs will see patients with more perceived stigma compared with mental health 
specialists. Receiving care from mental health specialists could be labeled as having mental 
health issues, so patients with higher perceived stigma might be more reluctant to seek help 
from them. In such a case, the effect of mental health specialists on patients’ antidepressant 
adherence might be partially explained by differences in patients’ perceived stigma. Similarly, 
patients seen by PCPs might be less likely to make follow-up appointment partially because 
they are uncertain that depression is a legitimate reason for seeing the doctor due to higher 
perceived stigma.75 
Attitudes toward treatment for depression. Attitudes toward depression treatment are 
also a predisposing health belief variable based on Andersen’s Behavioral Model. A study 
showed that  individuals who strongly endorsed specific concerns about antidepressants were 
reported to have poorer adherence to medication.76, 77  Compared with mental health 
specialist patients, the primary care patients had lower perceived need for care and lower 
levels of acceptability of evidence-based treatments for depression in a previous study.72 
Patients may be more likely to seek care from the type of provider who will confirm their 
belief systems and subsequently reject information offered by the physicians that contradict 
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their beliefs. Such differences may influence whether patients are willing to initiate the 
treatment as well as whether to continue. Hence, the effect of provider specialty on patients’ 
follow-up visits or antidepressant adherence might be partially explained by patients’ own 
motivation to comply. 
Depression severity. Depression severity is a need variable based on Andersen’s 
Behavioral Model. Higher self-rated severity of illness has shown to be associated with better 
adherence to recommended medication regimen among patients with depression.73 Even 
though it is reasonable to assume that mental health specialists are more likely to see or be 
referred more severe or complicated cases, it is unclear whether the ability to adhere will be 
compromised by self perceived or actual depression severity. If depression severity affects 
both provider choice and outcomes examined, not being able to control for it will introduce 
bias of the provider effects.  
 Among the patient factors that might be relevant to the study analyses, unobserved 
depression severity is traditionally the concern for secondary data analyses. Furthermore, the 
direction of its effect on follow-up visits and antidepressant adherence remains unclear. 
Perceived stigma and attitude toward treatment for depression are hypothesized to confound 
the provider effect. In other words, the observed effect of receiving care from mental health 
specialists on follow-up visits and antidepressant adherence in the literature may be due to 
patients’ self-selection. However, perceived stigma, attitude toward treatment for depression 
and depression severity are unobserved in our data. 
2.2.2.3 Health Plan Characteristics 
Health insurance plan types and insurance policies may influence access to specialty 
care medications. Based on the CCM, changes at the organizational level may also have 
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impact on patient-provider interactions. In the Medical Outcomes Study, it was found that 
depressed patients in pre-paid plans are significantly less like to see a psychiatrist than 
patients in fee-for-service plans, and the average patient-provider relationship is significantly 
shorter in pre-paid plans.46 Our data do not have individual insurance plan designs such as 
Preferred Provider Organization or Health Maintenance Organization (HMO). The latter plan 
usually requires gate-keeping to limit access to specialty care. We could only aggregate 
claims level data to create some indicators of health insurance plan characteristics. In our 
model, we included a proxy for initial provider reimbursed on a capitated basis. 
Reimbursement based on capitation may influence provider’s incentive to schedule follow-up. 
We also do not have information on individual benefit structure such as premium, co-
insurance, and copayment. In this dissertation, we used the out-of-pocket copayment 
recorded on the service claims for primary care provider visits and initial antidepressant 
prescription drug copayment to as proxies for burden to care.  
2.2.2.4 Antidepressant Characteristics 
Second-generation antidepressants examined in this dissertation have similar efficacy 
in the treatment for MDD 78, but individuals may still experience differences in side effects 
or adverse events. Initial antidepressants were included in the statistical models to control for 
this aspect. Complex regimen could also impose burden for patients to adhere to 
antidepressants.79  Number of pills for daily doses was controlled for such difference between 
antidepressants.  
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2.3 Summary 
Andersen’s Behavioral Model incorporates the outcomes of interests and identifies 
the patient factors that impact the outcomes examined in this dissertation. Controlling for 
these patient-level potential confounders or modifiers is crucial in isolating the true provider 
effects. The CCM provides a context of management for depression where characteristics of 
healthcare system and provider are supply side factors that explain variation in outcomes.  
Laying out the differences in patient and provider characteristics from previous 
literature also helps understand the potential direction of biases due to unobservable variables, 
which is important to interpret the results of this dissertation. In addition, outlining the 
potential reasons for outcomes variation will support interpretation of results and serve as a 
bridge that leads to future research. 
CHAPTER III 
METHODS 
This chapter discusses the data and the sample selection for the dissertation (Section 
3.1). Variables are described (Section 3.2) and statistical models and power analyses for each 
aim are presented (Section 3.3, 3.4). Sensitivity analysis (Section 3.5), statistical issues 
(Section 3.6), and limitations (Section 3.7) are discussed.
  52 
3.1 Data Source 
The data for this study originated from a large national health plan affiliated with i3 
Innovus with working-age adults and their dependents. The underlying population is 
geographically diverse across the United States. The data are from January 1, 2000 to 
December 31, 2004, and organized as four files: member enrollment, service claims, facility 
claims, and prescription claims. Files can be linked by encrypted patient identifier. Details of 
variables included in each file are listed in Appendix 2. 
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3.2 Study Design and Sample 
This study was conducted using a retrospective cohort design. The advantages of a 
retrospective cohort study include being much less costly than other types of study designs 
(e.g. randomized controlled trial), enabling large sample sizes, and no need to wait for 
outcomes to occur like prospective cohort studies. Because retrospective cohort studies rely 
on existing records, some information might be unavailable or otherwise un-collectible.80 In 
addition, causal inference depends on strength of design. 
To be included in this sample, patients had to meet the following inclusion criteria: 1) 
they were diagnosed with major depressive disorder (MDD) single episode between July 1, 
2000 and December 31, 2002 using the ICD-9-CM (the International Classification of 
Diseases, 9th revision, Clinical Modification) diagnosis code of 296.20-296.24 in any 
diagnosis field; 2) they had to have been  continuously enrolled for at least 6 months prior to 
index diagnosis to control for pre-diagnosis characteristics; 3) they had to have been 
continuously enrolled for at least 2 years after index diagnosis so there was enough follow-up 
time to observe the outcomes of interests; and 4) they filled a second-generation 
antidepressant prescription claim within 45 days of the index diagnosis. The timeframe for 
the cohort and the pre-period and follow-up for a typical subject are listed in Figure 3.1.  
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Figure 3.1 Follow-up Design 
 
These four inclusion criteria yielded a sample of 8,570 subjects (Figure 3.2). Several 
exclusion criteria were applied to obtain the final sample used in this dissertation. Patients 
under 18 years old were excluded (n=1,474) because antidepressant management for children 
and adolescents is different from adults. Individuals were excluded from the analysis if they 
had an ICD-9 diagnosis code of bipolar disorder or schizophrenia (295.xx, 296.0x, 296.4x, 
296.5x, 296.7X, 296.89, 296.80) because these mental health conditions might compromise 
their ability to take medication (n=533). To ensure that patients were newly started on the 
current course of antidepressant treatment (naïve users), patients could not have received an 
antidepressant prescription in the 6-month pre-index period (n=1,132). This new-user design 
eliminated prevalent user bias by restricting study population to persons under observation at 
the start of current course of treatment.81  
2001 2002 2003 2004 2000 
July 1, 2000 December 31, 2002 
Index diagnosis screening period 
   
6 months pre-index  2 years follow-up  
Index date 
Sample Subject 
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 We restricted the sample further to enrollees taking the following second generation 
antidepressants: bupropion, citalopram, escitalopram, fluoxetine, mirtazapine, paroxetine, 
sertraline, and venlafaxine, which were commonly prescribed in this sample and have better 
safety profiles than first-generation antidepressants. Patients prescribed trazodone, 
fluvoxamine, nefazodone, and a specific formulation of fluoxetine (Sarafem®, Warner 
Chilcott, Rockaway, NJ) were excluded because their sample size was too small (n=34). 
Patients who had evidence of overlapping supply of another antidepressant which indicates 
augmentation of the treatment were excluded, because antidepressant use was based on 
prescription refill records and might not be estimated accurately with augmentation (n=407). 
In other words, the dissertation focuses on mono-therapy users. Finally, patients with 
unknown provider specialty in their index antidepressant prescription claim were excluded 
because the provider type was the independent variable of interest (n=825).  The final sample 
consists of 4,102 antidepressant users aged more than 18 years old with an MDD diagnosis.  
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Figure 3.2 Sample Selection 
 
- Diagnosis for major depressive disorder 
- Filled a second generation antidepressant 
- Continuously enrolled for six months prior and two years after the index diagnosis 
N=8,507 
Age < 18 (N=1,474) N=7,033 
Diagnosis code for bipolar disorder of schizophrenia (N=533) N=6,500 
Antidepressant claims during six-month pre-index period (N=1,132) N=5,368 
N=5,334 
N=4,927 
N=4,102 
Specific drugs due to small sample size (N=34) 
Unknown provider specialty on initial antidepressant (N=825) 
Inclusion Criteria 
Exclusion Criteria 
Evidence of augmentation of antidepressant treatment (N=407) 
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3.3 Variables 
This section describes the definition and identification of several key variables that 
serve as dependent or main independent variables in specific aims, followed by a description 
of control variables.  
3.3.1 Provider Specialty 
Provider specialty is the independent variable of interest of this dissertation. The index 
antidepressant prescription claim for each patient was the first antidepressant prescription 
after the initial diagnosis of MDD. The provider specialty was identified for each patient 
based on the specialty of the provider of this first antidepressant prescription. We used 
prescription as the source of provider specialty because we assumed that patients received 
this initial antidepressant prescription from the providers who initiated and subsequently 
managed their antidepressant therapy. In a test of this assumption, we found that only 5% of 
patients received subsequent antidepressant prescriptions from different types of providers. 
The provider specialty was categorized into three mutually exclusive groups: a) primary care 
providers (PCP) include providers with specialties of family practice, internal medicine, 
obstetrics/gynaecology, pediatrics, and geriatrics; b) psychiatrists; c) non-psychiatric 
specialists (e.g. cardiologist, gastroenterologist, and oncologist).  
3.3.2 Receipt of Guideline-concordant Follow-up Visits 
Receipt of guideline-concordant follow-up visits is the first of two outcome variables 
in aim 2 and was constructed based on the Healthcare Effectiveness Data Information Set 
(HEDIS) measures.12 Follow-up visits were identified by outpatient service claims with a 
non-mental health practitioner or mental health practitioner coded with a mental health 
diagnosis. Mental health diagnosis was defined with ICD-9 codes 210 to 319 inclusive, based 
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on any diagnosis field. Patients were considered to have guideline-concordant follow-up 
visits if they 1) received at least three follow-up visits during the first 90 days since the index 
antidepressant prescription (acute phase), AND 2) had at least one of the three follow-up 
visits with a prescribing practitioner (e.g., licensed physician, physician assistant, or other 
practitioner with prescribing privileges).  
To evaluate whether the criteria used in HEDIS with any mental health diagnosis to 
be too inclusive, we descriptively examined the distribution of the diagnosis code on the 
visits identified. We found 84% of the claims had a depression-related mental health 
diagnosis.  
3.3.3 Antidepressant Treatment Phases Completion 
Antidepressant treatment phase completion is the second of two outcome variables in 
aim 2. Several methods have been developed to evaluate medication adherence (whether a 
patient takes a prescribed medication according to schedule) and persistence (whether a 
patient stays on therapy) using automated databases.82 A successful completion of an 
antidepressant treatment phase requires adherence and persistency of the regimen. Such 
hybrid metrics are more stringent than adherence or persistency measurement alone and are 
preferred because of the tendency for claims data to overestimate medication use.83  
Adherence was assessed using the medication possession ratio (MPR). MPR is 
defined using the continuous, multiple-interval medications available methodology, which 
has been widely used in assessment of medication use.84 MPR is calculated as the sum of 
days-of-supply of all antidepressant prescriptions divided by the total number of days during 
the specified period. The formula for calculating MPR is specified as below: 
MPR= (Sum of days of supply of prescriptions)/(Total number of days) 
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It is assumed perfect adherence during the days immediately preceding the end of acute 
phase (day 90). The over-supply of last refill in acute phase was carried to continuation phase. 
Patients who stayed in the hospital were assumed to be given the medication prescribed to 
them. Therefore, those days were considered as perfect adherence, and were added to the 
numerator of the MPR calculation. In addition, patients who switched antidepressants had 
their supply of the pre-switch medication truncated at the date when a different 
antidepressant medication was filled. MPR ranges from 0%, indicating no adherence to 100%, 
indicating perfect adherence. In the case of oversupply, MPR could be greater than 100%. 
We truncated MPR at 100%. Patient adherence was computed as a binary indicator. We used 
80% as cut point based on prior literature.82 Patients were assigned a score of 1 if they 
achieved an MPR greater or equal to 80%, or 0 if the MPR was less than 80%. 
Persistency was measured as a function of gaps between refills.85 Patients were 
classified as persistent if they had no evidence of a gap of more than half of the days-of-
supply since the end of the last antidepressant prescription, which is based on clinical 
rationale from practicing psychiatrists and past studies.86, 87  For example, a patient receiving 
prescription with a 30-day supply could have a gap between refills no longer than 45 days. 
Hence, only patients not having a gap and with at least 80% of MPR during the entire phase 
were deemed to have completed the phase.  
Two dichotomous variables were created for antidepressant treatment. First, 
completion of acute phase (day 1 to day 90 since index antidepressant prescription claim) 
was defined for the whole population considering both MPR and gap. (Table 3.1) Ninety 
days was chosen based on guideline recommendations that acute phase regimen should last a 
minimum of 6-8 weeks and on average it takes 10-12 weeks to achieve full remission.8, 9 
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Next, for the sub-sample who completed acute phase, another variable of continuation phase 
(day 91 to day 270 since index antidepressant prescription claim) completion was defined 
based on MPR and gap. (Table 3.1) A period of 180 days was chosen to represent the 
average of recommended duration for continuation phase treatment (4-9 months).8, 9  
Table 3.1 Definition of Completion of Antidepressant Treatment Phases 
Antidepressant treatment phase Definition 
Complete acute phase Patients having at least 72 days of antidepressant supply during 
the first 90 days period since first prescription refill 
(MPR≥80%), and not having a gap of more than 1.5 of the days-
of-supply of previous antidepressant prescription between refills 
were deemed completed. Patients will be coded as completion=1 
if met the above criteria, and 0 otherwise. 
Complete continuous phase Among patients who completed acute phase, those having at 
least 144 days of antidepressant supply during the first 180 days 
period since the completion of acute phase (MPR≥80%), and not 
having a gap of more than 1.5 of the days-of-supply of previous 
antidepressant prescription between refills were deemed 
completed. Patients will be coded as completion=1 if met the 
above criteria, and 0 otherwise. 
 
3.3.4 All-cause and Mental Health-related Hospitalization/Emergency Room Visit 
All-cause and mental health-related hospitalization and emergency room visits were 
the outcomes for Aim 3. We examined whether these events occurred in the one-year period 
after the end of the acute phase or the end of the continuation phase. For the model that 
assesses acute phase treatment, the one-year period begins at the end of acute phase and runs 
from day 91 to day 466 after the index antidepressant prescription (Figure 3.3). In the sub-
sample of patients who completed acute phase and were assessed for continuation phase 
completion, the one-year period begins at the end of continuation phase and runs from day 
271 to day 636 after the index antidepressant prescription (Figure 3.3). The purpose of 
examining the period after completion of a phase is to avoid simultaneity of the exposure 
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(completion of antidepressant treatment phase) and outcome (hospitalization/emergency 
room visit) measure.  
Figure 3.3 Timeframe for Follow-up Period of Utilization 
 
A binary variable was created to indicate whether a hospital admission or emergency 
room visit for any reason occurred in the one-year period for each individual. This variable 
represents all-cause utilization. Another binary variable was created for one or more all-cause 
hospitalizations. Binary variables for mental health-related utilization (hospital admission or 
emergency room visit) and hospitalization were also created, based on the ICD-9 codes 210 
to 319 inclusive in any diagnosis field (Table 3.2). 
   
6 months pre-index  2 years follow-up  
Index diagnosis 
Sample Subject 
Acute phase 1-year utilization window 
Acute phase evaluation 
Acute phase 1-year utilization window 
Continuation phase evaluation 
Continuation 
phase 
Index prescription 
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Table 3.2 Definition of Outcomes in Aim 3 
Variables Acute Phase Continuation Phase 
 Examined Period 
 day 91 to day 466 since the index 
antidepressant prescription 
day 271 to day 636 since the index 
antidepressant prescription 
 
 Definition 
All-cause utilization Hospital admissions or emergency 
room visits 
Hospital admissions or emergency 
room visits 
 
All-cause hospitalization 
 
Hospital admissions Hospital admissions 
Mental health-related 
utilization 
Hospital admissions or emergency 
room visits with ICD-9 codes 210-
319 inclusive in any diagnosis field 
Hospital admissions or emergency 
room visits with ICD-9 codes 210-
319 inclusive in any diagnosis field 
 
Mental health-related 
hospitalization 
Hospital admissions with ICD-9 
codes 210-319 inclusive in any 
diagnosis field 
Hospital admissions with ICD-9 
codes 210-319 inclusive in any 
diagnosis field 
 
3.3.5 Control Variables 
Control variables were chosen based on the conceptual framework from Chapter II 
including predisposing, enabling, need, treatment-related, and health insurance plan variables. 
Table 3.3 summarizes the control variables used for the analyses. 
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Table 3.3 Control Variables  
Type of Variable Variable Type Range/Categories 
Predisposing Age at diagnosis Continuous ≥18 
 Age categories Categorical 18-34 (reference), 35-49, 50-
64, ≥65 
 Gender Dichotomous 1=Male; 0=Female 
 Region of residence Categorical east north central, east south 
central, middle Atlantic, 
mountain, New England, 
pacific, south Atlantic 
(reference), west north central 
and west south central 
Enabling Median household income in 
the state of residence 
Continuous $29,411-$54,535 
 Percent of population with 
high school education in state 
of residence 
Continuous 72.9%-88.3% 
 Previous specialty care Dichotomous  
Need Hospitalization during pre-
index period 
Dichotomous  
 Chronic Disease Score Continuous 0-8 
 Comorbid anxiety Dichotomous  
 Alcohol or substance abuse Dichotomous  
 Received pregnancy-related 
visits 
Dichotomous  
Treatment-related Type of initial antidepressant Categorical bupropion, citalopram, 
escitalopram, fluoxetine 
(reference), mirtazapine, 
paroxetine, sertraline, and 
venlafaxine 
 Complexity of daily 
antidepressant regimen 
Dichotomous Once daily (reference), ≥ 2 
pills a day 
 Quarter of year when initial 
antidepressant was prescribed 
Categorical first quarter of year 
(reference), second, third, and 
forth quarter of year 
Health Insurance Average 30-day 
antidepressant copayment 
Continuous $0-$196, median=$17 
 30-day copayment categories Categorical $0-$10, $11-$15, $16-$20, 
>$20 (reference) 
 Copayment for primary care 
visits 
Continuous $0-$111, median=$11 
 Copayment for primary care 
visits categories 
Categorical $0 (reference), $1-$10, $11-
$20, >$20 
 Initial provider reimbursed 
on a capitated basis 
Dichotomous  
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  Predisposing variables available in the data are age at diagnosis, gender, and region of 
residence (east north central, east south central, middle Atlantic, mountain, New England, 
pacific, south Atlantic, west north central and west south central). Age presented in the 
model in categorical forms (18-34 [reference], 35-49, 50-64, and ≥65).  
Because there was no individual socio-economic status available in the data, we 
constructed median household income of the residing state as a proxy for economic status,88 
and percentage of population 25 years or older with high school degree of the residing state 
as a proxy for education level.89 These are important patient socio-demographic variables 
from Andersen’s Behavioral Model.  
A binary variable indicating whether patients received any specialty care during the 
6-month pre-index period was included as a proxy for specialty care access as well as 
patients’ preference toward specialty care. Specialty care was defined based on provider 
specialty on the service claim including immunology, dermatology, neurology, psychiatry, 
urology, cardiology, gastroenterology, hematology, nephrology, rheumatology, 
endocrinology, oncology, pulmonary, infectious disease, ophthalmology, podiatry, and 
audiology.  
Several need variables were constructed because they are the most immediate reasons 
for healthcare utilization based on Andersen’s Behavioral Model. An indicator variable was 
created if a patient had any hospitalization during pre-index period. This variable served as 
an important proxy for health status as events like hospitalization usually indicate worse 
health. Inclusion of measure of comorbidity is important to adjust for patient case-mix. 
Several comorbidity measures have been shown to predict mortality or hospitalization.90 The 
Chronic Disease Score (CDS)91 is a medication-based risk-adjustment measure based on age, 
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gender, and history of dispensed drugs and it has empirically shown to predict comorbidity.92, 
93
 Medical service claims in 6-month pre-index period were examined to identify conditions. 
Anxiety and substance abuse are common comorbid conditions for depression. Indicators for 
pre-existing anxiety (ICD-9 code in 300.00 or 300.02) and alcohol/substance abuse (ICD-9 in 
303.xx-305.xx) were created to capture the mental health status of these patients. 
Psychological illness is an important confounding variable, and these mental health condition 
indicators may partially control for it. An indicator of pregnancy was created if the patient 
had any pregnancy-related outpatient visits based on ICD-9 code V22.xx or V23.xx in any 
diagnosis field to control for potential pregnancy in statistical models for Aims 2 and 3. This 
variable was included because pregnancy may influence the decision to prescribe or use an 
antidepressant and the outcome of all-cause hospitalization.  
Treatment-related variables were also controlled for. Initial antidepressants including, 
bupropion, citalopram, escitalopram, fluoxetine, mirtazapine, paroxetine, sertraline, and 
venlafaxine were adjusted in the model to account for different side effect profiles that may 
influence the decision to continue/switch antidepressant therapy and the need for follow-up 
visits. The number of pills for daily doses was also included as an indicator for the 
complexity of the antidepressant regimen. Quarter of year when the initial antidepressant was 
prescribed was included in the models to control for seasonality differences.  
Several variables were created for health plan characteristics. The full benefit 
structure of out-of-pocket payment and reimbursement scheme (fee-for-service or capitation) 
was not available. We constructed several proxies based on aggregated claims level 
information. Out-of-pocket copayment for a 30-days antidepressant prescription and out-of-
pocket copayment for primary care provider visits were included as proxies for barriers of 
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access to care. All cost data has been adjusted for inflation to 2004 value using Consumer 
Price Index for medical care.94 We also examined the reimbursement scheme of patient’s 
initial prescriber specialty. Majority of providers were reimbursed based on fee-for-service. 
Small number of patients provider was reimbursed based on both fee-for-service and 
capitation basis. We created a binary indicator variable if more than 40% of claims for initial 
prescriber specialty during the whole study period were reimbursed on a capitated basis. 40% 
was chosen based on the median of individuals who had both claims reimbursed based on 
fee-for-service and capitation. 
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3.4 Statistical Models by Aim 
This section describes the statistical models utilized in each aim. Table 3.4 
summarizes the statistical models. Data construction was conducted using SAS 9.1 (Cary, 
NC), and statistical models were run using STATA 9.0 (College Station, TX).  
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Table 3.4 Summary of the Statistical Models 
 Aim 1 Aim 2 Aim 3 
       Dependent  
variable 
Independent  
variables  
Initial 
prescriber 
specialty 
Guideline-
concordant 
follow-up 
visits 
Acute/ 
continuation 
phase completion 
All-cause and mental 
health-related 
utilization/ 
hospitalization 
Initial Prescriber Specialty  X X X 
Receipt of guideline-
concordant follow-up 
visits 
  X  
Acute phase/continuation 
phase completion 
   X 
Predisposing variables     
Age at diagnosis X X X X 
Gender X X X X 
Region of residence X X X X 
Enabling variables     
Median income in state of 
residence 
X X X X 
% with high school 
education in state of 
residence 
X X X X 
Prior specialty care  X    
Need variables     
Chronic disease score X X X X 
Anxiety X X X X 
Alcohol or substance 
abuse 
X X X X 
Pregnancy-related visits  X X X 
Prior hospitalization    X 
Treatment-related 
variables 
    
Type of initial 
antidepressant 
 X X X 
Complexity of daily 
regimen 
  X  
Quarter of year when 
initial antidepressant 
prescribed 
 X X X 
Health insurance plan 
variables 
    
30-days antidepressant 
copayment 
  X  
Copayment for primary 
care visit 
X X   
Initial provider reimbursed 
on capitated basis 
 X   
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3.4.1 Aim1 
To examine characteristics among patients initially prescribed an antidepressant by 
providers with different specialties to treat major depressive disorder (MDD) 
This aim examines patient characteristics among those who received an initial 
antidepressant prescription from different types of providers. Subjects were categorized into 
three groups based on their initial prescriber: PCPs, psychiatrists, and non-psychiatric 
specialists. A descriptive analysis of patient characteristics was conducted to examine 
unadjusted differences by initial prescriber specialty to inform analyses in Aims 2 and 3. 
Pearson’s Chi-squared tests were used to determine whether categorical variables were 
different between groups, and analysis of variance (ANOVA) was used to examine the 
differences in continuous variables.  
Since the outcome for this aim is un-ordered (PCP vs. psychiatrist vs. non-psychiatric 
specialist), multinomial logit model was used.95 This model assumes that the alternatives are 
independently irrelevant. The probabilities for the three alternatives for a decision maker 
with characteristics xi are 
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Estimation of models is based on the method of maximum likelihood. Robust variance 
estimator was used for all regressions in this dissertation to account for heteroskedasticity.96, 
97
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The specification of this model is as follows: 
Pr (initial prescriber specialty) =α + β1*AGE + β2*MALE + β3*REGION + β4*INCOME + 
β5*EDUCATION+ β6*PRIOR_SPECIALTY + β7*CDS + β8*ANXIETY + β9*SUBSTANCE + 
β10*COPAY + ε 
Where Pr (initial prescriber specialty) =0 if PCP; 1 if psychiatrist; 2 if non-psychiatric 
specialist 
 AGE = vector of age categories 
MALE = indicator variable for male gender 
REGION = vector of region indicator variables 
INCOME = median household income of the residing state in per $1,000 
EDUCATION = % population with high school education of the residing state 
PRIOR_SPECIALTY = indicator of any specialty care in pre-index period 
CDS = Chronic disease score 
ANXIETY = indicator variable for comorbid anxiety in pre-index period 
SUBSTANCE = indicator variable for substance abuse in pre-index period 
COPAY = vector of indicator variables for copayment level for primary care visits 
Demographic and clinical characteristics where included a priori based on 
information in the literature.7, 13, 43, 46-48 Demographic and socioeconomic variables include 
age, gender, region, and median household income and percentage of population with high 
school education of the residing state.46 Use of specialty care in pre-index period was 
included to adjust for patient attitudes toward specialty care, access to specialty care, and 
established relationship between patients and specialists. Any prior use of specialty care is 
hypothesized to predict choosing specialists as their initial prescribing provider for MDD. 
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Chronic disease score serves as a proxy for health status using overall comorbid conditions, 
and is hypothesized to be a strong predictor for receiving care from specialists. Pre-existence 
of comorbid mental health conditions including anxiety and substance abuse may indicate the 
need for mental health specialty care, and is hypothesized to predict care from a psychiatrist. 
The copayment for PCP visits was included to proxy barriers to care. Out-of-pocket 
copayment for PCP visits was constructed to serve as a baseline burden a patient face for 
health service use because there is no information on the premium, copayment, or 
coinsurance of the study population. 
The results were presented as odds ratios. The results from this model inform what 
variables differ among patients initially prescribed an antidepressant by different types of 
providers. The knowledge is important to identify potential confounders of provider effects 
in Aims 2 and 3.  
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3.4.2 Aim 2 
To examine the association of antidepressant treatment with initial prescriber specialty 
and receipt of guideline-concordant outpatient follow-up visits among patients with 
MDD 
3.4.2.1 Receipt of guideline-concordant outpatient follow-up visits varies by initial 
prescriber specialty 
3.4.2.1.1 Analysis of Outpatient Follow-up Visits 
This aim examines how the probability of receipt of guideline-concordant outpatient 
follow-up visits during the acute phase differs by the specialty of the provider prescribing the 
index antidepressant. First, the frequency of total number of visits during acute phase (90 
days since index antidepressant prescription) was examined by initial prescriber specialty 
groups, followed by the proportion that received guideline-concordant of outpatient follow-
up visits (at least three mental health-related visits and at least one visit made to provider 
with prescribing privileges). The mean number of follow-up visits during acute phase was 
compared between provider specialty groups using two-tailed student t-tests and the 
proportion that achieved guideline-concordant follow-up visits was compared between 
provider specialty groups using Pearson’s Chi-square statistics.  
The outcomes examined in this aim are discrete, and discrete dependent-variable 
models can be viewed as a reflection of an underlying utility function.95 There is a latent 
variable y* such that 
εβ += '* xy  
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Latent y* is unobserved. Instead, the observation is 
 y=1 if y* > 0 
 y=0 if y* ≤ 0 
For this type of binary outcome, a logit model can be estimated with a logistic 
distribution.95 The logistic model assumes that 1) the logit link function is correct, 2) the 
relation between dependent variable and independent variables are linear and all necessary 
predictors are in the model, and 3) observations are independent. Maximum likelihood 
estimation is used assuming the logistic distribution of the dependent variable. The likelihood 
function for maximization is: 
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with X as all covariates and β as the coefficients. 
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The model of this aim is specified as follows: 
Pr (receipt of guideline-concordant outpatient follow-up visits) = α + β1*PROVIDER + 
β2*AGE + β3*MALE + β4*REGION + β5*INCOME + β6*EDUCATION + β7*CDS + 
β8*PREGNANCY + β9*ANXIETY + β10*SUBSTANCE + β11*COPAY + β12*CAPITATED + 
β13*ANTIDEPRESSANT + β14*QUARTER + ε 
Where Pr (receipt of guideline-concordant outpatient follow-up) = 1 if patient had 3 or more 
mental health-related visits and at least one of the three visits was  made to providers with 
prescribing privileges during 90 days since index antidepressant prescription; 0 otherwise 
 PROVIDER = vector of provider specialty indicator variables 
 AGE = vector of age categories 
MALE = indicator variable for male gender 
REGION = vector of region indicator variables 
INCOME = median household income of the residing state in per $1,000 
EDUCATION = % population with high school education of the residing state 
CDS = Chronic disease score 
PREGNANCY = indicator variable for pregnancy-related visits during acute phase 
ANXIETY = indicator variable for comorbid anxiety in pre-index period 
SUBSTANCE = indicator variable for substance abuse in pre-index period 
COPAY = vector of indicator variables for copayment level for primary care visits 
CAPITATED = indicator that the initial provider received capitated reimbursement 
ANTIDEPRESSANT = vector of indicator variables for initial antidepressant 
QUARTER = vector of indicators for quarter of year when treatment was initiated 
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PROVIDER represents a vector of provider specialty variables, including a PCP as 
initial prescriber (reference group), a psychiatrist as initial prescriber, and a non-psychiatric 
specialist as initial prescriber. These variables are the independent variables of interest. 
Sociodemographic variables such as age, gender, region of residence, and proxy of income 
and education were included as some were found to be significantly associated with follow-
up visits.4, 6 Chronic disease score, pregnancy, pre-existing anxiety and substance abuse were 
included because they might affect what types of provider they go to (e.g. the need for 
specialty care) and tendency to go for outpatient follow-up visits (e.g. the need for more 
frequent visits). Health plan characteristics included in the model were copayment for 
primary care visits and whether the patient saw an initial prescriber who was paid on a 
capitated basis. Higher out-of-pocket copayment that patients face might impose a burden on 
making medical visits. Capitated reimbursement provides incentive for providers to schedule 
medical visits less frequently.6 Inclusion of these variables controls for cost containment on 
both patients and providers. Initial antidepressant was included in the model to control for 
potential differences in side effect profile that may result in more outpatient visits.6 Quarter 
of year when the treatment was initiated to also control for seasonality. The results were 
presented with odds ratios.  
3.4.2.1.2 Sensitivity Analyses 
Sensitivity analysis is a useful tool to understand how study results may change 
according to certain parameters or definitions. For this research question, two sensitivity 
analyses were conducted to examine how provider specialty differences might change by 
varying the approaches to identify follow-up visits.  
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Figure 3.4 Illustration of Sensitivity Analyses for Follow-up 
 
Note: the figure does not represent the actual proportion of the visits 
Figure 3.4 illustrates the approaches to identify follow-up visits. The main approach 
already described using HEDIS measure identifies all visits with a mental health diagnosis 
(circle with horizontal lines). However, some of the visits were made to providers without 
prescribing privileges such as a psychologist or a social worker. These providers are not able 
to change patient’s antidepressant therapy. In the first sensitivity analysis, we only consider 
someone having adequate outpatient follow-up visits if they had three or more visits to 
providers with prescribing privileges.  
There are several reasons why depression care may be not be coded correctly on the 
claim. A scenario called “code creep”, which refers to coding for another higher reimbursed 
diagnosis in place of an actual but lower reimbursed diagnosis, might happen in practice. In 
research using administrative data, code creep might result in misclassification when 
All MH visits 
 
No prescribing 
privileges 
Prescribing 
privileges 
Sensitivity #1 
AD prescriber 
Sensitivity #2 
Visits with 
prescribing privileges 
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variables are constructed based on diagnosis fields. Mental health diagnoses are also 
commonly under-coded in primary care due to patient’s stigma.22 To address this possibility 
in the second sensitivity analysis, we linked the provider from antidepressant prescription 
claims to outpatient service claims based on encrypted provider identification. Those visits, 
regardless of diagnosis code, made to the same provider who wrote the initial antidepressant 
prescription were identified. These visits were added on top of the ones used in the first 
sensitivity analysis as the outcome in the second sensitivity analysis (circle with vertical 
lines).  
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3.4.2.2 Completion of antidepressant acute and continuation phase varies by initial 
prescriber specialty 
Aim 2 also examines whether completion of acute phase and continuation phase 
antidepressant treatment varies by initial prescriber specialty. Acute phase antidepressant use 
was measured based on prescription refill records during the first 90 days since index 
antidepressant prescription. Patients must have MPR ≥ 80% and no significant gap between 
refills to be considered as completed.82 The same criteria were used to evaluate continuation 
phase completion during the 180 days after the acute phase for the sub-population who 
completed the acute phase. Descriptive analyses for independent variables were conducted 
between those who completed a phase versus those who did not using Pearson’s Chi-squared 
tests for categorical variables and two-tailed student t-tests for continuous variables. The 
dependent variable is binary, so a logit regression was run for each phase.  
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3.4.2.2.1 Acute Phase  
The acute phase model was specified as follows: 
Pr (completion of acute phase) = α + β1*PROVIDER + β2*FOLLOW-UP + 
β3*PSY*FOLLOW-UP + β4*AGE + β5*MALE + β6*REGION + β7*INCOME + 
β8*EDUCATION + β9*CDS + β10*PREGNANCY +β11*ANXIETY + β12*SUBSTANCE + 
β13*AD_COPAY + β14*DAILY_PILL + β15*ANTIDEPRESSANT + β16*QUARTER + ε 
Where Pr (completion of acute phase) = 1 if patient completed acute phase; 0 otherwise 
 PROVIDER = vector of provider specialty indicator variables 
 FOLLOW-UP = indicator variable for receipt guideline-concordant follow-up visits 
 PSY*FOLLOW-UP = psychiatrist dummy and follow-up interaction 
 AGE = vector of age categories 
MALE = indicator variable for male gender 
REGION = vector of region indicator variables 
INCOME = median household income of the residing state in per $1,000 
EDUCATION = % population with high school education of the residing state 
CDS = Chronic disease score 
PREGNANCY = indicator variable for pregnancy-related visits during acute phase 
ANXIETY = indicator variable for comorbid anxiety in pre-index period 
SUBSTANCE = indicator variable for substance abuse in pre-index period 
AD_COPAY = vector of indicator variables for index antidepressant copayment level  
DAILY_PILL = indicator variable for more than once-daily doses 
ANTIDEPRESSANT = vector of indicator variables for initial antidepressant 
QUARTER = vector of variables for quarter of year when treatment was initiated 
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The independent variable of interest is provider specialty variables (PROVIDER). We 
were also interested in whether patients who had guideline-concordant outpatient follow-up 
visits (FOLLOW-UP) were more likely to complete acute phase. An interaction term between 
the provider specialty variable and receipt of guideline-concordant follow-up visits 
(PSY*FOLLOW-UP) was included to account for any synergistic effects of care from 
psychiatrists and follow-up on acute phase completion. Based on the discussion in Chapter II, 
we do not consider non-psychiatric specialists differ from PCPs in knowledge and attitude 
toward depression treatment, so the interaction term between non-psychiatric specialist and 
follow-up was not included. Sociodemographic variables including age, gender, geographic 
region, and proxies for income and education at state level were included based on prior 
literature.2, 4, 6, 13, 15, 16, 43 Chronic disease score was included to control for patient case-mix, 
even though it is unclear whether more comorbidities impose a burden to adhere or to 
increase the need for adherence.2, 4, 6 Pre-existing anxiety serves as a need factor which is 
expected to be a positive predictor of adherence because antidepressants are also indicated to 
treat anxiety.4, 16, 43 Substance abuse in the pre-index period was included because it is a 
comorbidity of depression and might impose a burden to antidepressant adherence.2 
Copayment for antidepressant prescriptions was included as a health plan characteristics. 
Higher copayments might discourage patients from refilling prescriptions.98 Initial 
antidepressant type entered the model to control for potential differences in side effects that 
may result in discontinuation of treatment.2, 6, 13, 15, 17 Number of pills of daily antidepressant 
doses was controlled for because the complexity of regimen might result in difficulties for 
patients to comply with treatment.79 Finally, quarter of year when the antidepressant 
treatment was initiated was included to control for any seasonal effect.  
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Since the logistic regression model included an interaction term, the interpretation of 
odds ratio is not straight forward. Hence, the results were presented as marginal effects using 
the average of the probabilities method. The significance of the interaction term was 
examined using methods developed by Norton et al.99, 100 To address the simultaneous nature 
and potential correlation between the error terms in guideline-concordant follow-up visits 
model and acute phase antidepressant completion model, a seemingly unrelated regression 
was run with bivariate probit model to examine the correlation.95 
3.4.2.2.2 Continuation Phase 
The continuation model was run on the sub-sample who completed acute phase 
(n=1,921). The dependent variable was a binary outcome of continuation phase completion.   
The specification of most of the independent variables was similar to the acute phase model. 
The interaction terms between provider specialty dummies and follow-up were not included 
because of the time lag between initial prescriber specialty and continuation phase (3 
months). We also tested with inclusion of interaction term, but it was not significant. To 
assess whether the impact of follow-up visits in the acute phase was carried over to the 
continuation phase or if the follow-up visits during the continuation phase might be 
associated with antidepressant completion, we tested the correlation between number of 
follow-up visits in acute phase and number of follow-up visits in continuation phase. A high 
correlation of 0.68 was found. We also tested several different specifications for follow-up in 
the continuation phase because there are no guideline-recommended intervals. We examined 
continuous, binary (<3 vs. ≥3 visits), and categorical forms (0 visit, 1-2 visits, and 3 or more 
visits). The specification tests showed that the binary form was more appropriate (Appendix 
3).  
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3.4.3 Aim 3 
To examine the association of subsequent healthcare utilization with initial prescriber 
specialty and antidepressant treatment among patients with MDD 
 This aim examines how initial prescriber specialty and antidepressant treatment 
completion may associate with subsequent healthcare utilization. There were four binary 
outcomes identified during the one-year follow-up after a phase was completed: 1) all-cause 
utilization (hospitalization and emergency room visits), 2) all-cause hospitalization, 3) mental 
health-related utilization, and 4) mental health-related hospitalization.  
3.4.3.1 Healthcare Utilization in the One-year Period after Acute Phase 
A descriptive analysis for independent variables was conducted between those who 
had all-cause utilization (any hospitalization or emergency room visits) in the one-year 
period after the acute phase. Similar descriptive analyses were conducted for all-cause 
hospitalization, mental health-related utilization, and mental health-related hospitalization 
(See Table 3.2 for definition).  Differences in categorical variables were tested with 
Pearson’s Chi-squared test and two-tailed student t-tests were used for continuous variables.  
Four logistic regressions were run to understand the influence of provider specialty 
and completion of acute phase antidepressant treatment on subsequent healthcare utilization. 
The dependent variable of the first regression was all-cause utilization. The second model 
was run with mental health-related utilization as the dependent variable with the same model 
specification. The third and forth models replaced utilization with all-cause hospitalization 
and mental health-related hospitalization, respectively.  
  83 
The specification of the first model is: 
Pr (all-cause utilization) =α + β1*ACUTE + β2*PROVIDER + β3*AGE + β4*MALE + 
β5*REGION + β6 INCOME + β7EDUCATION + β8*PREGNANCY + β9*PRIOR_HOS + 
β10*CDS + β11*ANXIETY + β12*SUBSTANCE + β13*QUARTER + ε 
Where Pr (all-cause utilization) = 1 if patient has all-cause hospitalization or emergency  
        room visits; 0 otherwise, 
 ACUTE = binary acute phase completion variable 
PROVIDER = vector of provider specialty indicator variables 
 AGE = vector of age categories 
MALE = indicator variable for male gender 
REGION = vector of region indicator variables  
INCOME = median household income of the residing state in per $1,000 
EDUCATION = % population with high school education of the residing state 
PREGNANCY = indicator variable for pregnancy-related visits during acute phase 
PRIOR_HOS = indicator variable for prior hospitalization in pre-index period 
CDS = Chronic disease score 
ANXIETY = indicator variable for comorbid anxiety in pre-index period 
SUBSTANCE = indicator variable for substance abuse in pre-index period 
QUARTER = vector of variables for quarter of year when treatment was initiated 
The dependent variable in the first model is a binary variable indicating the presence 
of any all-cause hospitalization/emergency room visits during the one-year period after acute 
phase. Acute phase completion (ACUTE) is a binary variable with non-completion as 
reference. PROVIDER is a vector of provider specialty variables in the model to test whether 
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patients initially prescribed an antidepressant by psychiatrists or by non-psychiatric 
specialists used more healthcare resources. Differences in utilization have been found in 
different socio-demographic groups, so these variables were included in the model.18, 19 Since 
the all-cause utilization identified did not distinguish the reason for hospitalization and 
inpatient service for birth delivery is not considered an adverse event, an indicator variable of 
pregnancy-related outpatient visits during acute phase was included in the model to adjust for 
it. Without such adjustment, the effect of acute phase completion might be confounded if 
patients who were pregnant were more likely to terminate the treatment while having an 
inpatient service for birth delivery during the follow-up period. Other risk variables such as 
prior hospitalization, chronic disease score, anxiety, and substance abuse based on history in 
6-month pre-index date period were included to adjust for case-mix.18, 19 Quarter of year 
when the antidepressant treatment was initiated was included to control for any seasonal 
effect.  
3.4.3.2 Healthcare Utilization in the One-year Period after Continuation Phase 
Healthcare utilization in the year following the continuation phase was considered by 
those who completed the acute phase and had continuation phase antidepressant treatment. 
(n=1,921) A descriptive analysis for independent variables was conducted between those 
who had utilization (any hospitalization or emergency room visits) during one-year of 
follow-up after continuation phase versus those who did not. Similar descriptive analyses 
were conducted for all-cause hospitalization, mental health-related utilization, and mental 
health-related hospitalization.  
Four logistic regressions were run on the sub-sample who completed acute phase to 
understand the influence of initial prescriber specialty and completion of continuation phase. 
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The dependent variable of the first regression was all-cause utilization. Three similar models 
were run with all-cause hospitalization, mental health-related utilization, and mental health-
related utilization as dependent variables respectively. The specification of independent 
variables was similar to the acute phase model. The results were presented with odds ratios.  
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3.5 Specification Tests 
A Hausman test was performed to examine whether the assumption of independence 
of irrelevant alternatives (IIA) for multinomial logit model holds for the Aim 1 model.101 The 
test evaluates the significance of an estimator (multinomial logit model) versus an alternative 
estimator (logit model omitting an alternative in multinomial logit model). Robust standard 
errors were used for all logistic regression to adjust for heteroskedasticity. A diagnostic test 
for specification error using Stata command “linktest” was used after logistic regression 
models for Aim 2 and Aim 3.102 It tests whether the logit of the outcome variable is indeed a 
linear combination of the independent variables and whether there is omitted variable 
misspecification. Model fit of the logistic regression was tested using the Hosmer and 
Lemeshow’s goodness-of-fit test.102 Multicollinearity among independent variables was 
tested using tolerance and variance inflation factor (VIF). C-statistics were also reported for 
logistic regression model to indicate the discriminative ability of the model. Results of 
specification tests for each analytical model are presented in Appendix 4. 
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3.6 Power Analysis 
Power analyses were conducted for the models for Aim 2, and Aim 3 using STATA 
9.0 (College Station, TX). Power calculation was based on two-sample comparison of 
proportions (Patients initially prescribed an antidepressant by PCPs and patients initially 
prescribed an antidepressant by psychiatrists). The parameters needed for power calculation 
are: 
• Actual sample size of each group 
• Proportion with positive response (Y=1) when X=0 
• Proportion with positive response (Y=1)  when X=1 
• Alpha is the probability of rejecting a true null hypothesis. 
Alpha was set as 0.05 for all power calculations.  
3.6.1 Aim 2 Follow-up   
 For the model that estimated receipt of guideline-concordant follow-up visits, a power 
analysis was conducted to evaluate whether the model had power to detect differences 
between patients initially prescribed an antidepressant by PCPs and patients initially 
prescribed an antidepressant by psychiatrists. In this dissertation, we have a sample of 2,441 
PCP patients (19% of whom received guideline-concordant follow-up visits) and 1,443 
psychiatrist patients (52% of whom received guideline-concordant follow-up visits). We 
calculated the power with various levels of relative and absolute differences (Table 3.5). Our 
sample allows us to detect a relative 21% increase (an absolute 4% increase) with 83% of 
power. 
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Table 3.5 Power Analysis for Aim 2 Follow-up Model 
Parameter Inputted for 
PCP Group 
(%) 
Parameter Inputted for 
Psy Group 
(%) 
Relative 
Increase  
(%) 
Absolute 
Increase  
(%) 
Power 
(%) 
19 21 10 2 31 
19 22 15 3 60 
19 23 21 4 83 
19 24 26 5 95 
19 52 174 33 100 
Note: row in italic is data from the sample 
3.6.2 Aim 2 Acute Phase 
A power analysis was conducted to test whether the model for acute phase 
completion has power to detect differences between patients initially prescribed an 
antidepressant by PCPs and patients initially prescribed an antidepressant by psychiatrists. 
We have a sample of 2,441 PCP patients (46% of whom completed acute phase) and 1,443 
psychiatrist patients (48% of whom completed acute phase). We calculated the power with 
various levels of relative and absolute differences (Table 3.6). Our sample allows us to detect 
a relative 11% increase (an absolute 5% increase) with 84% of power. 
Table 3.6 Power Analysis for Aim 2 Acute Phase Model 
Parameter Inputted for 
PCP Group 
(%) 
Parameter Inputted for 
Psy Group 
(%) 
Relative 
Increase  
(%) 
Absolute 
Increase  
(%) 
Power 
(%) 
46 48 4 2 21 
46 49 7 3 43 
46 50 9 4 66 
46 51 11 5 84 
46 52 13 6 94 
Note: row in italic is data from the sample 
3.6.3 Aim 2 Continuation Phase 
A power analysis was conducted to test whether the model for continuation phase 
completion has power to detect differences between patients initially prescribed an 
antidepressant by PCPs and patients initially treated by psychiatrists. We have a sample of 
1,129 PCP patients (45% of whom completed continuation phase) and 694 psychiatrist 
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patients (46% of whom completed continuation phase). We calculated the power with 
various levels of relative and absolute differences (Table 3.7). Our sample allows us to detect 
a relative 16% increase (an absolute 7% increase) with 82% of power. 
Table 3.7 Power Analysis for Aim 2 Continuation Phase Model 
Parameter Inputted for 
PCP Group 
(%) 
Parameter Inputted for 
Psy Group 
(%) 
Relative 
Increase  
(%) 
Absolute 
Increase  
(%) 
Power 
(%) 
45 46 2 1 6 
45 48 7 3 22 
45 50 11 5 52 
45 52 16 7 82 
45 54 20 9 96 
Note: row in italic is data from the sample 
3.6.4 Aim 3 Acute Phase 
 It is of particular interest to understand whether models for psychiatric 
utilization/hospitalization were under-powered because those events were relatively rare. We 
have a sample of 2,441 PCP patients and 1,443 psychiatrist patients. We calculated the power 
with various levels of relative and absolute differences (Table 3.8). Our sample allows us to 
detect a relative 24% increase (an absolute 4% increase) with 86% of power for all-cause 
utilization, a relative 75% increase (an absolute 3% increase) with 87% of power for mental 
health-related utilization, a relative 43% increase (an absolute 3% increase) with 78% of 
power for all-cause hospitalization, and a relative 67% increase (an absolute 2% increase) 
with 86% of power for mental health-related hospitalization. 
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Table 3.8 Power Analysis for Aim 3 Acute Phase Model 
Parameter Inputted for 
PCP Group 
(%) 
Parameter Inputted for 
Psy Group 
(%) 
Relative 
Increase  
(%) 
Absolute 
Increase  
(%) 
Power 
(%) 
All-cause Utilization 
17 19 12 2 34 
17 20 18 3 63 
17 21 24 4 86 
17 22 29 5 96 
17 23 35 6 99 
Mental Health-related Utilization 
4 5 25 1 12 
4 6 50 2 57 
4 7 75 3 87 
4 8 100 4 99 
4 9 125 5 100 
All-cause Hospitalization 
7 9 30 2 22 
7 10 43 3 78 
7 11 57 4 96 
7 12 71 5 100 
7 13 86 6 100 
Mental Health-related Hospitalization 
3 4 33 1 47 
3 5 67 2 86 
3 6 100 3 99 
3 7 133 4 100 
3 8 167 5 100 
Note: row in italic is data from the sample 
3.6.5 Aim 3 Continuation Phase 
We have a sample of sample of 1,129 PCP patients and 694 psychiatrist patients in 
the continuation phase analyses. We calculated the power with various levels of relative and 
absolute differences (Table 3.9). Our sample allows us to detect a relative 50% increase (an 
absolute 4% increase) with 83% of power for all-cause utilization, a relative 60% increase 
(an absolute 3% increase) with 83% of power for mental health-related utilization, a relative 
63% increase (an absolute 5% increase) with 87% of power for all-cause hospitalization, and 
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a relative 133% increase (an absolute 4% increase) with 91% of power for mental health-
related hospitalization. 
Table 3.9 Power Analysis for Aim 3 Continuation Phase Model 
Parameter Inputted for 
PCP Group 
(%) 
Parameter Inputted for 
Psy Group 
(%) 
Relative 
Increase  
(%) 
Absolute 
Increase  
(%) 
Power 
(%) 
All-cause Utilization 
16 20 25 4 72 
16 21 50 5 83 
16 22 100 6 93 
16 23 125 7 97 
16 24 150 8 99 
Mental Health-related Utilization 
5 6 20 1 45 
5 7 40 2 58 
5 8 60 3 83 
5 9 80 4 95 
5 10 100 5 99 
All-cause Hospitalization 
8 9 13 1 5 
8 10 25 2 21 
8 11 38 3 45 
8 12 50 4 70 
8 13 63 5 87 
Mental Health-related Hospitalization 
3 5 67 2 19 
3 6 100 3 70 
3 7 133 4 91 
3 8 167 5 98 
3 9 200 6 100 
Note: row in italic is data from the sample 
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3.7 Statistical Issue 
3.7.1 Imbalance of Observable Variables 
In a randomized-controlled experiment, randomization will guarantee the balance of 
observed and unobserved characteristics between groups and ensure that there are no 
systematic differences. In observational studies, however, the investigators have no control 
over a subject’s group membership. There might be some systematic observed differences 
between group members. If such differences affect both the assignment of group membership 
and outcome of interest, failure to control for them will result in biased estimates. Since the 
patients in this dissertation were not randomly assigned to be treated by different types of 
providers, our analyses were subject to this issue. Several approaches have been used to 
control for imbalance in observed variables including matching, stratification, covariate 
adjustment via regressions, and propensity scores. In this dissertation, we used propensity 
score matching to adjust for imbalance of variables between patients who were initially 
prescribed an antidepressant by a PCP and patients who were initially prescribed an 
antidepressant by a psychiatrist.  
3.7.1.1 Summary of Propensity Score 
Propensity scores were first proposed by Rosenbaum and Rubin for confounder 
control in observational studies.103 The propensity score for an individual is the probability 
that he or she will be assigned to the treatment group conditional on that individual’s 
observed characteristics. A propensity score provides a scalar summary of the covariates 
which does not limit the number of covariates, unlike other methods for adjustment. Use of 
propensity score enables an observational study to appear to be “quasi-randomized” on 
observed variables for the groups. Ideally, pairing individuals with the same propensity score 
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will, on average, lead to similar distribution of the observed characteristics, although the 
individual values of the characteristics may differ within paired groups.104 The propensity 
score model should include confounders of exposure and outcome in the model to reduce 
bias.105 In addition, it is suggested that variables that are unrelated to the exposure but related 
to the outcome should always be included in a propensity score model to decrease the 
variance of an estimated exposure effect without increasing bias.106  
The three most commonly used techniques based on the propensity score to control 
for confounding are matching, stratification, and regression adjustment.107 We chose to apply 
propensity score matching because a simulation study showed that propensity score matching 
resulted in least bias in estimating marginal odds ratios among the three approaches.108 
Matching based on propensity scores will obtain unbiased treatment effect estimates if 
several assumptions hold. The key assumptions are that all confounding covariates are 
observed and the model generating propensity scores is correctly specified.103 
3.7.1.2 Propensity Score Matching Strategies 
The treatment group tends to have a distribution with higher propensity to receive 
treatment, while the control group has a distribution with lower propensity to receive 
treatment (Fig 3.5). It is important to have enough overlap to be able to match a sufficient 
number of treatment and control group subjects. In this example, the subjects of upper tail of 
the treatment group and lower tail of the control group will be left out of the analyses 
because there are no exact matches.   
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Figure 3.5 Distribution of Propensity of Exposed and Unexposed Group 
Treatment groupControl group
 
Several matching strategies has been proposed including 1) nearest available 
matching on the estimated propensity score, 2) Mahalanobis metric matching including the 
propensity score, 3) nearest available Mahalanobis metric matching within calipers defined 
by the propensity score, and 4) greedy matching.104, 109 The following paragraph describes 
each method.  
1) Nearest available matching on the estimated propensity score method randomly 
orders the treated and control subjects, then selects the first treated subject with the closet 
propensity score. They are removed from consideration after being matched.104 2) 
Mahalanobis metric matching uses several background covariates including the propensity 
score to calculate the Mahalanobis distance between treated and control subjects: 
 )()(),( 1 vuCvujid T −−= −  
where u and v are values of the matching variables for the treated subject i and control 
subject j, and C is the sample covariance matrix of the matching variables from the full set of 
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control subjects. Subjects are randomly ordered, and the first treated subject will be matched 
based on the control with the smallest Mahalanobis distance from the treated subject’s 
propensity score.104 3) Nearest available Mahalanobis metric matching within calipers 
defined by the propensity score combines the first two methods. The first treated subject is 
selected in a random order, and controls within a preset amount of the treated subject’s 
propensity score are selected to calculate Mahalanobis distances based on a smaller number 
of covariates.104 4) Greedy matching utilizes a hierarchical sequence to make the “best” 
matches first and “next best” matches next will be used. The greedy matching procedure first 
identifies match-pairs within a closeness range of 0.00001 of the propensity score, then if not 
individuals can be found, next matched pairs in range of 0.0001 will be searched and so on 
up to a closeness range of 0.1. If more than one un-matched control matches to a case, the 
control will be selected at random. Once the match is made, the match is not reconsidered 
(without replacement).109 
3.7.1.3 Diagnostic Test 
The discrimination of the propensity score can be measured by the area under the 
receiver operating characteristics (ROC) curve or c-statistic.110 The c-statistic will range 
between 0.5, indicating a model that performs no better than chance, and 1.0, indicating the 
ability to perfectly distinguish subjects. In addition, standardized differences, which is 
insensitive to sample size, can be calculated to examine the balance of covariates.111 
Standardized differences are calculated as follows: 
2
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where x is the sample mean and s is the sample standard deviations of covariates, 
respectively. Standardized differences less than 20 are considered small differences.112 
Successful propensity score matching should significantly improved balance and achieve 
balance of all observable variables between groups. 
3.7.1.4 Propensity Score Building for the Study Sample 
In this dissertation, we matched the population based on the propensity score of 
whether they received an initial antidepressant from a psychiatrist as opposed to from a PCP. 
Patients initially prescribed an antidepressant by non-psychiatric specialists were excluded 
because they account for less than 5% of population and matching would be difficult for this 
group.  
A propensity score model was built to predict the likelihood that patients are initially 
prescribed an antidepressant by psychiatrists as opposed to by primary care providers. The 
variables included in the propensity score models were potential confounders, and predictors 
of outcome or exposure. Major categories included socio-demographic characteristics (age, 
gender, region), health plan characteristics (primary care copayment), prior utilization 
(specialty care, psychotherapy, hospitalization, medication use), and proxies for physical and 
mental health status (comorbidities, chronic disease score). Interaction between variables was 
performed, and interaction terms which reached statistical significance (p<0.05) remained in 
the model. Table 3.10 presents the 41 variables included in the propensity score model. The 
associations and c-statistic were based on logit models of specialty of the initial provider with 
each variable entered one at a time. The model which included all variables resulted in an 
overall c-statistic of 0.716. 
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Table 3.10 Association between Patient characteristics and Initial Prescriber Specialty 
Rank Variable OR 95% CI c-statistics 
1 Prior mental health specialty care 3.760 3.135-4.511 0.590 
2 Age 0.980 0.974-0.985 0.570 
3 Male 1.672 1.460-1.915 0.559 
4 Prior psychotherapy 3.096 2.519-3.806 0.558 
5 Prior mental health care x psychotherapy 3.065 2.484-3.782 0.555 
6 Region (east north central) 0.585 0.502-0.681 0.551 
7 Chronic disease score 0.941 0.867-1.020 0.535 
8 Prior non-mental health specialty care 1.368 1.189-1.572 0.534 
9 Region (west north central) 1.678 1.361-1.997 0.528 
10 % with high school education in the state 0.987 0.966-1.008 0.525 
11 Number of medication 0.988 0.970-1.007 0.522 
12 Prior hospitalization 1.933 1.492-2.503 0.521 
13 Region (west south central) 0.634 0.505-0.795 0.520 
14 Time of diagnosis (forth quarter of year) 0.846 0.735-0.974 0.518 
15 Positive primary care copay 0.677 0.769-0.999 0.516 
16 Psychotropic agent 1.216 1.037-1.425 0.516 
17 Anxiety  1.504 1.188-1.902 0.515 
18 Region (mountain) 0.522 0.280-0.719 0.515 
19 Substance abuse 1.629 1.194-2.222 0.510 
20 Region (east south central) 0.610 0.432-0.861 0.510 
21 Time of diagnosis (third quarter of year) 1.093 0.950-1.258 0.510 
22 State median income in 1000 0.989 0.972-1.005 0.508 
23 Hypertension 0.865 0.700-1.069 0.507 
24 Region (pacific) 0.745 0.501-1.110 0.504 
25 Region (new england) 1.226 0.859-1.751 0.503 
26 Region (middle atlantic) 1.362 0.875-2.122 0.503 
27 Chronic pulmonary disease 1.504 0.855-2.647 0.503 
28 Headache and migraine 0.933 0.722-1.204 0.502 
29 Congestive heart failure 0.281 0.063-1.257 0.502 
30 Peripheral vascular disease 0.676 0.212-2.159 0.502 
31 Hemiplegia 0.307 0.068-1.385 0.502 
32 Dementia 2.543 0.717-9.027 0.501 
33 Cerebrovascular disease 0.338 0.039-2.895 0.501 
34 Connective tissue disease 0.704 0.247-2.002 0.501 
35 Moderate or severe renal disease 2.374 0.752-7.495 0.501 
36 Diabetes 0.945 0.614-1.455 0.501 
37 Myocardial infarction 0.987 0.388-2.512 0.500 
38 Mild liver disease 1.354 0.363-5.051 0.500 
39 Metastatic solid tumor 1.693 0.238-12.03 0.500 
40 Moderate or severe liver disease 0.967 0.283-3.308 0.500 
41 Time of diagnosis (second quarter of year) 1.006 0.852-1.187 0.500 
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 After the propensity scores were generated, patients initially prescribed an 
antidepressant by psychiatrists were matched to patients initially prescribed an antidepressant 
by PCPs. In a study comparing nearest available matching, Mahalanobis metric matching, 
and Nearest available Mahalanobis metric matching within calipers, Rosenbaum and Rubin 
concluded that the third technique produces the best balance between the covariates among 
the three matching strategies.104 An empirical study comparing these methods also came to 
the same conclusion.113 Therefore, we dropped the first two matching strategies from 
consideration. However, there has been no published comparison between greedy matching 
and nearest available Mahalanobis metric matching within calipers, so we conducted an 
analysis of the two matching techniques to identify the best method for our sample. The 
criteria for choosing strategy for matching were: 1) best balance of observed variables 
between groups via standardized differences, 2) maximum number of matches. The matching 
was conducted using SAS 9.1 (Cary, NC). 
After applying greedy matching and nearest available Mahalanobis metric matching 
within calipers, the balance between controls and treated before and after matching is 
summarized in Table 3.11 
Table 3.11 Pre-matching and Post-matching Comparison 
 Pre-matching Post-matching 
Matching 
Strategies 
 Greedy matching Nearest available 
Mahalanobis metric 
matching within calipers 
Initial prescriber PCP Psychiatrist PCP Psychiatrist PCP Psychiatrist 
Sample size 2,441 1,443 1,204 1,204 1,219 1,219 
% psychiatrist 
group matched 
 83% 84% 
Mean PS 0.321 0.458 0.407 0.407 0.404 0.409 
Minimum PS 0.007 0.100 0.096 0.100 0.099 0.100 
Maximum PS 0.912 0.951 0.912 0.910 0.912 0.910 
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Greedy matching resulted in 83% of patients initially treated by psychiatrists being 
matched, and Mahalonobis matching with calipers resulted in 84% patients initially treated 
by psychiatrist being matched. Figure 3.6, 3.7 and 3.8 present the distribution of propensity 
scores of the original sample, post-matching sample based on greedy matching, and post-
matching sample based on nearest available Mahalanobis metric matching within calipers, 
respectively. 
 
Figure 3.6 Distributions of Propensity Score before Matching between Primary Care Provider 
and Psychiatrist Group 
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Figure 3.7 Distributions of Propensity Score after Greedy Matching between Primary Care 
Provider and Psychiatrist Group 
 
Figure 3.8 Distributions of Propensity Score after Mahalanobis Matching with Caliper 
between Primary Care Provider and Psychiatrist Group 
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By comparing the distribution of the propensity score between greedy matching and 
Mahalanobis matching with calipers in Table 3.10 and Figure 3.7 and 3.8, the post-matching 
distribution of propensity scores appeared to be similar between the two approaches. The 
balance between patient characteristics requires examination to choose which method to 
apply. 
The differences in baseline characteristics before and after the match were examined 
to determine the performance of the match using two-tailed student t-test, Pearson’s Chi-
square statistics, and standardized differences. Table 3.12 summarizes the patient 
characteristics before and after matching. 
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Table 3.12 Patient Characteristics Before and After Propensity Score Matching 
 
 Pre-matching Post-greedy matching  Post-Mahalanobis matching with calipers 
Number of observations PCP Psy P-value Std Dif PCP Psy P-value Std Dif PCP Psy P-value Std Dif 
 2,441 1,443   1,204 1,204   1,219 1,219   
% of sample 62.8 37.2   50.0 50.0   50.0 50.0   
Age 41.0 
(11.8) 
38.1 
(11.9) 
<0.001 24.33 39.0 
(11.5) 
39.0 
(11.9) 
0.848 0.78 39.2 
(11.7) 
39.0 
(11.8) 
0.605 2.09 
Male (%) 30.4 42.2 <0.001 24.73 39.0 40.5 0.560 2.37 40.0 39.5 0.804 1.01 
Region             
East North Central (%) 31.4 21.1 <0.001 23.52 22.9 23.9 0.564 2.35 24.5 23.8 0.670 1.72 
East South Central (%) 5.1 3.2 0.005 9.70 3.2 3.3 0.909 0.47 3.0 3.3 0.641 1.89 
Middle Atlantic (%) 1.8 2.5 0.170 4.47 2.4 2.2 0.787 1.10 2.4 2.6 0.697 1.58 
Mountain (%) 6.7 3.6 <0.001 13.95 4.6 4.1 0.548 1.34 4.4 3.9 0.611 2.06 
New England (%) 3.1 3.7 0.260 3.69 3.3 3.5 0.822 2.45 3.5 3.6 0.826 0.89 
Pacific (%) 3.3 2.5 0.147 4.90 2.9 2.7 0.710 0.91 2.5 2.8 0.706 1.53 
South Atlantic (%) 26.3 39.4 <0.001 28.32 36.3 36.0 0.865 1.51 37.2 37.4 0.900 0.51 
West North Central (%) 10.4 16.0 <0.001 16.73 15.0 15.3 0.865 0.69 14.1 14.1 1.000 0.00 
West South Central (%) 11.9 7.9 <0.001 13.48 9.3 9.1 0.832 0.86 8.5 8.5 0.942 0.29 
Median household income of 
the residing state 
41,656 
(3,911) 
41,479 
(3,956) 
0.175 4.50 41,591 
(3,736) 
41,541 
(4,063) 
0.754 1.28 41,602 
(3,674) 
41,512 
(4,007) 
0.564 2.34 
% of population with high 
school education of the 
residing state 
80.5 
(3.3) 
80.4 
(2.8) 
0.214 4.21 80.4 
(3.0) 
80.4 
(2.8) 
0.824 0.90 80.4 
(3.0) 
80.4 
(2.8) 
0.892 0.55 
Use of mental health-related 
specialty care during pre-
index period (%) 
8.9 26.7 <0.001 48.12 16.9 17.2 0.828 0.88 17.0 17.9 0.557 2.38 
Use of non-mental health-
related specialty care during 
pre-index period (%) 
28.2 34.9 <0.001 14.54 33.3 33.1 0.931 0.35 33.6 32.7 0.667 1.74 
Prior psychotherapy (%) 6.8 18.4 <0.001 35.58 12.7 12.3 0.758 1.26 13.0 13.4 0.765 1.21 
Myocardial infarct (%) 0.49 0.48 0.978 0.09 0.33 0.42 0.738 1.36 0.33 0.49 0.526 2.57 
Congestive heart failure (%) 0.49 0.14 0.076 6.30 0.08 0.17 0.564 2.35 0.16 0.16 1.000 0.00 
Peripheral vascular disease 
(%) 
0.41 0.28 0.506 2.26 0.25 0.25 1.000 0.00 0.41 0.25 0.479 2.87 
Dementia (%) 0.16 0.42 0.134 4.69 0.33 0.25 0.705 1.54 0.25 0.33 0.705 1.53 
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 Pre-matching Post-greedy matching  Post-Mahalanobis matching with calipers 
Number of observations PCP Psy P-value Std Dif PCP Psy P-value Std Dif PCP Psy P-value Std Dif 
Cerebrovascular disease (%) 0.20 0.07 0.299 3.66 0.08 0.08 1.000 0.00 0 0.08 0.317 4.05 
Chronic pulmonary disease 
(%) 
1.07 1.59 0.154 4.62 1.50 1.50 1.000 0.00 1.31 1.64 0.502 2.72 
Connective tissue disease (%) 0.49 0.35 0.508 2.25 0.33 0.42 0.738 1.36 0.49 0.41 0.763 1.22 
Mild liver disease (%) 0.20 0.28 0.650 1.48 0.25 0.17 0.654 1.82 0.16 0.16 1.000 0.00 
Hemiplegia (%) 0.45 0.14 0.104 5.76 0.25 0.17 0.654 1.82 0.16 0.16 1.000 0.00 
Moderate or severe renal 
disease (%) 
0.20 0.48 0.128 4.78 0.25 0.33 0.705 1.54 0.25 0.33 0.705 1.53 
Diabetes (%) 2.42 2.29 0.797 0.86 2.33 1.91 0.479 2.88 1.72 2.21 0.382 3.54 
Any tumor (%) 1.07 0.69 0.242 3.99 0.50 0.83 0.316 4.09 0.98 0.82 0.668 1.73 
Moderate or severe liver 
disease (%) 
0.29 0.28 0.957 0.18 0.25 0.25 1.000 0.00 0.25 0.33 0.705 1.53 
Metastatic solid tumor (%) 0.08 0.14 0.595 1.71 0.08 0.17 0.564 2.35 0.16 0.16 1.000 0.00 
Chronic disease score 1.77 
(0.79) 
1.73 
(0.84) 
0.139 4.87 1.74 
(0.74) 
1.74 
(0.85) 
0.989 0.05 1.77 
(0.80) 
1.75 
(0.84) 
0.574 2.28 
Hypertension (%) 11.5 10.1 0.180 4.49 10.1 10.3 0.893 0.54 9.9 10.2 0.840 0.82 
Anxiety (%) 11.5 10.1 0.180 11.11 8.0 7.6 0.703 1.55 7.3 7.6 0.758 1.25 
Substance abuse (%) 6.7 9.8 0.001 10.02 4.7 4.5 0.771 1.19 4.0 4.7 0.427 3.22 
Posttraumatic stress disorder 
(%) 
3.5 5.6 0.002 4.69 1.1 0.9 0.682 1.67 1.1 0.8 0.530 2.54 
Headache and migraine (%) 7.3 6.8 0.144 1.80 6.1 6.7 0.505 2.71 6.8 6.8 1.000 0.00 
Prior Hospitalization (%) 8.9 4.8 <0.001 16.26 6.9 7.1 0.873 0.65 6.5 7.0 0.628 1.96 
Number of unique medication 
in pre-index period 
3.5 (3.5) 3.3 
(3.6) 
0.001 4.21 3.3 
(3.2) 
3.3 
(3.6) 
0.886 0.58 3.4 
(3.4) 
3.4 
(3.6) 
0.945 0.82 
Use of any psychotropic 
agent (%) 
19.4 22.7 0.016 7.96 22.1 20.9 0.457 3.03 22.2 21.7 0.732 1.39 
Average copayment for 
primary care visit 
7.7 (7.8) 7.5 
(7.7) 
0.438 2.56 7.5 
(8.1) 
7.6 
(8.0) 
0.716 1.48 7.3 
(8.0) 
7.7 
(8.0) 
0.185 5.37 
Quarter of year of treatment 
initiation 
            
Quarter 1 (%) 17.9 19.5 0.215 4.10 20.4 18.9 0.356 3.77 18.4 19.2 0.604 2.10 
Quarter 2 (%) 19.0 19.1 0.945 0.23 19.5 19.9 0.798 1.04 19.4 20.3 0.612 2.06 
Quarter 3 (%) 29.9 31.8 0.214 4.12 31.6 31.3 0.861 0.12 31.6 31.0 0.760 1.23 
Quarter 4 (%) 33.2 29.6 0.020 7.74 28.5 29.9 0.446 3.10 30.6 29.5 0.566 2.32 
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Matching yielded more balanced groups as indicated by smaller standardized 
differences. All the observed variables had no significant differences between groups after 
matching. In addition, greedy matching provider better balance with smaller standardized 
differences compared to Mahalanobis matching with calipers. Therefore, greedy matching 
was chosen to be used as the matching strategy of the propensity score analysis in this 
dissertation. Results for Aims 2 and Aim 3 were compared before and after matching.  
Key characteristics were compared between individuals who were matched and un-
matched (Table 3.13). As expected, they differed in the characteristics that strongly predict 
the likelihood of provider choice in Table 3.10 and resulted in difficulties in finding matches. 
Patients initially prescribed an antidepressant by PCPs but were unable to be matched with 
similar patients initially prescribed an antidepressant by psychiatrist were more likely to be 
older, female, without prior mental health and non-mental health specialty care, without prior 
psychotherapy, without prior use of psychotropic agent, without pre-existing anxiety and 
substance abuse, and had a higher Chronic Disease Score compared with patients initially 
prescribed an antidepressant by PCPs who were matched. Patients initially prescribed an 
antidepressant by psychiatrists but were unable to be matched with similar patients initially 
prescribed an antidepressant by PCPs were more likely to be younger, male, had prior mental 
health and non-mental health specialty care, prior psychotherapy, use of psychotropic agents, 
and had pre-existing anxiety and substance abuse compared with patients initially prescribed 
by psychiatrists who were matched. The comparison shows that individuals who were left out 
had a much higher or lower propensity score because it is difficult to find a match. It 
highlights the limitation that the findings found based on the matched cohort might not be 
generalized to those who were discarded. 
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Table 3.13 Characteristics between Matched and Un-matched Individuals 
 PCP PSY 
 Matched Unmatched P-value Matched Unmatched P-value 
Number of 
observations 
1,204 1,237  1,204 239  
Age 39.0 42.9 <0.001 38.2  32.7 <0.001 
Male (%) 39.3 21.8 <0.001 40.5 51.1 0.002 
Use of mental health-
related specialty care 
during pre-index 
period (%) 
16.9 1.1 <0.001 17.2 74.9 <0.001 
Use of non-mental 
health-related specialty 
care during pre-index 
period (%) 
33.3 
 
 
23.2 <0.001 33.1 43.9 0.001 
Prior psychotherapy 
(%) 
12.7 1.1 <0.001 12.3 49.4 <0.001 
Chronic disease score 1.7 1.8 0.028 1.73 1.71 0.702 
Anxiety (%) 8.0 5.5 0.015 7.6 20.9 <0.001 
Substance abuse (%) 4.7 2.3 0.001 4.5 11.3 <0.001 
Prior Hospitalization 
(%) 
6.9 2.8 <0.001 7.1 18.4 <0.001 
Use of any 
psychotropic agent (%) 
22.1 16.8 0.001 20.8 31.8 <0.001 
Average copay for 
primary care visit 
7.5 7.9 0.191 7.6 6.9 0.232 
 
All analyses in Aim 2 and 3 have been performed with original sample and propensity 
score matched sample. If there are no unobservable confounders and effect modification, the 
propensity score method should produce similar results with overlapping confidence intervals 
when the confounders are also correctly adjusted in the regression models. 
  106 
 
3.7.2 Unobservable Confounding 
Confounding is a scenario of mixing effects of exposure with that of a third factor. 
Confounding will distort the apparent effect of an exposure brought about by the association 
with other factors that can influence the outcome. A confounder must be associated with both 
outcome and exposure, but not be part of the causal pathway. Bias results from omitted 
variables which is a confounder of exposure and outcome.  
One of the relationships particularly subject to unobservable confounding in this 
dissertation is between receipt of guideline-concordant follow-up visits and acute phase 
completion. These two outcomes were measured in the same time period; hence, it is 
plausible that there are common omitted variables influencing both of them. In other words, 
the error terms of these two equations might be correlated. Initial efforts have been made to 
identify an instrument for follow-up visits in this dissertation.114 After exploration of internal 
and external data sources, all the hypothesized instruments, including primary care visit 
copayment and number of psychiatrist per 10,000 of the residing state, were insignificant or 
weak instruments based on the F-test.  
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3.8 Summary 
This dissertation utilized a retrospective cohort design with claims data. Initial 
prescriber specialty was obtained from the index antidepressant prescription which we 
considered a reliable source since the provider who wrote the prescription is most likely the 
provider who educate and manage the antidepressant therapy. Guideline-concordant follow-
up visits, acute phase and continuation phase antidepressant treatment completion, and 
subsequent healthcare utilization were extracted based on medical service claims, 
prescription claims, and facility claims, respectively. Logistic regressions were run to 
examine the specific aims. In addition, sensitivity analyses were conducted to understand 
how results may differ by varying the approaches to identify follow-up visits. Finally, 
propensity score matching was used to achieve balance between patients initially prescribed 
an antidepressant by PCPs and patients initially prescribed an antidepressant by psychiatrists 
to adjust for confounding. 
 
CHAPTER IV 
RESULTS 
 This chapter presents the results of this dissertation. Section 4.1 first describes the 
overall study population, and then follows the results of each aim (section 4.2-4.4). 
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4.1 Baseline Characteristics of the Study Cohort 
 This study cohort includes 4,102 patients with MDD who initiated antidepressant 
treatment. (Table 4.1) They are commercially insured working adults and their dependents 
(mean age=40). Women account for a larger proportion (65.3%) of the sample likely because 
depression is more prevalent among women.1 The majority (85.7%) of the study cohort came 
from the south and midwest regions of the United States. The median household income of 
the state of residence averaged $41,600, and the proportion of population with high school 
education based on the state of residence averaged 80.5%. Forty-one percent of the sample 
received specialty care during the 6-month period prior to index diagnosis of MDD. The 
mean Chronic Disease Score (CDS) was 1.77 (min=0.16; max=7.5). 7.7 percent of the study 
cohort had a diagnosis of anxiety, 4.3% had a diagnosis of alcohol or substance abuse, and 
6.7% were hospitalized in the 6-month pre-index period. A small proportion of the cohort 
had an initial prescriber who was paid on capitated basis (1.5%). The mean out-of-pocket 
copayment of a 30-day-supply of the initial antidepressant prescription was $13, and the 
majority of patients (65.8%) were required to pay more than $15. The mean copayment for a 
primary care provider visit was $7.6. Forty-four percent of patients saw their primary care 
provider without copayment, while the rest paid a copayment in the $10-$20 range (46%). 
The majority of patients received an SSRI as initial antidepressant (76.6%). The majority of 
patients (98.7%) started on a once-daily antidepressant regimen. More patients (62.5%) 
initiated the antidepressant treatment during the last two quarters of the year (June-December) 
likely due to the enrollment eligibility window of the study. 
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Table 4.1 Baseline Characteristics of Study Population 
  
 Number of observations  4,102 
 Initial prescriber specialty (%) Primary Care Provider 59.5 
  Psychiatrist  35.2 
  Other specialist  5.3 
Predisposing Age (mean, S.D.)  40.0 (12.0) 
 Male (%)  34.7 
 Region (%) East North Central  27.7 
  East South Central  4.4 
  Middle Atlantic  2.0 
  Mountain  5.8 
  New England  3.5 
  Pacific  3.0 
  South Atlantic  30.8 
  West North Central  12.5 
  West South Central  10.3 
Enabling Median household income in state of residence  41,600 (3,919) 
 Percent of population with high school 
education in state of residence  
 80.5 (3.1) 
 Any use of specialty care during pre-index 
period (%) 
 41.0 
Need Chronic disease score  1.77 (0.82) 
 Anxiety (%)  7.7 
 Substance abuse (%)  4.3 
 Prior Hospitalization (%)  6.7 
Health Plan Capitated initial prescriber (%)  1.5 
 30-day copayment for index antidepressant   18.7 (10.9) 
 30-day copayment categories for index 
antidepressant (%) 
$0-$10 12.9 
  $10-$15 21.3 
  $16-$20 28.6 
  >$20 37.2 
 Copayment for primary care visit  7.6 (7.9) 
 Copayment category for primary care visit (%) $0 44.0 
  $1-$20 50.9 
  >$20 5.2 
Therapy Initial antidepressant Bupropion 10.7 
  Citalopram 20.9 
 
 Escitalopram 2.3 
  Fluoxetine 12.9 
  Mirtazapine 2.8 
  Paroxetine 17.0 
  Sertraline 23.5 
  Venlafaxine 10.0 
 Pills for daily doses of initial antidepressant (%) 1  98.7 
  ≥2 1.3 
 Quarter of year of treatment initiation (%) Quarter 1 18.5 
  Quarter 2 19.0 
  Quarter 3 30.8 
  Quarter 4 31.7 
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4.2 Aim 1 
To examine characteristics among patients initially prescribed an antidepressant by 
providers with different specialties to treat major depressive disorder (MDD) 
4.2.1 Descriptive Analysis 
Aim 1 examines characteristics among patients initially prescribed an antidepressant 
by providers with different specialties to treat MDD. Table 4.2 summarizes the descriptive 
results of Aim 1, stratified by initial prescriber specialty. 59.5 percent of patients received 
their initial antidepressant prescription from a primary care provider (PCP), 35.2% from a 
psychiatrist, and 5.3% from a non-psychiatric specialist. Patients initially prescribed an 
antidepressant by psychiatrists are more likely to be younger (38.1) compared to patients 
initially prescribed an antidepressant by PCPs (41.0) or by non-psychiatric specialist (41.1) 
(p<0.001). Patients initially prescribed an antidepressant by psychiatrists are more likely to 
be male (42.2%) compared to patients initially prescribed an antidepressant by PCPs (30.4%) 
or by non-psychiatric specialist (33.9%) (p<0.001). Patients initially prescribed an 
antidepressant by psychiatrists (51.1%) or by non-psychiatric specialists (49.5%) are more 
likely to utilized specialty care in the pre-index period compared to patients initially 
prescribed an antidepressant by PCPs (34.2%) (p<0.001). Patients initially prescribed an 
antidepressant by non-psychiatric specialists had a significantly higher CDS (1.95, p<0,001), 
while no differences were found between patients initially prescribed an antidepressant by 
PCPs (1.77) and by psychiatrists (1.73). Patients initially prescribed an antidepressant by 
psychiatrists were more likely to have pre-existing anxiety (9.8% vs. 6.7%, p=0.001) and pre-
existing substance abuse (5.6% vs. 3.5%, p=0.007) compared to patients initially prescribed 
an antidepressant by PCPs.  
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Table 4.2 Baseline Characteristics by Initial Provider Specialty 
* p<0.05 compared to primary care provider group  
Standard deviation in parentheses for continuous variables  
 
 Primary Care 
Provider 
Psychiatrist Non-
psychiatric 
Specialist 
P-value 
Number of observations 2,441 1,443 218  
% of sample 59.5 35.2 5.3  
Predisposing     
Age  41.0 (11.8) 38.1 
(11.9)* 
41.1 (12.8) <0.001 
Age categories (%)     
18-34 30.4 38.5* 31.7 <0.001 
35-49 45.8 44.4 42.7 0.543 
50-64 21.7 15.5* 23.9 <0.001 
≥65 2.1 1.5 1.8 0.409 
Male (%) 30.4 42.2* 33.9 <0.001 
Region (%)     
East North Central 31.4 21.1* 30.3 <0.001 
East South Central 5.1 3.2* 5.1 0.017 
Middle Atlantic 1.8 2.5 0.9 0.186 
Mountain 6.7 3.6* 9.6 <0.001 
New England 3.1 3.7 6.9* 0.012 
Pacific 3.3 2.5 2.3 0.286 
South Atlantic 26.3 39.4* 24.8 <0.001 
West North Central 10.4 16.0* 12.4 <0.001 
West South Central 11.9 7.9* 7.8 <0.001 
Enabling     
Median household income in state of residence  41,656 
(3,911) 
41,479 
(3,956) 
41,773 
(3,751) 
0.316 
Percent of population with high school 
education in state of residence 
80.5 (3.3) 80.4 (2.8) 80.8 (3.4) 0.083 
Use of specialty care during pre-index period 
(%) 
34.2 51.1* 49.5* <0.001 
Need     
Chronic disease score (CDS)  1.77 (0.79) 1.73 (0.84) 1.95* (1.00) <0.001 
CDS > 2 (%) 28.4 26.8 38.5* 0.002 
CDS >3 (%) 7.7 7.6 11.9* 0.075 
Anxiety (%) 6.7 9.8* 5.1 0.001 
Substance abuse (%) 3.5 5.6* 5.1 0.007 
Health Plan-related     
Copayment for primary care visit 7.7 (7.8) 7.5 (8.0) 7.7 (7.4) 0.726 
Copayment category for primary care visit (%)     
$0 42.8 46.0 43.1 0.139 
$1-$20 51.9 48.9 53.2 0.145 
>$20 5.3 5.1 3.7 0.569 
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4.2.2 Multivariate Regression Analysis 
Results from multivariate multinomial logistic regression are presented in Table 4.3. 
The coefficients are presented as odds ratios of each variable comparing receipt of an initial 
antidepressant prescription from a psychiatrist (psychiatrist model) and a non-psychiatric 
specialist (non-psychiatric specialist model). Initial receipt of antidepressant prescription 
from a PCP was the reference category.  
In the psychiatrist model, patients with older age were significantly less likely to have 
a psychiatrist as their initial prescriber for antidepressant treatment (age group 35-49: 
OR=0.74, 95% CI=0.63-0.86; age group 50-64: OR=0.50, 95% CI=0.40-0.61; age group ≥65: 
OR=0.43, 95% CI=0.25-0.76; age group18-34 as reference). Male patients were more likely 
to have psychiatrists as the initial prescriber (OR=1.77, 95% CI=1.53-2.04). Patients with 
prior specialty care (OR=2.08, 95% CI=1.80-2.40), pre-existing anxiety (OR=1.37, 95% 
CI=1.07-1.76), and pre-existing substance abuse (OR=1.47, 95% CI=1.06-2.07) were more 
likely to have a psychiatrist as the initial prescriber. Finally, patients with a PCP copayment 
greater than zero were less likely to have a psychiatrist as their initial provider (OR=0.85, 
95% CI=0.73-0.97).  
In the non-psychiatric specialist model, patients having a higher CDS (OR=1.22, 95% 
CI=1.04-1.42), or having prior specialty care (OR=1.76, 95% CI=1.32-2.35) were more 
likely to receive an initial antidepressant prescription from a non-psychiatric specialist. 
The Hausman test showed the assumption of independence of irrelevant alternatives 
(IIA) multinomial logit model was not violated, so that the data could be estimated with this 
model. 
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In summary, we found that several pre-disposing, enabling and need variables differ 
among patients initially prescribed an antidepressant by different types of providers. Our 
results indicate that patients initially prescribed an antidepressant by psychiatrists appear to 
be more mentally ill, and patients by non-psychiatric specialists tend to have greater physical 
sickness compared with patients by PCPs. 
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Table 4.3Multinominal Logistic Regression for Initial Provider Specialty 
Psychiatrist  Odds Ratio 95% CI Interval 
Age group 18-34 Reference  
 35-49 0.74 (0.63-0.86) 
 50-64 0.50 (0.40-0.61) 
 ≥65 0.43 (0.25-0.76) 
Male  1.77 (1.53-2.04) 
Region East North Central  0.50 (0.39-0.63) 
 East South Central  0.37 (0.24-0.56) 
 Middle Atlantic  0.91 (0.58-1.44) 
 Mountain  0.39 (0.26-0.59) 
 New England  0.84 (0.56-1.28) 
 Pacific  0.54 (0.34-0.87) 
 South Atlantic  Reference  
 West North Central  1.16 (0.87-1.51) 
 West South Central  0.40 (0.30-0.53) 
Median household income (per 1000)  0.98 (0.95-1.01) 
Percent with high school education   0.99 (0.95-1.03) 
Prior specialty care   2.08 (1.80-2.40) 
Chronic disease score  0.91 (0.83-1.00) 
Anxiety   1.37 (1.07-1.76) 
Substance abuse  1.47 (1.06-2.07) 
Copayment of PCP visits $0 Reference  
 >$0 0.85 (0.73-0.97) 
    
Non-psychiatric Specialist    
Age group 18-34 Reference  
 35-49 0.83 (0.60-1.16) 
 50-64 0.81 (0.54-1.21) 
 ≥65 0.54 (0.19-1.55) 
Male  1.21 (0.90-1.62) 
Region East North Central  1.22 (0.74-2.00) 
 East South Central  0.92 (0.43-1.96) 
 Middle Atlantic  0.64 (0.15-2.75) 
 Mountain  1.82 (0.98-3.38) 
 New England  2.78 (1.34-5.73) 
 Pacific  1.04 (0.38-2.80) 
 South Atlantic  Reference  
 West North Central  1.55 (0.87-2.78) 
 West South Central  0.64 (0.34-1.21) 
Median household income (per 1000)  0.96 (0.90-1.01) 
Percent with high school education   1.01 (0.93-1.09) 
Prior specialty care   1.76 (1.32-2.35) 
Chronic disease score  1.22 (1.04-1.42) 
Anxiety   0.61 (0.32-1.17) 
Substance abuse  1.21 (0.64-2.28) 
Copayment for PCP visits $0 Reference  
 >$0 1.01 (0.75-1.34) 
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4.3 Aim 2 
To examine the association of antidepressant treatment with initial prescriber specialty 
and receipt of guideline-concordant outpatient follow-up visits among patients with 
MDD 
 We sought to understand the association between initial prescriber specialty, receipt 
of guideline-concordant outpatient follow-up visits, and antidepressant treatment among 
patients with MDD in research Aim 2. We first present the results investigating how initial 
prescriber specialty and other factors might affect receipt of guideline-concordant follow-up 
visits in section 4.3.1. Next, findings with antidepressant treatment completion as the 
dependent variable are presented in section 4.3.2. 
4.3.1 Follow-up Analysis 
H2.1: Receipt of guideline-concordant outpatient follow-up visits varies by initial prescriber 
specialty 
4.3.1.1 Descriptive Analyses 
The mean number of follow-up visits in the entire sample of 4,102 patients was 2.64. 
When stratified by provider specialty, patients initially prescribed an antidepressant by a 
psychiatrist had a statistically significantly higher mean number of visits (3.8) compared with 
patients initially prescribed an antidepressant by a non-psychiatric specialist (2.8) or a PCP 
(2.0) (p<0.05) (Figure 4.1). The proportion of patients who received guideline-concordant 
follow-up visits, defined by having at least three mental health-related visits and at least one 
visit made to a provider with prescribing privileges during the 90 days since index 
antidepressant prescription based on HEDIS measures, was the highest for the psychiatrists 
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group (52%), followed by other specialists group (27%) and PCP group (19%) (p<0.05) 
(Figure 4.2). 
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Figure 4.1 Mean Number of Follow-up Visits by Initial Prescriber Specialty 
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Figure 4.2 Proportion of Patient Who Received Guideline-concordant Follow-up Visits by 
Initial Prescriber Specialty 
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Table 4.4 presents the descriptive results for Aim 2 that compares patients who 
received guideline-concordant follow-up visits with patients who did not. Thirty-one percent 
of overall cohort received guideline-concordant follow-up visits. A statistically significantly 
lower proportion of patients who had guideline-concordant follow-up visits received their 
initial prescription from a PCP (37%) than patients who did not have guideline-concordant 
follow-up visits (70%) (p<0.001). A statistically significantly higher proportion of patients 
who had guideline-concordant follow-up visits received their initial prescription from a 
psychiatrist (59%) than patients who did not have guideline-concordant follow-up visits 
(25%) (p<0.001). Patients who received guideline-concordant follow-up visits were 
statistically significantly younger (38.8) than patients who did not receive guideline-
concordant follow-up visits (40.5) (p<0.001). Patients who received guideline-concordant 
follow-up visits were more likely to be male (39% vs. 33%, p<0.001), resided in states with a 
higher median household income ($41,926 vs. $41,454, p<0.001) and in states with a higher 
proportion of population with high school education (80.7% vs. 80.4%, p=0.002) than 
patients who did not receive guideline-concordant follow-up visits. The CDS was similar 
between groups, but the guideline-concordant group appeared to have more mental health 
needs with a statistically significantly higher proportion of patients having pre-existing 
anxiety (11.2% vs. 6.1%, p<0.001) and substance abuse (5.6% vs. 3.8%, p=0.008) compared 
with non-guideline-concordant group. A higher proportion of patients who did not receive 
guideline-concordant follow-up visits were in the highest PCP copayment group (>$20) than 
patients who received guideline-concordant follow-up visits (5.8% vs. 3.8%, p=0.008).  
  120 
 
Table 4.4 Baseline Characteristics between Patients who Received Guideline-concordant 
Follow-up Visits and Patients Who Did Not 
 Receipt of Guideline-
concordant Follow-up 
No Receipt of Guideline-
concordant Follow-up 
P-value 
Number of observations 1,265 2,837  
% of sample 30.8 69.2  
Primary care provider (%) 36.7 69.7 <0.001 
Psychiatrist (%) 58.7 24.7 <0.001 
Non-psychiatric specialist (%) 4.6 5.6 0.164 
Age  38.8 (11.4) 40.5 (12.2) <0.001 
Age categories (%)    
18-34 35.5 32.4 0.052 
35-49 47.4 44.1 0.056 
50-64 16.4 21.1 <0.001 
≥65 0.8 2.4 0.001 
Male (%) 39.1 32.8 <0.001 
Region (%)    
East North Central 29.2 27.1 0.173 
East South Central 2.9 5.2 0.001 
Middle Atlantic 2.4 1.9 0.290 
Mountain 4.3 6.4 0.006 
New England 5.8 2.5 <0.001 
Pacific 2.9 3.0 0.747 
South Atlantic 32.7 30.0 0.089 
West North Central 12.4 12.5 0.952 
West South Central 7.7 11.5 <0.001 
Median income in state of residence 41,926 (3,869) 41,454 (3,933) <0.001 
% high school education in state of residence 80.7 (2.9) 80.4 (3.2) 0.002 
Chronic disease score  1.77 (0.83) 1.77 (0.82) 0.930 
Anxiety (%) 11.2 6.1 <0.001 
Substance abuse (%) 5.6 3.8 0.008 
Pregnancy-related visits during acute phase (%) 0.3 0.7 0.132 
Capitated initial prescriber (%) 1.4 1.5 0.821 
Copayment for PCP visits 7.4 (7.6) 7.8 (8.0) 0.139 
Copayment category for PCP visit (%)    
$0 44.0 43.9 0.930 
$1-$10 5.3 4.8 0.462 
$11-$20 46.9 45.6 0.440 
>$20 3.8 5.8 0.008 
Initial antidepressant (%)    
Bupropion 9.4 11.2 0.084 
Citalopram 20.6 21.0 0.721 
Escitalopram 2.6 2.2 0.448 
Fluoxetine 12.3 13.2 0.453 
Mirtazapine 3.6 2.5 0.051 
Paroxetine 16.7 17.1 0.743 
Sertraline 23.8 23.3 0.748 
Venlafaxine 11.1 9.5 0.109 
Received psychotherapy in acute phase (%) 79.4 18.2 <0.001 
Quarter of year of treatment initiation (%)    
Quarter 1 18.3 18.6 0.790 
Quarter 2 18.5 19.2 0.591 
Quarter 3 32.7 30.0 0.085 
Quarter 4 30.6 32.2 0.302 
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4.3.1.2 Multivariate Regression Analysis 
 Results from the logistic regression examining receipt of guideline-concordant 
follow-up visits are presented in Table 4.5. We found that patients initially prescribed an 
antidepressant by psychiatrists statistically significantly more likely to receive guideline-
concordant follow-up visits than patients initially prescribed an antidepressant by PCPs 
(OR=4.60, 95% CI =3.94-5.37). Initial antidepressant prescription from non-psychiatric 
specialists was also significant (OR=1.46, 95% CI =1.06-2.01). Patients aged 50-64 years old 
(OR=0.77, 95% CI = 0.62-0.96) and greater than 65 years old (OR=0.26, 95% CI=0.12-0.57) 
were statistically significantly less likely to receive guideline-concordant follow-up visits 
compared with patients aged 18-34 years old. Patients paying more than $20 for a PCP visit 
were less likely to receive guideline-concordant follow-up visits (OR=0.63, 95% CI=0.44-
0.90) compared with patients paying zero copayment. Finally, patients with pre-existing 
anxiety were more likely to receive guideline-concordant-follow-up visits. (OR=1.79, 95% 
CI=1.37-2.32)  
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Table 4.5 Logistic Regression for Receipt of Guideline-concordant Follow-up Visits 
  
 
Variable Category Odds Ratio 95% CI 
Primary care provider   Reference  
Psychiatrist   4.60 (3.94-5.37) 
Non-psychiatric specialist   1.46 (1.06-2.01) 
Age group 18-34 Reference  
 35-49 1.04 (0.87-1.23) 
 50-64 0.77 (0.62-0.96) 
 ≥65 0.26 (0.12-0.57) 
Male  1.12 (0.96-1.31) 
Region East North Central  1.13 (0.87-1.46) 
 East South Central  0.78 (0.50-1.24) 
 Middle Atlantic  1.06 (0.65-1.72) 
 Mountain  0.69 (0.46-1.05) 
 New England  2.27 (1.48-3.49) 
 Pacific  0.96 (0.57-1.62) 
 South Atlantic  Reference  
 West North Central  0.77 (0.57-1.04) 
 West South Central  0.94 (0.68-1.29) 
Median income (per 1000) in 
state of residence 
 1.02 (0.99-1.05) 
Percent with high school 
education  in state of residence 
 1.03 (0.98-1.08) 
Pregnancy-related visits during 
acute phase 
 0.32 (0.09-1.11) 
Chronic disease score  1.05 (0.96-1.15) 
Anxiety   1.79 (1.37-2.32) 
Substance abuse  1.27 (0.91-1.77) 
Capitated initial prescriber  0.87 (0.47-1.63) 
Copayment for PCP $0  Reference  
 $1-$20  1.03 (0.89-1.20) 
 >$20  0.63 (0.44-0.90) 
Initial antidepressant Bupropion  0.83 (0.62-1.12) 
 Citalopram 1.04 (0.81-1.35) 
 Escitalopram  1.07 (0.64-1.81) 
 Fluoxetine  Reference  
 Mirtazapine  0.90 (0.56-1.45) 
 Paroxetine  1.08 (0.83-1.41) 
 Sertraline  1.08 (0.84-1.38) 
 Venlafaxine 1.21 (0.90-1.63) 
Quarter of year  Quarter 1 Reference  
 Quarter 2 1.05 (0.83-1.33) 
 Quarter 3 1.17 (0.95-1.44) 
 Quarter 4 1.06 (0.86-1.31) 
Sample size = 4,102    
C-statistic = 0.72    
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4.3.1.3 Sensitivity Analyses 
Table 4.6 reports results of two sensitivity analyses that varied the approaches to 
identify follow-up visits. We limited the visits coded with mental health diagnosis only to 
those made to providers with prescribing privileges in the first sensitivity analysis because 
these providers, such as psychologists or social workers, can not change patient’s 
antidepressant regimen. We found a large reduction in mean number of visits from 2.6 to 1.4, 
and the proportion that met the criteria with three or more visits during acute phase dropped 
from 31% to 18%. In the regression model with this outcome specification, the odds ratios 
for provider specialty were similar.  
We added the visits made to the same provider who wrote the initial antidepressant 
prescription to the visits in the first sensitivity analysis as the outcome in the second 
sensitivity analysis. These additional visits, even though there might not be a mental health 
diagnosis coded on the claim, were made to the initial prescriber and provided opportunities 
for patients to discuss their antidepressant therapy. We also found a decrease in mean number 
of visits from 2.6 to 1.9, and the proportion that met the criteria with three or more visits 
during acute phase dropped from 31% to 27%. In the logistic regression, we found the odds 
ratio for psychiatrist became much smaller but still significant (OR=2.28, 95% CI=1.95-2.66). 
The odds ratio for other specialist became insignificant (OR=1.19, 95% CI=0.85-1.67).  
4.3.1.4 Propensity Score Matching 
Table 4.6 also presents the results from propensity score matching for main and 
sensitivity analyses. The odds ratio for psychiatrist in the main regression model became 
smaller in magnitude after the matching (OR=3.87, 95% CI=3.21-4.66), but remained 
significant after propensity score matching. However, the confidence intervals overlapped, so 
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there is little difference in results of the original model and propensity score model. The odds 
ratios for the two sensitivity analyses remained similar after the propensity score matching 
(Table 4.6). The confidence intervals of the odds ratios overlapped before and after matching. 
Table 4.6 Results from Sensitivity Analyses by Varying Approaches to Identify Follow-up 
Visits and Propensity Score Matching 
 Main analysis Sensitivity #1 Sensitivity #2 
Mean number of visits§ 2.64 (3.01) 1.44 (1.61) 1.93 (2.14) 
Receipt three or more visits 30.8% 18.0% 26.7% 
  Odds ratios from Pre-matching Logistic Regressionδ  
Sample size N=4,102 
Primary care provider Reference Reference Reference 
Psychiatrist 4.60*  (3.94-5.37) 4.43* (3.69-5.33) 2.28* (1.95-2.66) 
Non-psychiatric specialist 1.46*  (1.06-2.01) 1.64* (1.11-2.44) 1.19   (0.85-1.67) 
 Odds ratios from Post-matching Logistic Regressionδ 
Sample size N=2,408 
Primary care provider Reference Reference Reference 
Psychiatrist 3.87*  (3.21-4.66) 4.32* (3.42-5.45) 2.35* (1.94-2.85) 
Non-psychiatric specialist - - - 
Note: 95% CI in parentheses. Main analyses used HEDIS measure. Sensitivity analysis #1 restricted visits to only those 
made to providers with prescribing privileges. Sensitivity analysis #2 added visits made to the initial prescriber to the visits 
in sensitivity analysis #1. 
§Standard deviation in the parentheses for mean number of visits 
δRegressions include all the covariates listed in Table 4.5 
*p<0.05 
 
In summary, our findings from this aim show that initial prescription from a 
psychiatrist is the strongest predictor of guideline-concordant follow-up visits after 
conducting sensitivity analyses to address the issue of potential under-coding of mental 
health diagnosis. 
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4.3.2 Antidepressant Analyses 
H2.2: Completion of antidepressant acute and continuation phase varies by initial prescriber 
specialty 
This section presents results examining factors associated with acute phase 
completion (section 4.3.2.1) and continuation phase completion (4.3.2.2). Completion of 
acute and continuation phase were determined by examination of antidepressant refill records 
in concordance with guideline recommendations. Whether provider specialty affects 
antidepressant treatment completion was inconsistent in prior studies. This dissertation 
evaluates the association controlling for guideline-concordant follow-up visits. 
4.3.2.1 Acute Phase 
4.3.2.1.1 Descriptive Analyses 
Overall, 46.8% of the study cohort completed acute phase. When stratified by initial 
prescriber specialty, there was no statistically significant difference in rate of completion 
(Figure 4.3). When further stratified by initial prescriber specialty and receipt of guideline-
concordant follow-up visits, there was a significant difference of the follow-up visits within 
each provider specialty (Figure 4.4). This suggests that an interaction term may be 
appropriate to include in the regression analysis.  
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Figure 4.3 Proportion of Patients Completed Acute Phase by Initial Prescriber Specialty 
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Figure 4.4 Proportion of Patients Completed Acute Phase by Initial Prescriber Specialty and 
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 Table 4.7 presents the descriptive results between patients who completed acute phase 
and patients who did not. Similar to what Figure 4.3 showed, the proportion of patients who 
received initial antidepressant prescription from different provider specialties was similar 
across the groups. The proportion of patients who received guideline-concordant follow-up 
visits was statistically significantly higher among patients who completed acute phase 
(38.1%) than patients who did not (24.5%) (p<0.001). Patients who completed acute phase 
antidepressant treatment were statistically significantly older (41 vs. 39, p<0.001), lived in 
states with a higher median household income ($41,872 vs. $41,359, p<0.001) and in states 
with higher proportion of population with high school education (80.7% vs. 80.3%, p<0.001) 
than patients who did not complete acute phase. Patients who completed acute phase 
antidepressant treatment had a higher CDS (1.8 vs. 1.7, p=0.003), were less likely to have 
pre-existing substance abuse (3.5% vs. 5.1%, p=0.012), less likely to have pregnancy-related 
visits during acute phase (0.2% vs. 0.9%, p=0.003), and less likely to take a more-than-once-
daily antidepressant regimen (0.8% vs. 1.8%, p=0.003) compared with patients who 
completed acute phase.  
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Table 4.7 Baseline Characteristics between Patients who Completed Acute Phase and 
Patients Who Did Not 
Standard deviation in parentheses for continuous variables  
 Completed 
Acute Phase 
Not Completed 
Acute Phase 
P-value 
Number of observations 1,921 2,181  
% of sample 46.8 53.2  
Primary care provider (%) 58.8 60.2 0.367 
Psychiatrist (%) 36.1 34.3 0.232 
Non-psychiatric specialist (%) 5.1 5.5 0.568 
Guideline-concordant follow-up visits (%) 38.1 24.5 <0.001 
Age 41.0 (12.0) 39.1 (11.9) <0.001 
Age categories    
18-34 29.4 36.8 <0.001 
35-49 47.4 43.1 0.005 
50-64 20.6 18.8 0.156 
≥65 2.6 1.3 0.002 
Male (%) 34.2 35.2 0.497 
Region (%)    
East North Central 29.7 26.0 0.010 
East South Central 3.7 5.1 0.031 
Middle Atlantic 2.5 1.6 0.042 
Mountain 4.8 6.6 0.013 
New England 4.2 2.9 0.033 
Pacific 2.9 3.0 0.835 
South Atlantic 30.0 31.6 0.280 
West North Central 13.4 11.6 0.077 
West South Central 8.9 11.6 0.004 
Median household income in state of residence 41,872   (3,821) 41,359    (3,988) <0.001 
% with high school education is state of residence 80.7 (3.1) 80.3 (3.1) <0.001 
Chronic disease score 1.81 (0.85) 1.73 (0.80) 0.003 
Anxiety (%) 8.5 7.0 0.078 
Substance abuse (%) 3.5 5.1 0.012 
Pregnancy-related visits during acute phase (%) 0.2 0.9 0.003 
30-day copayment for index antidepressant 18.4 (10.0) 18.9 (11.6) 0.084 
30-day copayment categories for index antidepressant (%)    
$0-$10 12.6 13.1 0.623 
$11-$15 21.2 21.4 0.921 
$16-$20 30.0 27.5 0.075 
>$20 36.2 38.1 0.215 
Initial antidepressant (%)    
Bupropion 8.8 12.3 <0.001 
Citalopram 21.5 20.4 0.369 
Escitalopram 2.1 2.5 0.413 
Fluoxetine 13.5 12.4 0.314 
Mirtazapine 1.9 3.6 0.001 
Paroxetine 17.2 16.7 0.673 
Sertraline 23.9 23.1 0.554 
Venlafaxine 11.1 8.9 0.017 
More than one pill for daily antidepressant doses (%) 0.8 1.8 0.003 
Quarter of year of treatment initiation (%)    
Quarter 1 19.7 17.4 0.058 
Quarter 2 19.4 18.6 0.514 
Quarter 3 29.8 31.7 0.187 
Quarter 4 31.1 32.3 0.409 
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4.3.2.1.2 Multivariate Regression Analyses 
 Table 4.8 presents the odds ratios and 95% confidence intervals from the logistic 
regression model for acute phase antidepressant treatment completion. Since an interaction 
term between psychiatrist variable and the variable for receipt of guideline-concordant 
follow-up visits variable was included, the interpretation of the odds ratios is not straight 
forward because the outcome is binary. In addition, the significance of the interaction term 
needs to be examined with the marginal effects via the average of the probability method.99, 
100
 
The average of the probability based on the data showed that the interaction effect of 
psychiatrist and guideline-concordant follow-up visits was significant in some of the subjects. 
The marginal effect was 6.8 percentage points for the interaction term, which means receipt 
of guideline-concordant follow-up visits increased the probability of acute phase completion 
by additional 6.8 percentage points if patients were initially prescribed an antidepressant by a 
psychiatrist. The psychiatrist main effect was -4.6 percentage points, and the marginal effect 
of guideline-concordant follow-up visits was 13.1 percentage points. Combining the marginal 
effects all together, patients initially prescribed an antidepressant by a psychiatrist and having 
guideline-concordant follow-up visits had 15.3 percentage points higher probability of acute 
phase completion than patients initially prescribed an antidepressant by a PCP and not having 
guideline-concordant follow-up visits.  
Several other covariates were significant in predicting acute phase completion. 
Similar to prior studies2, 6, 13, 15, 43, we found older patients had higher odds of acute phase 
completion than younger patients (age group 35-49: OR=1.38, 95% CI=1.19-1.60; age group 
50-64: OR=1.39, 95% CI=1.15-1.68; age group ≥65: OR=2.77, 95% CI=1.67-4.58; age 
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group 18-34 as reference). Women who might have conceived during acute phase based on 
pregnancy-related medical visits were less likely to complete their acute phase antidepressant 
treatment (OR=0.26, 95% CI=0.08-0.80). It appeared that patients who were pregnant tend to 
terminate the antidepressant treatment although we were not able to distinguish whether that 
was based on clinical consideration by the provider or patients’ own willingness. Patients 
with a diagnosis of substance abuse (OR=0.62, 95% CI=0.45-0.86) or were on more complex 
daily antidepressant regimen (OR=0.32, 95% CI=0.17-0.58) were less likely to complete 
acute phase antidepressant treatment. Patients taking bupropion (OR=0.64, 95% CI=0.49-
0.84) and mirtazapine (OR=0.42, 95% CI=0.27-0.65) were less likely to complete acute 
phase compared with patients taking fluoxetine.  
The results based on seemingly unrelated regression using bivariate probit model to 
account for correlations between error terms of guideline-concordant follow-up visits and 
acute phase completion regressions found no difference. Hence, we modeled them separately 
as presented.  
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Table 4.8 Logistic Regression for Acute Phase Completion Model 
  
 
 
Variable Category Odds Ratio 95% CI 
Primary care provider   Reference  
Psychiatrist   0.82 (0.68-0.99) 
Non-psychiatric specialist   0.90 (0.67-1.19) 
Receipt of guideline-concordant follow-up   1.73 (1.41-2.11) 
Psychiatrist x follow-up interaction  1.34 (0.99-1.79) 
Age group 18-34 Reference  
 35-49 1.38 (1.19-1.60) 
 50-64 1.39 (1.15-1.68) 
 ≥65 2.77 (1.67-4.58) 
Male  0.94 (0.82-1.08) 
Region East North Central  1.08 (0.86-1.37) 
 East South Central  0.95 (0.66-1.38) 
 Middle Atlantic  1.44 (0.89-2.34) 
 Mountain  0.70 (0.49-1.01) 
 New England  1.20 (0.80-1.78) 
 Pacific  0.91 (0.60-1.38) 
 South Atlantic  Reference  
 West North Central  1.10 (0.84-1.43) 
 West South Central  0.95 (0.73-1.25) 
Income (in per 1000)  1.02 (0.99-1.04) 
% with high school education   1.02 (0.98-1.06) 
Pregnancy-related visits during acute phase  0.26 (0.08-0.80) 
Chronic disease score  1.07 (0.99-1.16) 
Anxiety   1.11 (0.87-1.41) 
Substance abuse  0.62 (0.45-0.86) 
30-day antidepressant copay $0-$10  0.88 (0.70-1.10) 
 $11-$15  0.97 (0.81-1.16) 
 $16-$20 1.09 (0.93-1.29) 
 >$20  Reference  
Daily number of pills 1 Reference  
 ≥2 0.32 (0.17-0.58) 
Initial antidepressant Bupropion  0.64 (0.49-0.84) 
 Citalopram 0.89 (0.71-1.11) 
 Escitalopram  0.80 (0.50-1.26) 
 Fluoxetine  Reference  
 Mirtazapine  0.42 (0.27-0.65) 
 Paroxetine  0.85 (0.67-1.08) 
 Sertraline  0.88 (0.71-1.10) 
 Venlafaxine 1.21 (0.91-1.60) 
Quarter of year  Quarter 1 Reference  
 Quarter 2 0.94 (0.76-1.16) 
 Quarter 3 0.83 (0.69-1.00) 
 Quarter 4 0.87 (0.72-1.05) 
Sample size= 4,102    
C-statistic=0.63    
  132 
 
 4.3.2.1.3 Propensity Score Matching 
 A similar logistic regression was run based on the cohort of 2,408 propensity score 
matched subjects with the same independent variables. Table 4.9 presents the odds ratios and 
marginal effects of several key independent variables before and after the propensity score 
matching. The psychiatrist coefficient became insignificant after matching, and the 
interaction effect also diminished. This is most likely due to marginal significance of these 
variables and decrease in sample size after the matching. The coefficient and marginal effect 
of receipt of guideline-concordant follow-up visits increased slightly compared to the pre-
matching coefficient. However, results are similar because the confidence intervals 
overlapped. 
Table 4.9 Odds Ratios and Marginal Effects of Provider and Follow-up for Acute Phase 
Model Before and After Propensity Score Matching 
Note: 95% CI in parentheses. Regressions include all the covariates listed in Table 4.8 
* p<0.05 
Variable Pre-matching Post-matching 
 
N=4,102 N=2,408 
 
Odds Ratio 
Primary care provider  Reference Reference 
Psychiatrist  0.82* (0.68-0.99) 0.85   (0.69-1.06) 
Non-psychiatric specialist  0.90   (0.67-1.19) - 
Receipt of guideline-concordant follow-up  1.73* (1.41-2.11) 1.90* (1.42-2.54) 
Psychiatrist x follow-up interaction 1.33   (0.99-1.79) 1.18   (0.81-1.72) 
 Marginal Effects 
Primary care provider Reference Reference 
Psychiatrist -0.046 -0.036 
Receipt of guideline-concordant follow-up 0.131 0.153 
Psychiatrist and follow-up interaction 0.068 0.039 
  133 
 
4.3.2.2 Continuation Phase 
4.3.2.2.1 Descriptive Analyses 
 Continuation phase analyses were conducted on the sub-sample who completed acute 
phase. (N=1,921). Overall, 44.9% of these patients completed continuation phase, and no 
significant difference was found when stratified by provider specialty (Figure 4.5). 
 When comparing the difference between patients who completed continuation phase 
and patients who did not in the descriptive analysis, few variables were significant (Table 
4.10). Patients who completed continuation phase antidepressant treatment were more likely 
to be older (42.5 vs. 39.8, p<0.001), to receive three or more outpatient follow-up visits 
during continuation phase (40.4% vs. 36.1%, p=0.047), and had a higher CDS (1.9 vs. 1.7, 
p<0.001), and less likely to be male (31.8% vs. 36.2%, p=0.044) than patients who did not 
complete continuation phase. There were no unadjusted differences by provider specialty. 
Figure 4.5 Proportion of Patients Completed Continuation Phase by Initial Prescriber 
Specialty 
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Table 4.10 Baseline Characteristics by Patients who Completed Continuation Phase and 
Patients Who Did Not 
Standard deviation in parentheses for continuous variables  
 Completed 
Continuation Phase 
Not Completed  
Continuation  Phase 
P-value 
Number of observations 862 1,059  
% of sample 44.9 55.1  
Primary care provider (%) 58.4 59.1 0.737 
Psychiatrist (%) 36.8 35.6 0.594 
Non-psychiatric specialist (%) 4.9 5.3 0.681 
≥3 follow-up visits in continuation phase (%) 40.4 36.1 0.047 
Age 42.5 (11.8) 39.8 (12.0) <0.001 
Age categories (%)    
18-34 24.7 33.2 <0.001 
35-49 48.3 46.7 0.508 
50-64 24.3 17.6 <0.001 
≥65 2.8 2.5 0.625 
Male (%) 31.8 36.2 0.044 
Region (%)    
East North Central 29.2 30.0 0.705 
East South Central 3.7 3.7 0.973 
Middle Atlantic 1.9 3.0 0.104 
Mountain 5.3 4.3 0.311 
New England 4.3 4.1 0.800 
Pacific 2.4 3.3 0.260 
South Atlantic 30.6 29.5 0.579 
West North Central 14.4 12.7 0.268 
West South Central 8.1 9.4 0.310 
Median household income in state of residence 41,844    (3,811) 41,896    (3,830) 0.768 
% with high school education in state of residence 80.7 (3.1) 80.6 (3.1) 0.702 
Chronic disease score 1.88 (0.88) 1.75 (0.82) <0.001 
Anxiety (%) 9.2 7.9 0.335 
Substance abuse (%) 3.3 3.7 0.606 
Pregnancy-related visits in continuation phase (%) 0.7 1.3 0.179 
30-day copayment for index antidepressant 18.3 (9.5) 18.4 (10.4) 0.777 
30-day copayment categories for antidepressant (%)    
$0-$10 12.5 12.7 0.935 
$11-$15 19.5 22.7 0.091 
$16-$20 31.8 28.5 0.120 
>$20 36.2 36.2 0.990 
Initial antidepressant (%)    
Bupropion 8.4 9.2 0.476 
Citalopram 20.8 22.0 0.552 
Escitalopram 2.0 2.3 0.657 
Fluoxetine 12.3 14.5 0.170 
Mirtazapine 2.0 1.8 0.775 
Paroxetine 17.89 16.7 0.506 
Sertraline 24.5 23.4 0.588 
Venlafaxine 12.3 10.2 0.146 
More than one pill for daily doses (%) 0.9 0.7 0.508 
Quarter of year of treatment initiation (%)    
Quarter 1 19.1 20.2 0.559 
Quarter 2 20.9 18.2 0.143 
Quarter 3 29.9 29.7 0.894 
Quarter 4 30.1 31.9 0.378 
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4.3.2.2.2 Multivariate Regression Analyses 
Table 4.11 presents the odds ratios and 95% confidence intervals from logistic 
regression for completion of continuation phase antidepressant treatment. Provider specialty 
was not significant. In this model, we examine receipt of three or more outpatient follow-up 
visits during the continuation phase and found an OR of 1.59 (95% CI=1.29-1.97). Compared 
with patients aged 18-34, patients aged 35-49 and aged 50-64 were significantly more likely 
to complete continuation phase (OR=1.4, 95% CI=1.12-1.74 and OR=1.8, 95% CI=1.36-2.39, 
respectively). Males were significantly less likely to complete continuation phase (OR=0.79, 
95% CI=0.65-0.97).  
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Table 4.11 Logistic Regression for Continuation Phase Completion Model 
  
Variable Category Odds Ratio 95% CI 
Primary care provider   Reference  
Psychiatrist   0.99 (0.79-1.21) 
Non-psychiatric specialist   0.82 (0.53-1.26) 
Received three or more follow-up visits 
during continuation phase 
 1.59 (1.29-1.97) 
Age group 18-34 Reference  
 35-49 1.40 (1.12-1.74) 
 50-64 1.81 (1.36-2.39) 
 ≥65 1.50 (0.81-2.80) 
Male  0.79 (0.65-0.97) 
Region East North Central  1.04 (0.74-1.45) 
 East South Central  0.99 (0.55-1.76) 
 Middle Atlantic  0.62 (0.33-1.17) 
 Mountain  1.44 (0.82-2.53) 
 New England  1.09 (0.64-1.87) 
 Pacific  0.74 (0.39-1.40) 
 South Atlantic  Reference  
 West North Central  1.30 (0.89-1.91) 
 West South Central  0.75 (0.50-1.14) 
Income (in per 1000)  0.99 (0.96-1.03) 
% with high school education   0.98 (0.92-1.04) 
Pregnancy-relate visits during continuation 
phase 
 0.60 (0.24-1.52) 
Chronic disease score  1.13 (1.00-1.27) 
Anxiety   1.08 (0.77-1.50) 
Substance abuse  0.75 (0.45-1.24) 
30-day antidepressant copayment $0-$10  1.05 (0.76-1.45) 
 $11-$15  0.86 (0.66-1.12) 
 $16-$20 1.14 (0.90-1.44) 
 >$20  Reference  
Daily number of pills 1 Reference  
 ≥2 1.15 (0.38-3.48) 
Initial antidepressant Bupropion  1.00 (0.66-1.51) 
 Citalopram 1.03 (0.74-1.43) 
 Escitalopram  1.10 (0.53-2.27) 
 Fluoxetine  Reference  
 Mirtazapine  1.17 (0.59-2.33) 
 Paroxetine  1.23 (0.87-1.73) 
 Sertraline  1.20 (0.87-1.66) 
 Venlafaxine 1.41 (0.95-2.08) 
Quarter of year  Quarter 1 Reference  
 Quarter 2 1.25 (0.93-1.68) 
 Quarter 3 1.11 (0.85-1.45) 
 Quarter 4 1.03 (0.79-1.35) 
Sample size=1,921    
c-statistic=0.62    
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4.3.2.2.3 Propensity Score Matching 
 A logistic regression was run on the sub-sample who completed acute phase based on 
the propensity score matched sample with the same model specification (N=1,121). Results 
are generally similar before and after the matching (Table 4.12). 
Table 4.12 Odds Ratios of Provider and Follow-up in Continuation Phase Model before and 
after Propensity Score Matching 
Note: 95% CI in parentheses. Regressions include all the covariates listed in Table 4.11 
* p<0.05 
 
In summary, our analyses shows that receipt of guideline-concordant follow-up visits 
in the acute phase and receipt of three or more visits during the continuation phase are the 
strongest predictors in antidepressant treatment completion in each phase respectively, and 
provider specialty is insignificant. 
Variable Odds Ratio 
 
Pre-matching Post-matching 
 
N=1,921 N=1,121 
Primary care provider    Reference   Reference 
Psychiatrist  0.98   (0.79-1.21)  0.94   (0.72-1.21) 
Non-psychiatric specialist  0.82   (0.53-1.26) - 
Received three or more follow-up visits 
during continuation phase 
1.59* (1.29-1.97) 1.86* (1.42-2.44) 
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4.4 Aim 3 
To examine the association of subsequent healthcare utilization with initial prescriber 
specialty and antidepressant treatment among patients with MDD  
This aim examines whether initial prescriber specialty and antidepressant treatment 
completion influence healthcare utilization in the subsequent one-year period. The following 
sections report the results from Aim 3 of acute phase model (4.4.1) and continuation phase 
models (4.4.2). 
4.4.1 Acute Phase 
4.4.1.1 Descriptive Analyses 
 Based on the whole study cohort, we found 18.8% of patients had all-cause utilization 
(hospitalization or emergency room visits) and 8.2% of patients had all-cause hospitalization 
during the one-year period after acute phase. When stratified by initial prescriber specialty, a 
statistically significantly higher proportion of patients initially prescribed an antidepressant 
by psychiatrists had all-cause utilization (21.5% vs. 16.6%, p<0.001), and a statistically 
significantly higher proportion of patients initially prescribed an antidepressant by non-
psychiatric specialists had all-cause utilization (26.2% vs. 16.6%, p<0.05) and hospitalization 
(15.1% vs. 7.4%, p<0.001) than patients initially prescribed an antidepressant by PCPs 
(Figure 4.6).  
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Figure 4.6 Proportion of All-cause Hospitalization and Utilization by Initial Prescriber 
Specialty during One-year after Acute Phase 
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* p<0.05 compared to PCP 
 
Table 4.13 gives the top ten diagnostic codes of all-cause utilization and 
hospitalization. The initial utilization, if any, usually was an emergency room visit which was 
more minor and may or may not lead to a consequent hospital stay. Hence, the distribution of 
primary diagnosis of these events for all-cause utilization was less concentrated (2.5% for the 
top ICD-9 code), and more symptom-related (e.g. headache, chest pain, abdominal pain).  
Mental health-related causes took up two of the top ten Diagnostic Related Group (DRG) in 
all-cause hospitalization (psychoses and substance abuse). Among the top ten DRG, three of 
the causes are related to birth delivery (Table 4.13). We did not consider these as adverse 
events, and we controlled for pregnancy in the statistical models.   
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 Table 4.13 List of Top 10 Primary ICD-9 Diagnosis Codes for All-cause Utilization and Top 
10 DRG Codes for All-cause Hospitalization during One Year after Acute Phase 
 All-cause Utilization 
Rank ICD-9 code ICD-9 description Frequency Percentage 
1 7840 Headache 19 2.46 
2 78659 Chest pain 16 2.07 
3 34690 Migraine 11 1.42 
4 5990 Urinary tract infection 10 1.30 
5 78909 Abdominal pain 10 1.30 
6 V7612 Screening for malignant neoplasm 10 1.30 
7 78650 Chest pain, unspecified 9 1.17 
8 8830 Open wound of fingers 9 1.17 
9 7242 Lumbogo 8 1.04 
10 7802 Syncope and collapse 8 1.04 
 All-cause Hospitalization 
 DRG code DRG description Frequency Percentage 
1 373 Vaginal delivery w/o complicating 
diagnoses 
25 7.44 
2 430 Psychoses 23 6.85 
3 359 Uterine & Adnexa procedure for non-
malignancy w/o complications 
16 4.76 
4 523 Alcohol/drug abuse or dependent w/o 
rehabilitation therapy w/o complications 
9 2.68 
5 288 O.R. procedures for obesity 8 2.38 
6 371 Cesarean section w/o complications 8 2.38 
7 024 Seizure & headache age>17 with 
complications 
6 1.79 
8 358 Uterine & Adnexa procedure for non-
malignancy with complications 
6 1.79 
9 372 Vaginal delivery with complicating 
diagnoses 
6 1.79 
10 520 Cervical spinal fusion w/o 
complications 
6 1.79 
 
  141 
 
 We found 5.3% of the study cohort had mental health-related utilization (hospital 
admissions and emergency room visits), and 3.4% of patients had mental health-related 
hospitalization. When stratified by initial prescriber specialty, a statistically significantly 
higher proportion of patients initially prescribed an antidepressant by psychiatrists had 
mental health-related utilization (6.8% vs. 4.4%, p<0.05) and mental health-related 
hospitalization (4.2% vs. 3.0%, p<0.05) than patients initially prescribed an antidepressant by 
PCPs (Figure 4.7). 
 
Figure 4.7 Proportion of Mental Health-related Hospitalization and Utilization by Initial 
Prescriber Specialty during One-year d after Acute Phase 
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Table 4.14 describes the baseline characteristics between patients who had utilization 
and patients who did not. Patients without all-cause utilization were more likely to complete 
acute phase antidepressant treatment (47.8% vs. 42.9%, p=0.015). Patients with all-cause 
utilization had statistically significantly lower proportion of male (31.1%) than patients 
without all-cause utilization (35.6%) (p<0.001), which might be confounded by pregnancy. A 
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statistically significantly higher proportion of patients who had prior hospitalization (12.7% 
vs. 5.3%, p<0.001), pre-existing substance abuse (6.9% vs. 3.8%, p<0.001), and a higher 
CDS (2.0 vs. 1.7, p<0.001) were found among patients who had all-cause utilization than 
patients who did not. Patients who had all-cause utilization were more likely to reside in 
states with higher median household income ($41,889 vs. $41,532, p=0.023) and in states 
with a higher proportion of population with high school education (80.8% vs. 80.3%, 
p<0.001) compared with patients who did not have all-cause utilization. 
Among patient with mental health-related utilization, we found a statistically 
significantly higher proportion of patients initially prescribed by a psychiatrist (45% vs. 35%, 
p=0.002) and a lower proportion of patients initially prescribed by a PCP (49% vs. 60%, 
p=0.002) compared with patients without mental health-related utilization. Patients who had 
mental health-related utilization were more likely to have prior hospitalization (14.3% vs. 
6.2%, p<0.001), a higher CDS (2.2 vs. 1.7, p<0.001), pre-existing anxiety (13.4% vs. 7.4 
%, p=0.001), and pre-existing substance abuse (13.4% vs. 3.8%, p<0.001) than patients who 
did not have mental health-related utilization. Patients who had mental health-related 
utilization were more likely to reside in states with a higher median household income 
($42,409 vs. $41,554, p=0.002) and in states with a higher proportion of population with high 
school education (81.3% vs. 80.4%, p<0.001) compared with patients who did not have 
mental health-related utilization. 
 Table 4.15 presents the descriptive results for hospitalization. A statistically 
significantly lower proportion of patients initially prescribed an antidepressant by a PCP 
(53.6% vs. 60.0%, p=0.021) and a higher proportion of patients initially prescribed by a non-
psychiatric specialist (9.8% vs. 4.9%, p<0.001) were found among patients who had all-cause 
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hospitalization compared with patients who did not have all-cause hospitalization. Patients 
who had all-cause hospitalization were more likely to be older (42.1 vs. 39.8, p<0.001), have 
prior hospitalization (14.9% vs. 5.9%, p<0.001), pregnancy-related visits during acute phase 
(4.8% vs. 0.2%, p<0.001), a higher CDS (2.3 s. 1.7, p<0.001), pre-existing anxiety (11.6% vs. 
7.4%, p=0.005), and pre-existing substance abuse (8.9% vs. 3.9% p<0.001) compared to 
patients who did not have all-cause hospitalization.  
Among patient with mental health-related hospitalization, we found a statistically 
significantly lower proportion of patients initially prescribed an antidepressant by a PCP 
(51.4% vs. 59.8%, p=0.048) compared with patients without mental health-related 
hospitalization. Patients who had mental health-related hospitalization had a statistically 
significantly higher proportion of patients in ≥65 age groups than patients who did not have 
mental health-related hospitalization (4.3% vs. 1.8%, p=0.036). Patients who had mental 
health-related hospitalization were more likely to have prior hospitalization (12.9% vs. 6.4%, 
p=0.003), pregnancy-related visits during acute phase (2.1% vs. 0.5%, p=0.014), a higher 
CDS (2.2 vs., 1.8, p<0.001), pre-existing anxiety (16.4% vs. 7.4%, p<0.001), and pre-
existing substance abuse (13.6% vs. 4.0%, p<0.001) compared with patients without mental 
health-related hospitalization. Patients who had mental health-related hospitalization were 
more likely to reside in states with higher a median household income ($42,746 vs. $41,559 
p<0.001) and in states with a higher proportion of population with high school education 
(81.3% vs. 80.4%, p=0.002) compared with patients without mental health-related 
hospitalization. 
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Table 4.14 Baseline Characteristics between Patients Who Had Utilization and Patients Who Did Not for Acute Phase Analysis 
Standard deviation in parentheses for continuous variables  
 All-cause Utilization Mental Health-related  Utilization 
 Had Utilization No Utilization P-value Had Utilization No Utilization P-value 
Number of observations 772 3,330  217 3,952  
% of sample 18.8 81.2  5.3 95.7  
Primary care provider (%) 52.5 61.1 0.021 49.3 60.1 0.002 
Psychiatrist (%) 40.2 34.0 0.001 45.2 34.6 0.002 
Non-psychiatric specialist (%) 7.4 4.8 0.004 5.5 5.3 0.884 
Complete acute phase antidepressant treatment (%) 42.9 47.8 0.015 41.9 47.1 0.138 
Age 40.0 (12.7) 40.0 (11.8) 0.920 40.9 (12.9) 39.9 (11.9) 0.266 
Age categories (%)       
18-34 34.7 33.0 0.372 32.3 33.4 0.726 
35-49 42.2 45.8 0.073 41.9 45.3 0.332 
50-64 20.7 19.4 0.393 22.6 15.9 0.260 
≥65 2.3 1.8 0.331 3.2 1.8 0.142 
Male (%) 31.1 35.6 0.018 36.9 34.6 0.499 
Median income in state of residence 41,889 (3,769) 41,532 (3,950) 0.023 42,409 (3,861) 41,554 (3,918) 0.002 
% population with high school education in state of residence 80.8 (2.9) 80.3 (3.2) <0.001 81.3 (2.9) 80.4 (3.1) <0.001 
Region (%)       
East North Central 33.9 26.3 <0.001 37.8 27.2 0.001 
East South Central 3.6 4.6 0.225 1.8 4.6 0.057 
Middle Atlantic 0.8 2.3 0.006 0.5 2.1 0.093 
Mountain 4.7 6.0 0.149 5.1 5.8 0.657 
New England 4.7 3.2 0.053 5.5 3.4 0.097 
Pacific 1.2 3.4 0.001 0.9 3.1 0.067 
South Atlantic 29.0 31.2 0.230 26.3 31.1 0.136 
West North Central 15.3 11.8 0.008 16.6 12.2 0.058 
West South Central 6.9 11.1 0.001 5.5 10.6 0.018 
Prior Hospitalization (%) 12.7 5.3 <0.001 14.3 6.2 <0.001 
Pregnancy visits during acute phase (%) 2.2 0.2 <0.001 1.4 0.5 0.114 
Chronic disease score 2.0 (1.01) 1.7 (0.77) <0.001 2.2 (1.01) 1.7 (0.81) <0.001 
Anxiety (%) 8.9 7.4 0.153 13.4 7.4 0.001 
Substance abuse (%) 6.9 3.8 <0.001 13.4 3.8 <0.001 
Quarter of year of treatment initiation (%)       
Quarter 1 20.1 18.1 0.211 21.2 18.4 0.293 
Quarter 2 20.6 18.6 0.207 22.6 18.8 0.166 
Quarter 3 30.1 31.0 0.622 27.2 31.0 0.238 
Quarter 4 29.3 32.3 0.106 29.0 31.9 0.383 
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Table 4.15 Baseline Characteristics between Patients Who Had Hospitalization and Patients Who Did Not for Acute Phase Analysis 
Standard deviation in parentheses for continuous variables  
 All-cause Hospitalization Mental Health-related Hospitalization 
 Hospitalized Not Hospitalized P-value Hospitalized Not Hospitalized P-value 
Number of observations 336 3,766  140 3,962  
% of sample 8.2 91.8  3.4 96.6  
Primary care provider (%) 53.6 60.0 0.021 51.4 59.8 0.048 
Psychiatrist (%) 36.6 35.1 0.567 42.9 34.9 0.053 
Non-psychiatric specialist (%) 9.8 4.9 <0.001 5.7 5.3 0.830 
Complete acute phase antidepressant treatment (%) 41.1 47.3 0.027 45.7 46.9 0.788 
Age 42.1 (13.2) 39.8 (11.9) <0.001 41.9 (13.3) 39.9 (11.9) 0.054 
Age categories       
18-34 (%) 30.4 33.6 0.225 30.7 33.4 0.501 
35-49 (%) 40.8 45.5 0.094 39.3 45.3 0.158 
50-64 (%) 24.4 19.2 0.021 19.4 25.7 0.065 
≥65 (%) 4.5 1.7 <0.001 4.3 1.8 0.036 
Male (%) 30.7 35.1 0.101 35.0 34.7 0.947 
Median income in state of residence 41,987 (4,151) 41,565 (3,896) 0.058 42,746 (4,049) 41,559 (3,909) <0.001 
% population with high school education in state of 
residence 
80.7 (3.1) 60.4 (3.1) 0.118 81.3 (3.0) 80.4 (3.1) 0.002 
East North Central (%) 31.3 27.4 0.134 35.7 27.5 0.032 
East South Central (%) 4.2 4.5 0.802 2.1 4.5 0.180 
Middle Atlantic (%) 1.8 2.1 0.747 0.7 2.1 0.263 
Mountain (%) 6.0 5.7 0.870 5.7 5.7 0.984 
New England (%) 4.5 3.4 0.321 5.7 3.4 0.149 
Pacific (%) 2.4 3.0 0.504 1.4 3.0 0.273 
South Atlantic (%) 26.2 31.2 0.055 23.6 31.1 0.059 
West North Central (%) 14.0 12.3 0.375 17.9 12.3 0.049 
West South Central (%) 9.8 10.3 0.769 7.1 10.4 0.213 
Prior Hospitalization (%) 14.9 5.9 <0.001 12.9 6.4 0.003 
Pregnancy visits during acute phase (%) 4.8 0.2 <0.001 2.1 0.5 0.014 
Chronic disease score 2.3 (1.16) 1.7 (0.77) <0.001 2.2 (1.06) 1.8 (0.81) <0.001 
Anxiety (%) 11.6 7.4 0.005 16.4 7.4 <0.001 
Substance abuse (%) 8.9 3.9 <0.001 13.6 4.0 <0.001 
Quarter of year of treatment initiation       
Quarter 1 (%) 18.8 18.5 0.903 20.0 18.5 0.643 
Quarter 2 (%) 19.6 18.9 0.750 24.3 18.8 0.104 
Quarter 3 (%) 31.6 30.7 0.753 25.7 31.0 0.186 
Quarter 4 (%) 30.1 31.9 0.496 30.0 31.8 0.657 
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4.4.1.2 Multivariate Regression Analyses 
 Table 4.16 presents the odds ratios and 95% confidence intervals from acute phase 
model for utilization. Patients initially prescribed an antidepressant by psychiatrists 
(OR=1.37, 95% CI=1.15-1.63) and non-psychiatric specialists (OR=1.57, 95% CI=1.12-2.19) 
were more likely to have all-cause utilization. Patients who completed acute phase were less 
likely to have all-cause utilization (OR=0.79, 95% CI=0.67-0.93). Men were less likely to 
have all-cause utilization than women (OR=0.8, 95% CI=0.67-0.95). Patients with 
pregnancy-related visits during acute phase were much more likely of having all-cause 
utilization than patients without pregnancy-related visits (OR=8.96, 95%CI=3.38-23.76). 
Need factors such as prior hospitalization (OR=1.76, 95% CI=1.32-2.35) and higher CDS 
(OR=1.47, 95% CI=1.33-1.62) appeared to be strong predictors of all-cause utilization. 
 When limited to mental health-related utilization, only an initial prescription from a 
psychiatrist was significant (OR=1.54, 95% CI=1.14-2.07). Completion of acute phase 
antidepressant treatment was marginally significant in preventing mental health-related 
utilization (OR=0.75, 95% CI=0.56-0.99). A higher CDS (OR=1.52, 95% CI= 1.32-1.75), 
pre-existing anxiety (OR=1.56, 95% CI=1.04-2.36) and substance abuse (OR=2.87, 95% 
CI=1.80-4.57) were significant in predicting greater likelihood of mental health-related 
utilization.  
 Table 4.17 presents the odds ratios from models for hospitalization. Patients initially 
prescribed an antidepressant by non-psychiatric specialists were more likely to have all-cause 
hospitalization (OR=1.99, 95% CI=1.28-3.07) than patients initially prescribed an 
antidepressant by PCPs. Completion of acute phase antidepressant treatment had a protective 
effect against risk of all-cause hospitalization (OR=0.75, 95% CI=0.59-0.95). Patients with 
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pregnancy-related visits during acute phase were much more likely to have all-cause 
hospitalization (OR=24.6, 95% CI=9.4-64.8). A higher CDS (OR=1.69, 95% CI=1.50-1.90) 
and pre-existing substance abuse (OR=1.79, 95% CI=1.14-2.82) increased the likelihood of 
all-cause hospitalization.  
 When limited to mental health-related hospitalization, neither provider specialty nor 
completion of acute phase was significant. Only need factors including pregnancy-related 
visits during acute phase (OR=3.9, 95% CI=1.17-12.95), higher CDS (OR=1.58, 95% 
CI=1.33-1.88), pre-existing anxiety (OR=2.01, 95% CI=1.26-3.20), and pre-existing 
substance abuse (OR=3.02, 95% CI=1.76-5.19) were significant.  
 
 
  
148
Table 4.16 Logistic Regressions for Utilization after Acute Phase 
  
 
 All-cause Utilization Mental Health-related Utilization 
Variable Category Odds Ratio 95% CI Odds Ratio 95% CI 
Primary care provider   Reference  Reference  
Psychiatrist   1.37 (1.15-1.63) 1.54 (1.14-2.07) 
Non-psychiatric specialist   1.57 (1.12-2.19) 1.05 (0.55-2.00) 
Completed acute phase  0.79 (0.67-0.93) 0.75 (0.56-0.99) 
Age group 18-34 Reference  Reference  
 35-49 0.83 (0.69-1.00) 0.85 (0.61-1.19) 
 50-64 0.79 (0.62-1.00) 0.87 (0.57-1.32) 
 ≥65 0.80 (0.44-1.49) 1.13 (0.47-2.73) 
Male  0.80 (0.67-0.95) 1.00 (0.74-1.34) 
Income (in per 1000)  1.00 (0.96-1.04) 1.02 (0.95-1.09) 
% with high school education   0.97 (0.92-1.02) 1.02 (0.93-1.11) 
Region East North Central  1.66 (1.23-2.25) 1.56 (0.92-2.63) 
 East South Central  0.79 (0.48-1.30) 0.59 (0.19-1.82) 
 Middle Atlantic  0.39 (0.17-0.89) 0.24 (0.03-1.91) 
 Mountain  1.03 (0.65-1.65) 1.01 (0.46-2.22) 
 New England  1.70 (1.05-2.74) 1.75 (0.76-4.03) 
 Pacific  0.41 (0.18-0.86) 0.36 (0.08-1.58) 
 South Atlantic  Reference  Reference  
 West North Central  1.60 (1.14-2.24) 1.46 (0.81-1.64) 
 West South Central  0.61 (0.42-0.89) 0.77 (0.37-1.58) 
Pregnancy visits during acute phase  8.96 (3.38-23.76) 2.14 (0.62-7.40) 
Prior Hospitalization  1.76 (1.32-2.35) 1.26 (0.80-1.98) 
Chronic disease score  1.47 (1.33-1.62) 1.52 (1.32-1.75) 
Anxiety   1.04 (0.77-1.40) 1.56 (1.04-2.36) 
Substance abuse  1.40 (0.98-1.99) 2.87 (1.80-4.57) 
Quarter of year  Quarter 1 Reference  Reference  
 Quarter 2 1.02 (0.79-1.33) 1.08 (0.71-1.65) 
 Quarter 3 0.92 (0.72-1.16) 0.77 (0.51-1.15) 
 Quarter 4 0.85 (0.67-1.07) 0.81 (0.54-1.21) 
Sample size=4,102 c-statistic=0.66   c-statistic=0.71  
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Table 4.17 Logistic Regressions for Hospitalization after Acute Phase 
  
 
 All-cause Hospitalization Mental Health-related 
Hospitalization 
Variable Category Odds Ratio 95% CI Odds Ratio 95% CI 
Primary care provider   Reference  Reference  
Psychiatrist   1.17 (0.90-1.51) 1.41 (0.97-2.04) 
Non-psychiatric specialist   1.99 (1.28-3.07) 1.09 (0.49-2.41) 
Completed acute phase  0.75 (0.59-0.95) 0.87 (0.61-1.25) 
Age group 18-34 Reference  Reference  
 35-49 0.92 (0.69-1.22) 0.83 (0.55-1.26) 
 50-64 1.02 (0.72-1.45) 1.04 (0.62-1.72) 
 ≥65 1.59 (0.82-3.10) 1.45 (0.56-3.79) 
Male  0.83 (0.64-1.06) 0.93 (0.64-1.35) 
Income (in per 1000)  1.05 (0.64-1.06) 1.08 (1.00-1.18) 
% with high school education   0.99 (0.91-1.07) 1.00 (0.90-1.11) 
Region East North Central  1.24 (0.80-1.91) 1.31 (0.70-2.45) 
 East South Central  1.40 (0.69-2.82) 1.02 (0.27-3.81) 
 Middle Atlantic  0.90 (0.38-2.13) 0.32 (0.04-2.64) 
 Mountain  1.11 (0.57-2.17) 1.02 (0.40-2.60) 
 New England  1.26 (0.62-2.55) 1.41 (0.51-3.94) 
 Pacific  0.73 (0.30-1.78) 0.41 (0.08-1.89) 
 South Atlantic  Reference  Reference  
 West North Central  1.20 (0.73-1.96) 1.39 (0.70-2.78) 
 West South Central  1.30 (0.78-2.19) 1.30 (0.57-2.99) 
Pregnancy visits during acute phase  24.63 (9.35-64.83) 3.90 (1.17-12.95) 
Prior Hospitalization  1.47 (1.00-2.15) 0.96 (0.54-1.72) 
Chronic disease score  1.69 (1.50-1.90) 1.58 (1.33-1.88) 
Anxiety   1.36 (0.94-1.97) 2.01 (1.26-3.20) 
Substance abuse  1.79 (1.14-2.82) 3.02 (1.76-5.19) 
Quarter of year  Quarter 1 Reference  Reference  
 Quarter 2 1.03 (0.71-1.50) 1.28 (0.76-2.14) 
 Quarter 3 1.01 (0.72-1.41) 0.78 (0.47-1.31) 
 Quarter 4 0.93 (0.66-1.32) 0.90 (0.55-1.48) 
Sample size=4,102 c-statistic=0.70   c-statistic=0.72  
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4.4.1.3 Propensity Score Matching 
 Similar logistic regressions were run based on the propensity score matched cohort of 
2,408 patients (Table 4.18). The results were generally consistent before and after matching 
except for the effect of acute phase completion for all-cause and mental health-related 
utilization model. Completion of acute phase antidepressant treatment had a significant 
protective effect against all-cause utilization before matching (OR=0.79, 95% CI=0.67-0.93), 
but such effect became insignificant in the logistic regression model based on the matched 
cohort (OR=0.86, 95% CI=0.69-1.07). Completion of acute phase antidepressant treatment 
had a marginally significant protective effect against mental health-related utilization before 
matching (OR=0.75, 95% CI=0.56-0.99), but such effect became insignificant after the 
matching (OR=0.79, 95% CI=0.51-1.22). 
Table 4.18 Odds Ratios of Utilization and Hospitalization for Acute Phase Model before and 
after Propensity Score Matching 
Note: 95% CI in parentheses. Regressions include all the covariates listed in Table 4.16 and Table 4.17 
*p<0.05 
 
In summary, we found patients initially prescribed an antidepressant by psychiatrists 
were statistically significantly more likely to have all-cause and mental health-related 
 
Utilization Hospitalization 
Variable All-cause Mental health-
related 
All-cause Mental health-
related 
 
Pre-matching 
Sample size N=4,102 
Primary care provider  Reference Reference Reference Reference 
Psychiatrist  1.37* (1.15-1.63) 1.54* (1.14-2.09) 1.17   (0.90-1.51) 1.41  (0.97-2.05) 
Non-psychiatric 
specialist  
1.57* (1.12-2.19) 1.05   (0.55-2.00) 1.99* (1.28-3.07) 1.09  (0.49-2.41) 
Completed acute phase 0.79* (0.67-0.93) 0.75*  (0.56-0.99) 0.75* (0.59-0.95) 0.87  (0.61-1.25) 
 Post-matching 
Sample size N=2,408 
Primary care provider  Reference Reference Reference Reference 
Psychiatrist  1.51* (1.22-1.86) 1.67* (1.07-2.61) 1.36 (0.99-1.86) 1.56 (0.99-2.45) 
Non-psychiatric 
specialist  
- - - - 
Completed acute phase 0.86   (0.70-1.07) 0.79  (0.51-1.22) 0.65* (0.47-0.89) 0.79 (0.49-1.19) 
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utilization during the one-year period after the acute phase, while patients initially prescribed 
an antidepressant by non-psychiatric specialists were more likely to have all-cause 
hospitalization compared with patients initially prescribed by PCPs. We also found that 
completion of acute phase have a protective effect over all-cause hospitalization.
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4.4.2 Continuation Phase 
 The following section presents the results based on the sub-population of patients 
who completed acute phase for continuation phase analyses. (N=1,921) 
4.4.2.1 Descriptive Analyses 
Overall, 17.4% of patients had all-cause utilization (hospitalization or emergency 
room visits), and 8.7% of patients had hospitalization during the one-year period after the 
continuation phase antidepressant treatment. When stratified by initial prescriber specialty, a 
statistically significantly higher proportion of patients initially prescribed an antidepressant 
by psychiatrists had all-cause utilization (20.3%) than patients initially prescribed an 
antidepressant by PCPs (15.5%) (p=0.008) (Figure 4.8). Differences were not found between 
patients initially prescribed an antidepressant by PCPs and by non-psychiatric specialists, 
which may due to small sample size of the latter group (N=98). 
The proportion of patients who had mental health-related utilization and mental 
health-related hospitalization was 5.3% and 3.7%, respectively. When stratified by initial 
prescriber specialty, a statistically significantly higher proportion of patients initially 
prescribed an antidepressant by psychiatrists had all-cause utilization (6.6%) than patients 
initially prescribed an antidepressant by PCPs (4.5%) (p<0.05) (Figure 4.9). 
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Figure 4.8 Proportion of All-cause Hospitalization and Utilization by Initial Prescriber 
Specialty during One-year after Continuation Phase 
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Figure 4.9 Proportion of Mental Health-related Hospitalization and Utilization by Initial 
Prescriber Specialty during One-year after Continuation Phase 
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 Table 4.19 presents baseline characteristics between patients who had utilization 
during the one-year period after the continuation phase and patients who did not. A 
statistically significantly lower proportion of patients were found to be initially prescribed an 
antidepressant by a PCP (52.2% vs. 60.1%, p=0.008) and a higher proportion was found to 
be initially prescribed an antidepressant by a psychiatrist (42.1% vs. 34.9%, p=0.012) among 
patients who had all-cause utilization than patients who did not have all-cause utilization. 
Patients who had all-cause utilization were more likely to be older (42.5 vs. 40.6, p=0.008), 
have prior hospitalization (12.8% vs. 5.1%, p<0.001), have a higher CDS (2.1 vs. 1.7, 
p<0.001), have pregnancy-related visits during continuation phase (3.9% vs. 0.4%, p<0.001), 
and have pre-existing substance abuse (11.0% vs. 7.9%, p=0.038) compared with patients 
who did not have all-cause utilization. Patients who had all-cause utilization were more likely 
to reside in states with a higher proportion of population with high school education (81.0% 
vs. 80.6%, p=0.031) compared with patients who did not have all-cause utilization. 
No difference in provider specialty and completion of continuation phase were found 
when examining mental health-related utilization. Patients who had mental health-related 
utilization were more likely to be older (44.9 vs. 40.7, p<0.001), have prior hospitalization 
(15.7% vs. 5.9%, p<0.001), have a higher CDS (2.4, vs. 1.8, p<0.001), have pre-existing 
anxiety (14.7% vs. 8.1%, p=0.021), have pre-existing substance abuse (11.7% vs. 3.0%, 
p<0.001), and have initial treatment during the first quarter of year (29.9% vs. 19.2%, 
p=0.012) compared with patients who did not have mental health-related utilization. Patients 
who had mental health-related utilization were more likely to reside in states with a higher 
median household income ($42,783 vs. $41,822, p=0.013) and in states with a higher 
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proportion of population with high school education (81.5% vs. 80.6%, p=0.003) than 
patients without mental health-related utilization. 
Table 4.20 presents baseline characteristics between patients who had hospitalization 
during the one-year period after the continuation phase and patients who did not. For all-
cause hospitalization, no differences were found in provider specialty and completion of 
continuation phase antidepressant treatment. Patients who had all-cause hospitalization were 
more likely to be older (45.6 vs. 40.5, p<0.001), have prior hospitalization (16.8% vs. 5.4%, 
p<0.001), have a higher CDS (2.4 vs. 1.8, p<0.001), have pregnancy-related visits during 
continuation phase (7.8% vs. 0.4%, p<0.001), have pre-existing anxiety (15.6% vs. 7.8%, 
p=0.001), and have pre-existing substance abuse (6.6% vs. 3.2%, p=0.022) compared with 
patients who did not have all-cause hospitalization. Patients who had all-cause hospitalization 
were more likely to reside in states with a higher median household income ($42,469 vs. 
$41,815, p=0.035) than patients without all-cause hospitalization. 
No differences were found in provider specialty and completion of continuation phase 
antidepressant treatment for mental health-related hospitalization. Patients who had mental 
health-related hospitalization were more likely to be older (47.5 vs. 40.7, p<0.001), have 
prior hospitalization (19.7% vs. 5.9%, p<0.001), have a higher CDS (2.4 vs. 1.8, p<0.001), 
have pre-existing anxiety (18.3% vs. 8.1%, p=0.002), have pre-existing substance abuse 
(8.5% vs. 3.3%, p=0.02), and have the initial treatment in the first quarter of year (33.8% vs. 
19.2%, p=0.002) compared with patients who did not have mental health-related 
hospitalization. Patients who had mental health-related hospitalization were more likely to 
reside in states with a higher median household income ($43,055 vs. $41,827, p=0.008) and 
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in states with a higher proportion of population with high school education (81.5% vs. 80.6%, 
p=0.012) than patients without mental health-related hospitalization. 
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Table 4.19 Baseline Characteristics between Patients Who Had Utilization and Patients Who Did Not for Continuation Phase Analysis 
Standard deviation in parentheses for continuous variables  
 All-cause Utilization Mental Health-related Utilization 
 Had Utilization No Utilization P-value Had Utilization No Utilization P-value 
Number of observations 335 1,586  102 1,819  
% of sample 17.4 82.6  5.3 94.7  
Primary care provider (%) 52.2 60.1 0.008 48.0 59.4 0.024 
Psychiatrist (%) 42.1 34.9 0.012 49.0 35.4 0.005 
Non-psychiatric specialist (%) 5.7 45.0 0.602 2.9 5.2 0.308 
Complete continuation phase antidepressant treatment (%) 45.4 44.8 0.839 47.1 44.8 0.648 
Age 42.5 (12.6) 40.6 (11.8) 0.008 44.9 (12.7) 40.7 (11.9) <0.001 
Age categories (%)       
18-34 27.5 29.8 0.389 18.6 30.0 0.014 
35-49 45.1 47.9 0.343 51.0 47.2 0.460 
50-64 22.7 20.1 0.290 23.5 30.4 0.446 
≥65 4.8 2.1 0.006 6.9 2.4 0.005 
Male (%) 33.7 34.3 0.842 40.2 33.9 0.190 
Median income in state of residence 42,197 (3,619) 41,804 (3,860) 0.087 42,783 (3,378) 41,822 (3,839) 0.013 
% population with high school education in state of 
residence 
81.0 (3.0) 80.6 (3.1) 0.031 81.5 (2.6) 80.6 (3.1) 0.003 
Region (%)       
East North Central 33.1 28.9 0.127 38.2 29.2 0.052 
East South Central 3.0 3.9 0.488 2.0 3.8 0.340 
Middle Atlantic 2.1 2.6 0.597 2.0 2.5 0.721 
Mountain 4.5 4.9 0.769 6.9 4.7 0.314 
New England 6.0 3.8 0.069 2.9 4.2 0.525 
Pacific 1.5 3.2 0.088 0 3.1 0.072 
South Atlantic 26.3 30.8 0.102 25.5 30.2 0.309 
West North Central 16.7 12.7 0.052 18.6 13.1 0.114 
West South Central 6.9 9.3 0.159 3.9 9.1 0.072 
Prior Hospitalization (%) 12.8 5.1 <0.001 15.7 5.9 <0.001 
Pregnancy visits during continuation phase (%) 3.9 0.4 <0.001 2.0 1.0 0.347 
Chronic disease score 2.1 (1.1) 1.7 (0.8) <0.001 2.4 (1.1) 1.8 (0.8) <0.001 
Anxiety (%) 11.0 7.9 0.064 14.7 8.1 0.021 
Substance abuse (%) 5.4 3.1 0.038 11.7 3.0 <0.001 
Quarter of year of treatment initiation (%)       
Quarter 1 22.7 19.1 0.134 29.4 19.2 0.012 
Quarter 2 10.1 19.5 0.874 13.7 19.7 0.135 
Quarter 3 29.0 30.0 0.718 27.5 29.9 0.598 
Quarter 4 29.3 31.5 0.427 29.4 21.2 0.709 
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Table 4.20 Baseline Characteristics between Patients Who Had Hospitalization and Patients Who Did Not for Continuation Phase 
Analysis 
Standard deviation in parentheses for continuous variables  
 All-cause Hospitalization Mental Health-related Hospitalization 
 Hospitalized Not Hospitalized P-value Hospitalized Not Hospitalized P-value 
Number of observations 167 1,754  71 1,850  
% of sample 8.7 91.3  3.7 96.3  
Primary care provider (%) 56.3 59.0 0.495 53.5 59.0 0.360 
Psychiatrist (%) 36.5 36.1 0.910 43.7 35.8 0.178 
Non-psychiatric specialist (%) 7.2 4.9 0.200 2.8 5.2 0.373 
Complete continuation phase antidepressant treatment (%) 50.9 44.3 0.101 53.5 44.5 0.135 
Age 45.6 (13.5) 40.5 (11.8) <0.001 47.5 (12.8) 40.7 (11.9) <0.001 
Age categories (%)       
18-34 21.6 30.2 0.020 12.7 30.1 0.002 
35-49 41.3 48.0 0.098 47.9 47.4 0.936 
50-64 28.7 19.8 0.006 31.0 20.2 0.027 
≥65 8.4 2.1 <0.001 8.5 2.4 0.002 
Male (%) 31.7 34.4 0.482 36.6 34.1 0.662 
Median income in state of residence 42,469 (3,950) 41,815 (3,805) 0.035 43,055 (3,547) 41,827 (3825) 0.008 
% population with high school education in state of residence 81.0 (3.2) 80.6 (3.1) 0.165 81.5 (2.9) 80.6 (3.1) 0.012 
Region (%)       
East North Central 27.5 29.9 0.529 32.4 29.6 0.609 
East South Central 2.4 3.8 0.351 2.8 3.7 0.689 
Middle Atlantic 4.1 2.3 0.142 2.8 2.5 0.861 
Mountain 6.6 4.6 0.255 8.5 4.7 0.141 
New England 6.6 3.9 0.101 4.2 4.2 0.979 
Pacific 2.4 3.0 0.676 0 3.0 0.137 
South Atlantic 21.6 30.8 0.013 21.1 30.3 0.097 
West North Central 18.6 12.9 0.042 22.5 13.1 0.022 
West South Central 10.2 8.7 0.527 5.6 9.0 0.331 
Prior Hospitalization (%) 16.8 5.4 <0.001 19.7 5.9 <0.001 
Pregnancy visits during continuation phase (%) 7.8 0.4 <0.001 2.8 1.0 0.133 
Chronic disease score 2.4 (1.2) 1.8 (0.8) <0.001 2.4 (1.1) 1.8 (0.8) <0.001 
Anxiety (%) 15.6 7.8 0.001 18.3 8.1 0.002 
Substance abuse (%) 6.6 3.2 0.022 8.5 3.3 0.020 
Quarter of year of treatment initiation (%)       
Quarter 1 25.2 19.2 0.065 33.8 19.2 0.002 
Quarter 2 14.4 19.9 0.085 11.3 19.7 0.077 
Quarter 3 28.7 29.9 0.760 23.9 20.0 0.273 
Quarter 4 31.7 31.0 0.847 31.0 31.1 0.986 
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4.4.2.2 Multivariate Logistic Analyses 
Table 4.21 presents the odds ratios for utilization of continuation phase model. 
Patients initially prescribed an antidepressant by psychiatrists were more likely to have all-
cause utilization (OR=1.34, 95% CI=1.05-1.79). Patients who had pregnancy-related visits 
during continuation phase were much more likely to have all-cause utilization (OR=11.2, 
95% CI=4.09-30.4). Prior hospitalization and higher CDS increased the likelihood of having 
all-cause utilization (OR=1.89, 95% CI=1.22-2.93 and OR=1.47 95% CI=1.28-1.69, 
respectively).  
In the model evaluating mental health-related utilization, both provider specialty and 
completion of continuation phase antidepressant treatment were not significant. Higher CDS 
(OR=1.77, 95% CI=1.45-2.17), and pre-existing substance abuse (OR=2.68, 95% CI=1.28-
5.58) increased the odds of having mental health-related utilization, while initial treatment 
during the second quarter of year decreased the likelihood (OR=0.43, 95% CI=0.22-0.84).  
Table 4.22 presents the odds ratios and 95% confidence intervals for hospitalization 
of continuation phase model. Provider specialty and completion of continuation phase 
antidepressant treatment were not significant. Patients older than 65 year were more likely to 
have all-cause hospitalization compared with patients aged 18-34 (OR=3.15, 95% CI=1.38-
7.21). Patients who had pregnancy-related visits during continuation phase were more likely 
to have all-cause hospitalization (OR=46, 95% CI=14.9-142.7). Prior hospitalization and a 
higher CDS increased the likelihood of having all-cause hospitalization (OR=2.07, 95% 
CI=1.21-3.53 and OR=1.68, 95% CI=1.43-1.98, respectively) while initial treatment during 
second quarter of year (OR=0.50, 95% CI=0.28-0.90) decreased the lielihood of having all-
cause hospitalization.  
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In the model evaluating mental health-related hospitalization, provider specialty and 
completion of continuation phase antidepressant treatment were not significant. Patients 
older than 65 year were more likely to have mental health-related hospitalization compared 
with patients aged 18-34 (OR=3.83, 95% CI=1.14-12.8). Pregnancy-related visits during 
continuation phase (OR=6.16 95% CI=1.29-29.43), a higher CDS (OR=1.85, 95% CI=1.47-
2.32) increased the likelihood of having mental health-related hospitalization, while initial 
treatment in the second quarter of year (OR=0.30, 95% CI=0.13-0.68) or the third quarter of 
year (OR=0.46, 95% CI=0.23-0.89) decreased the likelihood of having mental health-related 
hospitalization.  
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Table 4.21 Logistic Regressions for Utilization after Continuation Phase 
Note: Pacific region merged to reference region due to perfect prediction  
 
 All-cause Utilization Mental Health-related Utilization 
Variable Category Odds Ratio 95% CI Odds Ratio 95% CI 
Primary care provider   Reference  Reference  
Psychiatrist   1.34 (1.05-1.79) 1.71 (1.10-2.66) 
Non-psychiatric specialist   1.19 (0.69-2.05) 0.61 (0.19-1.98) 
Completed continuation phase  0.96 (0.75-1.23) 0.97 (0.65-1.46) 
Age group 18-34 Reference  Reference  
 35-49 1.00 (0.74-1.35) 1.46 (0.83-2.56) 
 50-64 0.97 (0.67-1.40) 1.13 (0.57-2.24) 
 ≥65 1.56 (0.78-3.11) 2.40 (0.88-6.60) 
Male  0.97 (0.75-1.26) 1.15 (0.74-1.78) 
Income (in per 1000)  1.01 (0.96-1.07) 1.04 (0.96-1.13) 
% with high school education   0.97 (0.90-1.04) 1.03 (0.92-1.15) 
Region East North Central  1.59 (1.01-2.51) 1.48 (0.69-3.16) 
 East South Central  0.96 (0.47-2.14) 1.08 (0.21-5.50) 
 Middle Atlantic  0.84 (0.36-1.93) 0.61 (0.11-3.32) 
 Mountain  1.36 (0.65-2.84) 1.65 (0.46-5.94) 
 New England  1.94 (0.96-3.92) 0.72 (0.15-3.42) 
 Pacific  0.55 (0.19-1.59) -  
 South Atlantic  Reference  Reference  
 West North Central  1.67 (1.01-2.76) 1.59 (0.67-3.76) 
 West South Central  0.82 (0.47-1.45) 0.63 (0.18-2.22) 
Pregnancy visits during continuation phase  11.16 (4.09-30.40) 3.04 (0.61-15.13) 
Prior Hospitalization  1.89 (1.22-2.93) 1.31 (0.67-2.55) 
Chronic disease score  1.47 (1.28-1.69) 1.77 (1.45-2.17) 
Anxiety   1.14 (0.75-1.74) 1.27 (0.80-2.32) 
Substance abuse  1.15 (0.62-2.13) 2.68 (1.28-5.58) 
Quarter of year  Quarter 1 Reference  Reference  
 Quarter 2 0.83 (0.57-1.29) 0.43 (0.22-0.84) 
 Quarter 3 0.86 (0.61-1.21) 0.61 (0.35-1.06) 
 Quarter 4 0.78 (0.56-1.10) 0.61 (0.35-1.05) 
Sample size=1,921      
 c-statistics=0.66   c-statistics=0.74  
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Table 4.22 Logistic Regressions for Hospitalization after Continuation Phase 
Note: Pacific region merged to reference region due to perfect prediction 
 
 All-cause Hospitalization Mental Health-related Hospitalization 
Variable Category Odds Ratio 95% CI Odds Ratio 95% CI 
Primary care provider   Reference  Reference  
Psychiatrist   1.03 (0.71-1.49) 1.37 (0.81-2.30) 
Non-psychiatric specialist   1.34 (0.66-2.74) 0.45 (0.12-1.73) 
Completed continuation phase  1.24 (0.88-1.73) 1.22 (0.76-1.98) 
Age group 18-34 Reference  Reference  
 35-49 1.21 (0.76-1.91) 2.09 (0.97-4.51) 
 50-64 1.59 (0.95-2.66) 2.24 (0.94-5.36) 
 ≥65 3.15 (1.38-7.21) 3.83 (1.14-12.83) 
Male  0.93 (0.64-1.34) 0.97 (0.57-1.65) 
Income (in per 1000)  1.07 (0.99-1.15) 1.09 (0.99-1.21) 
% with high school education   0.95  (0.86-1.06) 1.02 (0.90-1.17) 
Region East North Central  1.30 (0.68-2.46) 1.29 (0.50-3.34) 
 East South Central  1.18 (0.34-4.02) 2.42 (0.43-13.42) 
 Middle Atlantic  1.94 (0.74-5.04) 0.96 (0.17-5.62) 
 Mountain  2.10 (0.80-5.53) 2.05 (0.48-8.73) 
 New England  1.94 (0.73-5.16) 0.98 (0.17-5.81) 
 Pacific  0.89 (0.25-3.11) -  
 South Atlantic  Reference  Reference  
 West North Central  1.87 (0.93-3.76) 2.03 (0.74-5.58) 
 West South Central  1.80 (0.88-3.66) 1.33 (0.37-4.83) 
Pregnancy visits during continuation phase  46.03 (14.85-142.7) 6.16 (1.29-29.43) 
Prior Hospitalization  2.07 (1.21-3.53) 1.88 (0.89-3.99) 
Chronic disease score  1.68 (1.43-1.98) 1.85 (1.47-2.32) 
Anxiety   1.53 (0.90-2.59) 1.55 (0.76-3.14) 
Substance abuse  1.37 (0.63-2.96) 1.37 (0.52-3.56) 
Quarter of year  Quarter 1 Reference  Reference  
 Quarter 2 0.50 (0.28-0.90) 0.30 (0.13-0.68) 
 Quarter 3 0.78 (0.50-1.22) 0.46 (0.23-0.89) 
 Quarter 4 0.74 (0.47-1.17) 0.54 (0.29-1.01) 
Sample size=1,921      
 c-statistic=0.76   c-statistic=0.79  
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4.4.2.3 Propensity Score Matching 
Logistic regressions were run on the matched sub-sample who completed acute phase 
(N=1,121). The coefficient of psychiatrist became insignificant for mental health-related 
utilization model after the matching, which is likely due to decrease in sample size (Table 
4.23) .Odds ratios were consistent before and after the matching since the confidence 
intervals overlapped.  
Table 4.23 Odds Ratios of Utilization and Hospitalization for Continuation Phase Model 
before and after Propensity Score Matching 
Note: 95% CI in parentheses. Regressions include all the covariates listed in Table 4.21 and Table 4.22 
*p<0.05 
 
In summary, we found patients initially prescribed an antidepressant by psychiatrists 
has higher risk of all-cause and mental health-related utilization during the one-year period 
after the continuation phase, and we did not find an effect of completion of continuation 
phase on utilization or hospitalization. 
 
Utilization Hospitalization 
Variable All-cause Mental Health-
related 
All-cause Mental Health-
related 
 
Pre-matching 
 
N=1,921 
Primary care provider  Reference Reference Reference Reference 
Psychiatrist  1.37* (1.05-1.79) 1.71* (1.10-2.66) 1.03 (0.71-1.49) 1.37 (0.81-2.31) 
Non-psychiatric 
specialist  
1.19   (0.69-2.05) 0.61   (0.19-1.98) 1.34 (0.66-2.74) 0.45 (0.12-1.73) 
Completed 
continuation phase 
0.96   (0.75-1.23) 0.97   (0.65-1.46) 1.24 (0.88-1.73) 1.22 (0.76-1.98) 
 Post-matching 
 N=1,121 
Primary care provider  Reference Reference Reference Reference 
Psychiatrist  1.41* (1.03-1.95) 1.68  (0.88-3.23) 1.21 (0.74-1.97) 1.49 (0.74-2.98) 
Non-psychiatric 
specialist  
- - - - 
Completed 
continuation phase 
0.94   (0.68-1.30) 1.80  (0.95-3.40) 1.43 (0.88-2.31) 1.72 (0.87-3.42) 
CHAPTER V 
DISCUSSION 
This Chapter discusses the findings of each aim and its policy and clinical implication 
(Section 5.1), observed confounding and propensity score matching (Section 5.2), strength 
and limitations (Section 5.3-5.4), future research (Section 5.5), and conclusion (Section 5.6). 
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5.1 Discussion for Each Aim and Its Policy and Clinical Implications 
5.1.1 Aim 1 
To examine characteristics among patients initially prescribed an antidepressant by 
providers with different specialties to treat major depressive disorder (MDD) 
In Aim 1, we found differences among patients initially prescribed an antidepressant 
by providers with different specialties. Prior literature has suggested that psychological 
sickness is the strongest predictor for mental health specialty care.46 Although we did not 
have a direct measure of psychological sickness of the study population, comorbid 
psychological conditions of anxiety and substance abuse identified in the 6-month pre-index 
date period were strong predictors for initial antidepressant treatment with psychiatrists. On 
the other hand, Chronic Disease Score (CDS) which measures overall comorbidities was the 
strongest predictor to receive an initial antidepressant prescription from non-psychiatric 
specialists. These results are consistent with the role of which specialists were designated for 
treating patients with more needs for specialty care. We also found prior specialty care is a 
strong predictor of initiate prescriber for antidepressant treatment. This might indicate that 
these patients had better access to specialty care since they had been using it. It could also 
represent a pre-existing relationship with specialists which in turn increase the likelihood to 
initiate treatment with them. We do not have information on whether the insurance policy 
requires gatekeeping for each individual. Since the majority of our study population is under 
fee-for-service plans, prior specialty experience could be a good proxy for access. 
The findings from Aim 1 underscore the importance of including patient 
characteristics in analyses examining provider specialty differences in order to eliminate 
potential biases. In light of these results, interpretation of provider specialty effects in Aim 2 
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and Aim 3 must be made with caution. Depending on how much the residual patient 
differences were left in the error term and how that influenced the outcomes in Aims 2 and 
Aim 3, interpretation of results from those aims must be made with consideration of patient 
effects as well. 
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5.1.2 Aim 2 
To examine the association of antidepressant treatment with initial prescriber specialty 
and receipt of guideline-concordant outpatient follow-up visits among patients with 
MDD 
We first discuss the factors associated with receipt of guideline-concordant follow-up 
visits (Section 5.1.2.1). Next, we discuss the predictors for completion of antidepressant 
treatment phases (Section 5.1.2.2). Provider specialty is the explanatory variable of interest. 
5.1.2.1 Provider Specialty and Receipt of Guideline-concordant Follow-up Visits 
We found that only 31% of patients received guideline-concordant follow-up visits in 
our study population, which is similar to prior studies using the same HEDIS criteria4, 6, 49, 
but higher than NCQA’s report115 (Table 5.1).  In this dissertation, we only included patients 
with an MDD diagnosis while other studies have also included patients with dysthymia or 
depressive disorder not otherwise specified.4, 6, 49  
Table 5.1 Comparison of Proportion of Receipt of Guideline-concordant Follow-up Visits 
Data Source Study Year(s) Study Population Percentage 
Present study 2000-2004 Commercially insured 31 
Robinson6 2001-2004 Commercially insured 39 
Morrato49 1998-2005 Commercially insured 40 
Jones4 1997-2005 VA 27 
NCQA 2001 Commercially insured 19.8 
NCQA 2002 Commercially insured 19.2 
NCQA 2003 Commercially insured 20.3 
NCQA 2004 Commercially insured 20.0 
 
Frequent follow-up provides opportunities for providers to monitor side effects and 
clinical response and to educate patients about the treatment. For patients taking 
antidepressants to treat MDD, it is especially important to promote adherence as they may 
discontinue because of the time required to achieve response, or they may stop taking the 
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antidepressants once they start feeling better.116 Improvement for follow-up care should be 
taken into action particularly given the positive association with antidepressant completion.  
Not only the rate for guideline-concordant follow-up visits is low in general, we 
found that older patients (greater than 50 years old) are at risk of less frequent follow-up. 
Clinicians should pay special attention to this demographic group in their practice when they 
schedule follow-up visits. Interventions such as case management should also target this 
group where there is still much room for improvement. In addition, we also found that 
patients under burden of higher out-of-pocket copayment were less likely to have guideline-
concordant follow-up visits. Insurance plans should bear in mind the adverse consequences 
in follow-up care for the depressed patients when undergoing reform with cost-containment 
strategies.  
We found that initial treatment by a psychiatrist was the strongest predictor of receipt 
of guideline-concordat follow-up visits, which is consistent with studies by Robinson et al. 
and Jones et al even though they used different definitions for provider specialty.4, 6 We 
controlled for as many patient characteristics as were available, so the difference we 
observed is largely attributable to provider effect. Although we can not examine why such 
differences exist based on the data we have, the findings warrant the need to improve follow-
up for patients with depression managed in primary care settings. It is probably neither 
efficient nor realistic to channel all the depressed patients into specialty care. Focuses should 
be to improve management for depression in primary care, and many interventions have been 
examined in randomized controlled trials.117 The positive association found between initial 
prescription from a psychiatrist and guideline-concordant follow-up is suggestive for a 
greater degree of integration between primary and secondary care with consultation-liaison.  
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To test how the results may vary based on the definition used to identify follow-up 
visits, we conducted two sensitivity analyses. The HEDIS measures include follow-up visits 
made to providers without prescribing privileges such as psychologists. To count the visits 
more relevant to antidepressant management, we included only those visits made to providers 
with prescribing privileges as the outcome in the first sensitivity analysis. The odds ratios 
and significance of provider specialty were similar to the main analysis. Second, we 
identified the visits that were made to the provider who wrote the initial antidepressant 
prescription regardless of diagnosis. Visits made to the same provider who wrote the 
prescription provided an opportunity for patients to talk about antidepressant treatment, 
although it might not be the main reason for the visits. The odds ratios for psychiatrists 
became smaller and the difference between non-psychiatric specialists and PCPs diminished. 
Our conclusion that initiating antidepressant treatment with a psychiatrist was associated 
with greater likelihood of receipt of guideline-concordant follow-up visits did not change 
(Table 4.6). These sensitivity analyses give us confidence that there is a systematic difference 
between patients initially prescribed by primary care providers (PCPs) and patients initially 
prescribed by psychiatrists. The findings from these sensitivity analyses could be also 
indicative that the HEDIS measures provide an upper bound when examining follow-up 
visits, and alternative approaches may be worth exploring.  
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5.1.2.2 Antidepressant Treatment in the Real World 
We found that acute phase antidepressant treatment completion was suboptimal 
(46.8%), which mirrors the results of several prior studies (Table 5.2). The proportion of 
patients who completed acute phase antidepressant treatment based on empirical analyses is 
45-50% for commercially insured population.2, 6 The proportion was much lower in a VA 
sample (11%)4 and slightly higher based on NCQA historical reports.115  
Table 5.2 Comparison of Proportion of Acute Phase and Continuation Phase Completion 
Data Source Study 
Year(s) 
Study Population Acute phase 
completion (%) 
Continuation phase 
completion (%) 
Present study 2000-2004 Commercially insured 46.8 44.9 
Robinson6 2001-2004 Commercially insured 46.8 44.3 
Akincigil2 2003-2005 Commercially insured 51 41.5 
Jones4 1997-2005 VA 11 N/A 
NCQA 2002 Commercially insured 56.9 36.8 
NCQA 2003 Commercially insured 59.8 37.7 
NCQA 2004 Commercially insured 60.7 39.2 
 
The association between provider specialty and antidepressant adherence is not consistent in 
the literature. Five of the ten studies we examined in the literature review found that mental 
health specialty care significantly increased the likelihood of antidepressant treatment 
adherence.2, 3, 6, 16, 17 We found that the provider effects are more complicated. This 
dissertation is the first to consider an interaction effect between provider specialty and receipt 
of guideline-concordant follow-up visits in a general population.  
Patients who were initially prescribed an antidepressant by psychiatrists but failed to 
receive guideline-concordant follow-up visits were 4.6 percentage points less likely to 
complete the acute phase compared with patients initially prescribed an antidepressant by 
PCPs who did not have guideline-concordant outpatient follow-up visits (Figure 5.1). The 
marginal effect of guideline-concordant follow-up visits was 13.1 percentage points among 
patients initially prescribed by PCPs and 19.9 percentage points among patients initially 
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prescribed by psychiatrists. The combination of provider and follow-up effects results in a 
marginal effect of 15.3 percentage points for follow-up made by patients initially prescribed 
by psychiatrists compared with patients who were initially prescribed by PCPs and did not 
receive guideline-concordant follow-up visits (Figure 5.1). 
Figure 5.1 Marginal Effects of Provider Specialty and Guideline-concordant Follow-up 
Visits on Probability of Acute Phase Antidepressant Completion 
 
Note: PCP without follow-up as reference group 
If interpreting the effect of the interaction term as purely a provider effect, 
psychiatrists were more effective in encouraging patients to complete acute phase 
antidepressant treatment than PCPs when guideline-concordant follow-up visits were also 
delivered. Psychiatrists who failed to deliver guideline-concordant follow-up visits were less 
likely to have their patients completed the acute phase compared with PCPs who failed to 
deliver guideline-concordant follow-up visits. 
Before jumping into a conclusion of divergent provider effects between patients who 
received guideline-concordant follow-up visits and patients who did not, one must consider 
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differences in patient cohorts between PCPs and psychiatrists, particularly since these 
variables are marginally significant. One major unobservable confounder is depression 
severity which is expected to be different between patient cohort treated by PCPs and by 
psychiatrists. Mental health specialists tend to encounter more severely depressed patients.47 
However, how severity influences antidepressant adherence is unclear. There could be two 
hypotheses in the opposite directions. Patients with higher need (in terms of greater severity) 
might be more motivated and more compliant to provider’s direction regarding taking 
medications. On the other hand, severe depression itself might make patients resistant to any 
recommendations. It is possible that the latter group of patients may forego doctor’s follow-
up appointment and be reluctant to take their antidepressant as suggested. This scenario may 
be the reason why the marginal effect of psychiatrist is negative. To consider that even 
psychiatrists (who we hypothesized to have better skills and knowledge in treating depression) 
could not make those patients come for follow-up visits, it is probably not surprising how 
non-compliant these patients are in taking antidepressants. On the other hand, the more 
motivated patients treated by psychiatrists will comply with their doctor’s recommendation 
and the existence of this group of patients makes the interaction effect of psychiatrist and 
receipt of follow-up visits significant. Without complete measurement of motivation and 
depression severity in our analysis, the provider effects we observed in these results may be 
partially attributable to patient differences. 
We found a strong positive association between receipt of guideline-concordant 
follow-up visits and completion of acute phase antidepressant treatment. To our knowledge, 
this dissertation is the first study to examine this association in a commercially insured 
population. Only one study based on a VA population have examined this, and gave the 
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similar conclusion (OR=2.1, 95% CI=1.54-2.88).4 In addition, we considered the interaction 
effect between guideline-concordant follow-up visits and provider specialty. Our empirical 
analyses suggest that follow-up visits may promote patient adherence to antidepressant 
treatment because patients who were initially prescribed an antidepressant by PCPs or by 
psychiatrists and had guideline-concordant follow-up visits were more likely to complete 
acute phase antidepressant treatment. Our findings underscore the importance of providing 
frequent follow-up care to encourage patients to adhere to acute phase antidepressant 
treatment.  
We also examined completion of antidepressant treatment in the continuation phase 
on the sub-sample of patients who completed acute phase (n=1,921). The interpretation of the 
results is conditional on acute phase completion. As with acute phase completion, completion 
of continuation phase was suboptimal (45%, Table 5.2) Prior studies found that the 
proportion of continuation phase completion ranged from 35-45% based on the HEDIS 
measures.6, 115 Akincigil et al. constructed continuation phase completion in a similar way to 
consider that only those who completed acute phase entered into continuation phase. Their 
findings were very similar to ours, even though the threshold of MPR was lower in their 
study (75%). Among the patients who completed acute phase and entered into continuation 
phase, we found no differences in continuation phase antidepressant completion by provider 
specialty. Our study is the first to attempt to measure and evaluate follow-up visits during 
continuation phase. We found that having three or more follow-up visits during continuation 
phase was associated with antidepressant completion. It is suggestive that frequent follow-up 
is not only effective during the initiation of the treatment, but also important in a long run. 
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The sub-optimal rate of guideline-concordant antidepressant treatment remains a 
challenging problem. The results from the dissertation support the need for innovative 
protocols and interventions to achieve better care for depressed patient for post-prescription 
monitoring and management. Several strategies including collaborative care and case 
management that have been systematically evaluated to be effective in improving 
antidepressant adherence and depression clinical outcomes.117-119 Improvement can be 
targeted at two arenas for potential change. The first is organizational including a better 
systems of referral, collaboration programs, and on-site access to psychiatrists in primary 
care settings.120, 121 Case management with telephone medication counseling delivered by 
nurses or trained counselor and pharmacist-provider prescribing information exchange have 
been shown to be effective, and may involve minimum system change.117 The second is 
provider changes via physician education, psychiatric diagnostic screening tools, and 
increased consulting time.122 Multifaceted interventions with combination of two could be 
beneficial too.123 
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5.1.2.3 Aim 3 
To examine the association of subsequent healthcare utilization with initial prescriber 
specialty and antidepressant treatment among patients with MDD 
 In Aim 3, we sought to understand the association between provider specialty, 
antidepressant treatment completion and subsequent healthcare utilization (hospital 
admissions and emergency room visits). Our results suggest that patients initially prescribe 
an antidepressant by psychiatrists were more likely to have all-cause and mental health-
related utilization, and patients initially prescribed an antidepressant by non-psychiatric 
specialists were more likely to have all-cause utilization. Patient’s needs for healthcare are 
probably the main driving force of healthcare utilization, and need variables in our study 
(CDS in all-cause utilization model; anxiety and substance abuse in mental health-related 
utilization model) were indeed significant predictors. After controlling for comorbidity to 
adjust for patient case-mix, we still found a significant difference between PCPs and 
specialists as in prior literature.124 When we limited the outcome to hospitalization, only 
patients treated by non-psychiatric specialists were statistically significantly more likely to 
have all-cause hospitalization during one year following the end of acute phase. Inconsistent 
effects between utilization model and hospitalization model indicate that the difference found 
in utilization between patients initially prescribed an antidepressant by psychiatrists and 
patients initially prescribed an antidepressant by PCPs may be driven largely by emergency 
room visits. 
We found a protective effect of acute phase antidepressant treatment completion over 
all-cause utilization, mental health-related utilization, and all-cause hospitalization. This is 
consistent with a study conducted on a VA sample that found patients with adequate duration 
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of antidepressant treatment were significantly less likely to have all-cause hospitalization.18 
We failed to find an association between acute phase antidepressant treatment completion 
and mental health-related hospitalization as in this prior study.18 It might be due to the 
possibility that our study population is relatively mentally healthier than the VA population. 
For example, the rareness of mental health-related hospital admissions (3-4%) in our sample 
compared with the VA sample (7.6%) in this prior study prevents us from detecting the 
difference.18  
This dissertation is the first to examine the association between provider specialty, 
continuation phase antidepressant completion and subsequent healthcare utilization. Only the 
psychiatrist variable remained significant in the continuation model that evaluated all-cause 
and mental health-related utilization. There are two possible reasons why we observed 
inconsistent results of provider specialty between acute phase model and continuation phase 
model. First, only those who completed the acute phase antidepressant treatment entered the 
continuation phase model, which substantially reduced the sample size and the power to 
detect differences. Also, there was a nine-month gap (acute phase plus continuation phase) 
between index date and the period where we identified utilization in the continuation phase 
model. Such lag in time may weaken the association because patients may have stopped 
seeing the provider or changed to another provider during this period.  
In the sub-population that completed the acute phase, we were not able to find any 
significant effect of continuation phase antidepressant treatment completion on subsequent 
healthcare utilization or hospitalization. The explanation could be that, from a clinical stand 
point, acute phase aims at achieving remission. Acute phase completion should help patients 
eliminate depressive symptoms and allow them to restore mental health. This stage of 
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antidepressant treatment is more vital in a patient’s mental self-being, and the mental state 
might be influential to other physical conditions as well, which results in difference in 
subsequent utilization. Once entering into continuation phase, patients were assumed to be 
remitted. The purpose of continuation phase antidepressant treatment is to prevent relapse. 
With the absence of depressive symptoms in the sub-population who completed the acute 
phase, there might not be any effect of continuation phase over subsequent utilization.  
The empirical evidence of the protective effect of acute phase antidepressant 
treatment over the risk of subsequent healthcare utilization and hospitalization found in this 
dissertation translates guideline-recommended antidepressant use into improved health by 
reduction of costly adverse events. Our findings support the theory that the increase 
expenditures associated with antidepressant prescription early on may be offset by reductions 
in the costs of hospitalizations. In addition to clinical effectiveness, antidepressant therapy is 
economically effective in treating MDD if utilized properly based on guideline 
recommendations. When planning the intervention to promote antidepressant adherence, 
policymakers should factor the potential cost-saving associated with antidepressant 
adherence to budget and allocate the resources.  
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5.2 Observed Confounding and Propensity Score Matching 
This dissertation utilized propensity score matching which gives a comparable cohort 
between patient initially prescribed an antidepressant by PCPs and patient initially prescribed 
an antidepressant by psychiatrists in observable variables and potentially unobservable 
confounders as well. After propensity score matching, the distribution of severity among 
patients between groups should, ideally, become similar.  
In Aim 2 analyses, the findings are consistent before and after the matching for the 
model that evaluates guideline-concordant follow-up visits. In the model that evaluates acute 
phase antidepressant treatment completion, we found that the psychiatrist coefficient and its 
interaction term with guideline-concordant follow-up visits became insignificant after the 
matching. Two reasons may explain the inconsistent findings. First, these variables were at 
marginal significance in the original model. The decrease in sample size after the matching 
may decrease the power to detect the differences. Second, the interaction effect may be more 
profound among the patients who we were unable to find matches and were likely to be more 
severely ill. Exclusion of these patients in the propensity score matched population may 
preclude us from observing the significant effect. The findings are consistent before and after 
the matching for the model that evaluates continuation phase antidepressant treatment 
completion. 
In Aim 3 analyses, we had similar findings before and after the matching, except that 
we had an inconsistent finding of the protective effect of acute phase completion over all-
cause and mental health-related utilization. There could be three explanations. First, the 
reduction of the sample size resulted in losing power to detect differences. Second, acute 
phase completion might be more effective over a population that was eliminated during the 
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process of propensity score matching. Third, after examination of the principal diagnosis for 
utilization, we found that they were largely from emergency room visits where the causes 
were somewhat minor and less concentrated. The effect of acute phase completion might not 
be homogenous between more severe events like hospitalization and more minor events like 
emergency room visits. Combination of these two as an outcome might dilute the true effect 
over hospitalization that was consistently found before and after the matching.  
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5.3 Limitations 
This dissertation has several limitations. Since the source of information came from 
claims data, the validity of study results depends on the coding accuracy. We included 
patients who were diagnosed with major depressive disorder with a single episode (ICD-9 
code 296.20-296.24). Our intension was to identify new patients who were naïve users of 
antidepressant. Even though we have utilized data from 6-month prior to identify our target 
population, the tendency of how providers distinguish and code new and recurrent episodes 
of MDD could be influential for our sample inclusion process. In addition, the follow-up 
visits were identified based on service claims that had a mental health diagnosis code. If this 
piece of information was not coded accurately, it will influence the results particularly with 
regard to receipt of guideline-concordant follow-up visits and provider specialty. Depression 
is a common disease that is being under-diagnosed, and patients might not want it be 
recorded due to stigma.22 Some visits to manage antidepressant treatment might not be coded 
as such, and some visits coded for another purpose might include evaluation of 
antidepressant treatment. How such a scenario could influence our findings has been 
addressed by sensitivity analyses. Even though we were able to investigate the timing and 
frequency of follow-up visits, we were not able to know the quality of individual visits. In 
addition, the data provide no information on whether the follow-up visits have been 
scheduled, cancelled or missed. 
The prescription claims data only provide information on prescription refill patterns 
instead of actual medication use. Medication refill records do not necessarily reflect 
consumption of the medication. Samples from the doctors, pill splitting, and obtaining 
medication purely with out-of-pocket costs can not be observed in this data. Despite those 
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shortcomings, using prescription claims data to measure medication adherence remains valid 
and reliable.84 We constructed antidepressant treatment according to guideline 
recommendations. However, we could not distinguish the cases where the discontinuation 
was clinically appropriate and approved by providers. 
In the analytical model, we included state level median household income and 
percentage of population with high school education as proxies for socio-economic status. 
These state level data may only partially controlled for socio-economic status, and also limit 
the interpretation of these variables. We do not have provider variables such as gender, year 
of practice, practice setting, and patient volume in our data. These provider variables may be 
influential to the outcomes we examined. Insurance plan variables are limited, too. We do not 
have the benefit structure of each individual, and we were only able to create several proxies 
based on claims level information. In addition, we did not have information on whether any 
organizational intervention such as disease management and information technology has 
been implemented. These factors could affect both provider and patient behavior. 
Several hypothesized mechanisms of provider differences discussed in Chapter II are 
attitudes toward depression, knowledge about treatment and guidelines, and competing 
demand. Unfortunately, it is impossible to tell which mechanism is responsible for the 
provider effects, if any, from the current dataset. However, examining the total effect is still 
crucial for the purpose of this dissertation. Provider differences were found for guideline-
concordant follow-up visits and subsequent healthcare utilization. These findings support our 
hypotheses and warrant further investigation to examine why such differences exist.  
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Power could be an issue too. Events such as mental health-related hospital admissions 
are rare in this relatively healthy population. The small number of cases may preclude us 
from detecting small differences. 
Even though propensity score methods can increase efficiency to reduce bias, it still 
functions under the assumption that there are no unobservable confounders. This propensity 
score matching method can still lead to biased estimates if unobservable confounders exist. 
In addition, the success of propensity score adjustment requires substantial overlap between 
groups. Individuals that fall outside the region of common support have to be disregarded, 
but information from those individuals could be useful.  
Our data are originated from a large national health plan affiliated with i3 Innovus. 
Even though we were able to have a sample size of four thousand individuals to analyze, our 
findings might not be generalized to the whole U.S. population. Our study population is 
based on commercially insured individuals. Results may be different for people under other 
insurance coverage such as Medicaid or Medicare. In addition, the majority of the patients in 
our sample were under fee-for-service reimbursement scheme (98.5%), and the findings from 
this dissertation may not be applied to individuals under Health Maintenance Organization. 
Our study also excluded children, patients with concurrent bipolar or schizophrenia, and 
patients who were on augmented antidepressant treatment, and our findings may not be 
applicable for these patients. 
The most important limitation is that the observational design prohibits attribution of 
causality. Several potential unobservable patient characteristics have been discussed in 
Chapter II. If these unobservable variables are confounders which influence the independent 
variable of interest and the outcomes, it will lead to biased estimates. Unobservable patient 
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characteristics that might confound the provider effect include perceived stigma, attitude 
toward treatment for depression, and depression severity. Particularly, the absence of 
depression severity is a concern because it might directly impact both therapy decisions and 
the completion of the treatment.  
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5.4 Strengths 
 Despite the aforementioned limitations, this dissertation has several strengths. This 
dissertation contributes to the literature by carefully examining the relationship of several 
guideline components of antidepressant treatment within a geographically diverse 
commercially insured population. Our integrated data have comprehensive information for 
healthcare visits and prescriptions. The use of medication possession ratio and gap measure 
together incorporate both adherence and persistence in evaluation of antidepressant use.85, 125  
There are several strengths of our analytical models. We identified the provider 
specialty based on index antidepressant claim. We considered this source to more accurately 
point toward the providers who managed antidepressant therapy compared with other sources 
such as clinic types and provider specialty based on medical visits used in some prior 
studies.2-4, 6, 16, 43 Our study is the first to examine provider specialty and guideline-
concordant follow-up visits simultaneously in a more generalized population. Only one study 
based on veterans incorporated both variables, and the findings were consistent with ours.4 In 
addition, we further investigate the relationship of follow-up visits during continuation phase 
and antidepressant completion. To our knowledge, our study is the first to attempt to evaluate 
this relationship. The positive association found in our study can serve as a basis for 
hypothesis-generation to establish guidelines about the frequency of follow-up visits in 
continuation phase for antidepressant management. Our study is the first to evaluate whether 
daily regimen may influence antidepressant adherence. Patients who were required to take 
two or more pills a day were less likely to complete acute phase. This piece of evidence may 
be helpful for clinicians in choice of antidepressant agent. Finally, we used rigorous 
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methodologies including propensity score matching and sensitivity analyses to ensure the 
reliability of the reported findings. 
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5.5 Future Research 
In this dissertation, we found differences in characteristics between patients initially 
prescribed an antidepressant by PCPs and patients initially prescribed an antidepressant by 
psychiatrists (Aim 1). The administrative data allow us to examine this question with a large 
sample size in a naturalistic setting. Future research should incorporate different data sources 
or data collecting techniques to enrich our understanding in this regard.  
The findings from this dissertation suggest that follow-up visits are under-utilized for 
managing antidepressant treatment overall, particularly in primary care settings. This 
dissertation only points out that such difference exists, but can not answer the question of 
why because our data did not allow examination of the mechanisms that lead to such 
differences. The decision for follow-up visits could be driven by providers (whether 
recommendation of follow-up was given) and by patients (whether patients followed the 
recommendation and whether they have needs for follow-up). First, future research should 
use provider as the unit of analysis and systematically evaluate the differences in attitudes, 
knowledge, barriers and practice setting in treating depression with antidepressant between 
mental health specialists and primary care providers. Provider surveys could be a useful tool. 
In addition, studies should be conducted to examine how patient behavioral factors, such as 
attitude, knowledge, stigma, and clinical factors like depression severity may play a role. 
These studies could assist policymakers in understanding how to support primary care in 
providing more guideline-concordant care to depressed patients and to simulate effective 
organizational intervention to improve quality of care. 
In the main analysis, completion of follow-up visits during the acute phase was 
defined using the HEDIS measures with at least three visits as a threshold,36 which is 
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commonly used in the literature.3, 4, 6, 7 However, three visits may be a minimum standard. 
The AHCRP depression guidelines8 recommend that patients with more severe depression 
should be seen weekly for the first 6 to 8 weeks of acute treatment, and the APA also 
recommends that patients should be seen on a weekly basis during acute phase.9 According 
to these guidelines, a patient should receive at least six follow-up visits based on a 
conservative calculation. Based on descriptive analysis from Aim 2, only 9.7% of patients 
initially prescribed an antidepressant by a PCP, 24.1% of patients initially prescribed an 
antidepressant by a psychiatrist, and 17.4% of patients initially prescribed an antidepressant 
by a non-psychiatric specialist has six or more visits (Figure 5.2). Future research should 
focus on assessing what level of follow-up care is cost-effective and clinically appropriate. In 
our sensitivity analyses, we demonstrated that the results may differ based on the approaches 
to identify follow-up visits. Using the HEDIS measures which require mental health 
diagnosis may underestimate follow-up visits in primary care setting where under-coding is 
more likely to occur. Future research should focus on developing an algorithm to more 
precisely measure the follow-up visits for depression. 
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Figure 5.2 Frequency of Follow-up Visits During Acute Phase 
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This is the first study to assess the association between receipt of guideline-
concordant follow-up visits and antidepressant completion in a more generalized population. 
The positive association is not surprising, but it was disappointing that the overall rate of 
follow-up remains far from optimal. While performance measurement has become a 
prominent approach in both assessment and reimbursement in today’s healthcare system, it is 
vital to have timely empirical evidence supporting its reliability, accuracy, and effectiveness. 
Our finding of the positive association between follow-up visits and acute phase completion 
is encouraging in this aspect. Even though our finding is promising, future research should 
also examine how quality of the follow-up visits, such as time spent with patients and 
communication style, influence antidepressant use to give a complete picture. 
This dissertation showed that acute phase antidepressant completion significantly 
decreased the risk of all-cause hospitalization. Even though we failed to find an association 
  189 
between continuation phase completion and subsequent utilization, future research should 
empirically test the effectiveness of continuation phase antidepressant treatment with 
depression relapse as an endpoint to evaluate whether it serves its desirable purpose.  
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5.6 Conclusion 
Overall, the results of this dissertation are strongly suggestive of a large gap between 
clinical guideline recommendations and actual practice in treating MDD with antidepressant. 
We found only a small proportion of depressed patients received appropriate follow-up care 
for management of antidepressant treatment. There are differences between primary care and 
mental health specialty settings in follow-up visits, but why there were such differences 
requires further investigation. Many patients did not use antidepressant for a desirable 
duration.  We found receipt of guideline-concordant follow-up visits was associated with 
completion of antidepressant, and frequent follow-up should be encouraged to promote 
adherence. We also observed a protective effect of acute phase completion over all-cause 
hospitalization. This empirical evidence provides economical justification of the cost offset 
of expenditures associated with antidepressant treatment. The results of this dissertation 
present valuable knowledge of health service research in treatment for MDD with 
antidepressant therapy. It is our hope that findings from this dissertation will simulate future 
research to benefit the well-being of patients with MDD.  
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APPENDIX 
 
Appendix 1 DSM-IV criteria for major depressive episode  
 
A.  Five (or more) of the following symptoms have been present during the same 2-week period 
and represent a change from previous functioning; at least one of the symptoms is either (1) 
depressed mood or (2) loss of interest or pleasure. (Do not include symptoms that are clearly 
due to a general medical condition, or mood-incongruent delusions or hallucinations.)  
     1. Depressed mood most of the day, nearly every day, as indicated by either subjective         
report (e.g., feels sad or empty) or observation made by others (e.g., appears tearful) 
     2. Markedly diminished interest or pleasure in all, or almost all, activities most of the day, 
nearly every day (as indicated by either subjective account or observation made by others) 
     3. Significant weight loss when not dieting or weight gain (e.g., a change of >5% of body 
weight in a month), or decrease or increase in appetite nearly every day 
     4. Insomnia or hypersomnia nearly every day 
     5. Psychomotor agitation or retardation nearly every day (observable by others, not merely 
subjective feelings of restlessness or being slowed down) 
     6. Fatigue or loss of energy nearly every day 
     7. Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) 
nearly every day (not merely self-reproach or guilt about being sick) 
     8. Diminished ability to think or concentrate, or indecisiveness, nearly every day (either by 
subjective account or as observed by others) 
     9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a 
specific plan, or a suicide attempt or a specific plan for committing suicide 
B.  The symptoms do not meet criteria for a mixed episode 
C.  The symptoms cause clinically significant distress or impairment in social, occupational, or 
other important areas of functioning 
D.  The symptoms are not due to the direct physiologic effects of a substance (e.g., a drug of 
abuse, a medication) or a general medical condition (e.g., hypothyroidism) 
E.  The symptoms are not better accounted for by bereavement; i.e., after the loss of a loved one, 
the symptoms persist for >2 months or are characterized by marked functional impairment, 
morbid preoccupation with worthlessness, suicidal ideation, psychotic symptoms, or 
psychomotor retardation 
Source: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC, American 
Psychiatric Association, 2000. 
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Appendix 2 Variables included in the original dataset 
File Variables 
Membership Patient encrypted identification, age, gender, region of residence, start 
and end observed date 
Service claims Patient encrypted identification, amount reimbursed, amount of co-
payment, CPT procedure code, date of service, primary and secondary 
diagnosis codes, provider encrypted identification, provider specialty, 
place of service, encounter flag, benefit level of payment 
Facility claims Patient encrypted identification, amount reimbursed, amount of co-
payment, CPT procedure code, date of service, primary and secondary 
diagnosis codes, primary and secondary procedure codes, provider 
encrypted identification, provider specialty, place of service, source of 
admission, diagnostic related group, encounter flag, participating 
provider indicator, revenue code, benefit level of payment 
Prescription 
claims 
Patient encrypted identification, brand name, National Drug Code 
(NDC), dosage, strength, days-of-supply, quantity dispensed, mail order, 
therapdate of service, cost amount of claim, amount of patient co-
payment, encrypted provider identifier, and provider specialty 
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Appendix 3 Odds Ratios and Specification Tests for Continuation Phase Antidepressant 
Treatment Completion Model with Different Forms of Follow-up Visits 
 
 Model 1 Model 2 Model 3 
Continuation phase follow-up continuous 1.05 (1.02-1.08)   
Continuation phase follow-up binary    
0-2 visits  Reference  
3 or more visits  1.62 (1.31-2.02)  
Continuation phase follow-up categories    
0 visits   Reference 
1-2 visits   1.67 (1.34-2.10) 
3 or more visits   2.18 (1.70-2.79) 
linktest (p-value) § 0.016 0.158 0.028 
Note: the models have identical covariates except the forms of follow-up visits. 
§
 insignificant indicates correct model specification without omitted variable misspecification  
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Appendix 4 Results of Specification Tests 
 
Model c-statistic Linktest§ 
(p-value) 
Hosmer-Lemeshowδ 
(p-value) 
Aim 2    
Guideline-concordant follow-up visits 0.72 0.685 0.329 
Acute phase completion 0.63 0.053 0.223 
Continuation phase completion 0.62 0.073 0.636 
Aim 3    
Acute phase    
All-cause utilization 0.66 0.275 0.306 
Mental health-related utilization 0.71 0.657 0.972 
All-cause hospitalization 0.70 0.088 0.113 
Mental health-related hospitalization 0.72 0.779 0.158 
Continuation phase    
All-cause utilization 0.66 0.896 0.548 
Mental health-related utilization 0.74 0.592 0.136 
All-cause hospitalization 0.76 0.374 0.801 
Mental health-related hospitalization 0.79 0.662 0.671 
§
 insignificant indicates correct model specification without omitted variable misspecification 
δ
 insignificant, which shows a good model fit 
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